var title_f7_39_7792="Displaced fracture greater trochanter";
var content_f7_39_7792=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79836&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Displaced fracture of greater trochanter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 270px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This close-up view from an anteroposterior radiograph shows a fracture of the greater trochanter with obvious displacement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Koval KJ, Zuckerman JD. Intertrochanteric fractures. In: Rockwood and Green's Fractures in Adults, 5th ed,&nbsp;Bucholz RW, Heckman JD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2002. Copyright &copy; 2002 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7792=[""].join("\n");
var outline_f7_39_7792=null;
var title_f7_39_7793="Mutations in the Wiskott-Aldrich syndrome - WAS gene";
var content_f7_39_7793=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F66996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F66996&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 629px\">",
"   <div class=\"ttl\">",
"    Mutations in the Wiskott-Aldrich syndrome (WAS) gene",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 609px; height: 379px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    WAS gene mutations causing both classic Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Types of mutations are based upon molecular analysis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Jin Y, Mazza C, Christie JR, et al. Blood 2004; 104:4010 and Ochs HD, Thrasher AJ. J Allergy Clin Immunol 2006; 117:725 and Alber MH, Bittner TC, Nonoyama S, et al. Blood 2010; 115:3231.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7793=[""].join("\n");
var outline_f7_39_7793=null;
var title_f7_39_7794="Trichloroacetic acid: Drug information";
var content_f7_39_7794=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Trichloroacetic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/35/3635?source=see_link\">",
"    see \"Trichloroacetic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F230857\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Tri-Chlor&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F230861\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Keratolytic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F230852\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, topical:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Tri-Chlor&reg;: 80% (15 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F230846\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F230853\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Chemical used in compounding agents for the treatment of warts, skin resurfacing (chemical peels)",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1987560\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Appropriate use: For prescription compounding and application by physician as part of a procedure. Serious injuries, including skin damage, burns, swelling, and pain may occur following improper application.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F6223455\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13970319\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Effective for treatment when used topically for the treatment of genital condylomas in pregnant women (Schwartz, 1988).",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16324029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Tri-Chlor External)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     80% (15 mL): $63.75",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539947\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acido Tricloroacetico (IT);",
"     </li>",
"     <li>",
"      CL3 Bruciaporri (IT)",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Allen LV., \"Basics of Compounding for the Treatment of Warts,\"",
"      <i>",
"       International Journal of Pharmaceutical Compounding",
"      </i>",
"      , 2004,  8(3):126-9.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Sexually Transmitted Diseases Treatment Guidelines, 2010,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2010, 59(RR-12):1-110.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7794/abstract-text/21160459/pubmed\" id=\"21160459\" target=\"_blank\">",
"        21160459",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Demas PN, Bridenstine JB, and Braun TW, \"Pharmacology of Agents Used in the Management of Patients Having Skin Resurfacing,\"",
"      <i>",
"       J Oral Maxillofac Surg",
"      </i>",
"      ,  1997, 55(11):1255-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7794/abstract-text/9371116/pubmed\" id=\"9371116\" target=\"_blank\">",
"        9371116",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kodner C and Nasraty S, \"Management of Genital Warts,\"",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 2004, 70(12):2335-42.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7794/abstract-text/15617297/pubmed\" id=\"15617297\" target=\"_blank\">",
"        15617297",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Levine PJ, \"Chemical Facial Peel Formulations: An Overview,\"",
"      <i>",
"       International Journal of Pharmaceutical Compounding",
"      </i>",
"      , 1999, 3(5):375-7.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz DB, Greenberg MD, Daoud Y, et al, \"Genital Condylomas in Pregnancy: Use of Trichloroacetic Acid and Laser Therapy,\"",
"      <i>",
"       Am J Obstet Gynecol",
"      </i>",
"      , 1988, 158(6 Pt 1):1407-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7794/abstract-text/3381865/pubmed\" id=\"3381865\" target=\"_blank\">",
"        3381865",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10296 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-4EAA1F1B94-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7794=[""].join("\n");
var outline_f7_39_7794=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230857\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230861\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230852\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230846\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F230853\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1987560\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300170\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6223455\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13970319\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16324029\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539947\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10296\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/10296|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/35/3635?source=related_link\">",
"      Trichloroacetic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7795="Contents: Pediatric hematology";
var content_f7_39_7795=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric hematology",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric hematology",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Anemia due to decreased production",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/16/21767\">",
"           Macrocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/14/23782\">",
"           Physiology of vitamin B12 and folate deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/39/33400\">",
"           Shwachman-Diamond syndrome",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Blood transfusion",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/15/27898\">",
"           A primer of red blood cell antigens and antibodies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11672\">",
"           Administration and complications of red cell transfusion in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6646\">",
"           Complications of therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/51/11061\">",
"           Directed (designated) blood donation programs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/31/11769\">",
"           Immunologic blood transfusion reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/23/18808\">",
"           Indications for red blood cell transfusion in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/19/12597\">",
"           Indications for therapeutic plasma exchange",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/41/40601\">",
"           Laboratory testing of donated blood",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/5/24665\">",
"           Leukoreduction to prevent complications of blood transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/32/24073\">",
"           Oxygen carriers as alternatives to red cell transfusion",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/11/27832\">",
"           Red cell transfusion in infants and children: Selection of blood products",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/35/6710\">",
"           Transfusion-associated graft-versus-host disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone marrow failure",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/40/17030\">",
"           Hematopoietic cell transplantation for Diamond-Blackfan anemia and the myelodysplastic syndromes in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/24/12680\">",
"           Recombinant hematopoietic growth factors in inherited bone marrow failure syndromes",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bone marrow transplantation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/38/26218\">",
"           Donor selection for hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5529\">",
"           Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/51/33590\">",
"           Gene therapy for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/2/1066\">",
"           Hematopoietic cell transplantation for primary immunodeficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43591\">",
"           Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/33/34330\">",
"           Specific therapies for sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Coagulation disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/4/24650\">",
"           Acquired inhibitors of coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/59/37818\">",
"           Anticoagulants other than heparin and warfarin",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3722\">",
"           Approach to the child with bleeding symptoms",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22824\">",
"           Biology and normal function of factor VIII and factor IX",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17049\">",
"           Biology and normal function of von Willebrand factor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/8/44169\">",
"           Classification and pathophysiology of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/18/1322\">",
"           Clinical manifestations and diagnosis of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/13/24794\">",
"           Clinical presentation and diagnosis of von Willebrand disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/57/14234\">",
"           Diagnosis and treatment of venous thrombosis and thromboembolism in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/31/8697\">",
"           Disseminated intravascular coagulation in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/56/36746\">",
"           Factor VIII and factor IX inhibitors in patients with hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/5/33878\">",
"           Genetics of the hemophilias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/40/14986\">",
"           Management of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/35/27194\">",
"           Overview of hemostasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/28/25033\">",
"           Pathogenesis and clinical manifestations of venous thrombosis and thromboembolism in infants and children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/56/8073\">",
"           Pathogenesis and etiology of disseminated intravascular coagulation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/16/14600\">",
"           Pathogenesis, clinical features, and diagnosis of thrombosis in the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/52/841\">",
"           Protein C deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/55/13176\">",
"           Protein S deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/16/20743\">",
"           Prothrombin gene mutation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/30/14825\">",
"           Screening for inherited thrombophilia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/34/38442\">",
"           Treatment of hemophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/4/43082\">",
"           Treatment of lower extremity deep vein thrombosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/22/21866\">",
"           Treatment of von Willebrand disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hematopoiesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/31/16890\">",
"           Introduction to recombinant hematopoietic growth factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/34/25129\">",
"           Overview of hematopoiesis and stem cell function",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/10/20650\">",
"           Regulation of erythropoiesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/44/6858\">",
"           Regulation of myelopoiesis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemoglobins",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/33/8729\">",
"           Clinical features, diagnosis, and treatment of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/4/42055\">",
"           Genetic disorders of hemoglobin oxygen affinity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/46/4841\">",
"           Genetics and pathogenesis of methemoglobinemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/25/42392\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Absence of the GPI anchor",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/17/13593\">",
"           Pathogenesis of paroxysmal nocturnal hemoglobinuria: Missing cell proteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/29/23001\">",
"           Structure and function of normal human hemoglobins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/38/616\">",
"           Unstable hemoglobin variants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hemolytic anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/59/18362\">",
"           Autoimmune hemolytic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/51/19256\">",
"           Clinical features and diagnosis of autoimmune hemolytic anemia: Warm agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/56/33672\">",
"           Clinical features and treatment of autoimmune hemolytic anemia: Cold agglutinins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/50/14121\">",
"           Clinical manifestations of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/43/17082\">",
"           Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/46/43753\">",
"           Extrinsic nonautoimmune hemolytic anemia due to drugs and toxins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/62/9194\">",
"           Extrinsic nonimmune hemolytic anemia due to mechanical damage: Fragmentation hemolysis and hypersplenism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/52/3912\">",
"           Hemolytic disease of the newborn: RBC alloantibodies in pregnancy and associated serologic issues",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/60/43977\">",
"           Overview of hemolytic anemias in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/52/30535\">",
"           Pathogenesis of autoimmune hemolytic anemia: Cold agglutinin disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/2/20521\">",
"           Pathogenesis of autoimmune hemolytic anemia: Warm agglutinins and drugs",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/26/10665\">",
"           Postnatal diagnosis and management of alloimmune hemolytic disease of the newborn",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypoproliferative anemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/20/26954\">",
"           Anemia in children due to decreased red blood cell production",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Iron metabolism",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/13/2266\">",
"           Genetics of hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/61/33748\">",
"           Hepatic iron concentration and hepatic iron index in the diagnosis of iron overload and hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/60/38856\">",
"           Iron overload syndromes other than hereditary hemochromatosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/19/35129\">",
"           Pathophysiology and diagnosis of iron overload syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/37/21082\">",
"           Regulation of iron balance",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Laboratory evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/36/4682\">",
"           Clinical use of coagulation tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/29/15834\">",
"           Erythropoietic protoporphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/23/13689\">",
"           Evaluation of bone marrow aspirate smears",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/26/38313\">",
"           Evaluation of the peripheral blood smear",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/5/9305\">",
"           Spiculated cells (echinocytes and acanthocytes) and target cells",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Lead poisoning",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/24/394\">",
"           Childhood lead poisoning: Clinical manifestations and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/47/11001\">",
"           Childhood lead poisoning: Exposure and prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/5/21594\">",
"           Childhood lead poisoning: Management",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Miscellaneous",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/19/20792\">",
"           Anemia of prematurity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/0/24585\">",
"           Protection against malaria by abnormalities in red cell surface antigens and cytoskeletal proteins",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Platelet disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/63/25591\">",
"           Causes of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23833\">",
"           Clinical manifestations and diagnosis of immune thrombocytopenia (ITP) in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/46/24295\">",
"           Clinical manifestations and evaluation of thrombocytopenia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/22/4458\">",
"           Megakaryocyte biology and the production of platelets",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/9/14490\">",
"           Neonatal thrombocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/7/1146\">",
"           Platelet biology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/30/10727\">",
"           Platelet dysfunction in uremia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/59/23482\">",
"           Platelet function testing",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/53/37721\">",
"           Treatment and prognosis of immune (idiopathic) thrombocytopenic purpura in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Polycythemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/12/24777\">",
"           Diagnostic approach to the patient with polycythemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/17/29978\">",
"           Molecular pathogenesis of congenital polycythemic disorders and polycythemia vera",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/6/36968\">",
"           Neonatal polycythemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Porphyria",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/12/10439\">",
"           Clinical manifestations and diagnosis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/42/5801\">",
"           Congenital erythropoietic porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/16/40198\">",
"           Etiology and pathogenesis of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/20/3398\">",
"           Management of acute intermittent porphyria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/19/28984\">",
"           Porphyrias: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Red cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/41/3738\">",
"           Acquired aplastic anemia in children and young adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/54/43880\">",
"           Approach to the child with anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18506\">",
"           Bone and joint complications in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/37/36441\">",
"           Causes of congenital and acquired sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/63/6138\">",
"           Clinical aspects, diagnosis, and treatment of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/25/4505\">",
"           Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/50/39719\">",
"           Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/62/13289\">",
"           Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/18/11562\">",
"           Hematopoietic cell transplantation for idiopathic severe aplastic anemia and Fanconi anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/16/15623\">",
"           Hereditary elliptocytosis: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/56/43911\">",
"           Hereditary elliptocytosis: Genetics and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/1/20506\">",
"           Hereditary spherocytosis: Clinical features; diagnosis; and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8841\">",
"           Hereditary spherocytosis: Mechanism of hemolysis and pathogenesis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/13/26842\">",
"           Inherited aplastic anemia in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/37/16984\">",
"           Introduction to hemoglobin mutations",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/18/22826\">",
"           Iron deficiency in infants and young children: Screening, prevention, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38949\">",
"           Iron deficiency in infants and young children: Treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/14/4329\">",
"           Iron requirements and iron deficiency in adolescents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/58/35750\">",
"           Pathophysiology of the sideroblastic anemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/58/27559\">",
"           Pyruvate kinase deficiency",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/17/5399\">",
"           Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/13/42200\">",
"           Stomatocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/15/14583\">",
"           Xerocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sickle cell disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/4/18506\">",
"           Bone and joint complications in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/11/31930\">",
"           Cerebrovascular complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/30/23017\">",
"           Diagnosis and management of priapism in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/54/42856\">",
"           Diagnosis of sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/3/30775\">",
"           Hematopoietic cell transplantation in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/1/39961\">",
"           Management of fever in sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/11/42170\">",
"           Overview of the clinical manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39946\">",
"           Overview of the management of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27082\">",
"           Pulmonary complications of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/3/6202\">",
"           Renal manifestations of sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/1/38937\">",
"           Routine comprehensive care for children with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/25/30104\">",
"           Sickle hemoglobin polymer: Structure and functional properties",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/33/34330\">",
"           Specific therapies for sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/26/16810\">",
"           The acute chest syndrome in children and adolescents with sickle cell disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/5/5209\">",
"           Variant sickle cell syndromes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?13/63/14330\">",
"           Vasoocclusion in sickle cell disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Spleen and lymph nodes",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/34/12840\">",
"           Approach to the child with an enlarged spleen",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/22/33128\">",
"           Approach to the child with peripheral lymphadenopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30744\">",
"           Causes of peripheral lymphadenopathy in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/17/24857\">",
"           Diagnostic approach to and initial treatment of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/27/8632\">",
"           Etiology and clinical manifestations of cervical lymphadenitis in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Systemic disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35704\">",
"           Clinical manifestations and diagnosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/34/6697\">",
"           Extrinsic nonimmune hemolytic anemia due to systemic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/1/3098\">",
"           Hematologic manifestations of HIV infection: Anemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/0/44039\">",
"           Hematologic manifestations of HIV infection: Neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/11/14522\">",
"           Hematologic manifestations of HIV infection: Thrombocytopenia and coagulation abnormalities",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/42/27303\">",
"           Hematologic problems in children and adolescents with systemic lupus erythematosus",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/59/30649\">",
"           Treatment and prognosis of Shiga toxin associated (typical) hemolytic uremic syndrome in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Thalassemia",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/13/38106\">",
"           Clinical manifestations and diagnosis of the thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/25/5529\">",
"           Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/36/43591\">",
"           Long-term management of the thalassemic patient after hematopoietic cell transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/11/36025\">",
"           Pathophysiology of alpha thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/55/8058\">",
"           Pathophysiology of beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/26/24999\">",
"           Prenatal testing for the hemoglobinopathies and thalassemias",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/23/20858\">",
"           Protection against malaria in the hemoglobinopathies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25880\">",
"           Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7802\">",
"           Treatment of beta thalassemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         White cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/12/3274\">",
"           Approach to the patient with lymphocytosis or lymphocytopenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/52/29511\">",
"           Approach to the patient with neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/55/35705\">",
"           Causes of neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/53/21338\">",
"           Clinical manifestations, pathologic features, and diagnosis of Langerhans cell histiocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/22/24937\">",
"           Congenital neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/61/42966\">",
"           Cyclic neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31303\">",
"           Definition and mechanisms of leukocytosis and neutrophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/41/17048\">",
"           Determinants of neutrophil movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/21/21850\">",
"           Drug-induced neutropenia and agranulocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/3/20537\">",
"           Evaluation and management of fever in children with non-chemotherapy-induced neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/5/41050\">",
"           Hemophagocytic lymphohistiocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/33/42520\">",
"           Immune neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/14/10473\">",
"           Infectious causes of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/50/32551\">",
"           Langerhans cell histiocytosis (eosinophilic granuloma) of bone in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/31/6650\">",
"           Neutrophil functions other than movement",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/2/6185\">",
"           Normal neutrophil development and kinetics",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/47/18170\">",
"           Overview of neutropenia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/20/30022\">",
"           Risk of infection in children with fever and non-chemotherapy-induced neutropenia",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0605-95.154.198.148-F45331ABB0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_39_7795=[""].join("\n");
var outline_f7_39_7795=null;
var title_f7_39_7796="Prednicarbate: Pediatric drug information";
var content_f7_39_7796=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"19\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Prednicarbate: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?6/31/6644?source=see_link\">",
"    see \"Prednicarbate: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?3/30/3556?source=see_link\">",
"    see \"Prednicarbate: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F212804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Dermatop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F212805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Dermatop&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1032917\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenal Corticosteroid",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anti-inflammatory Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Corticosteroid, Topical",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Glucocorticoid",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1032931\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/31/6644?source=see_link\">",
"      see \"Prednicarbate: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Topical:",
"     <b>",
"      Note:",
"     </b>",
"     Therapy should be discontinued once control is achieved; if no improvement is seen within 2 weeks, reassessment of diagnosis may be necessary.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Children &ge;1 year and Adults: Apply a thin film to affected area twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Children &ge;10 year and Adults: Apply a thin film to affected area twice daily",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F212795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cream, topical: 0.1% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatop&reg;: 0.1% (60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ointment, topical: 0.1% (15 g, 60 g)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatop&reg;: 0.1% (60 g)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F212782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F13134798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Apply a thin film to clean, dry skin and rub in gently. For external use only. Do not use on diaper area, face, groin area, underarm, or open wounds. Do not cover with occlusive dressings.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F13134778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical cream: Store at 5&deg;C to 25&deg;C (41&deg;F to 77&deg;F).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topical ointment: Store at 15&deg;C to 30&deg;C (59&deg;F to 86&deg;F).",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1032918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cream: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium potency topical corticosteroid) (FDA approved in ages &ge;1 year and adults)",
"     <b>",
"      Note:",
"     </b>",
"     In pediatric patients, safety and efficacy &ge;3 weeks has not been established)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ointment: Relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses (medium-potency topical corticosteroid) (FDA approved in ages &ge;10 years and adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F212828\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Dermatop&reg; may be confused with Dimetapp&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F212827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Mild telangiectasia, shininess, skin atrophy, thinness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Acneiform eruptions, allergic contact dermatitis, burning, edema, folliculitis, hypopigmentation, miliaria, paresthesia, perioral dermatitis, pruritus, rash, secondary infection, striae, urticaria",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1032920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to prednicarbate or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F13134777\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not use for diaper dermatitis. Avoid use with occlusive dressing or application to denuded skin or to large surface areas. Avoid using higher than recommended doses; suppression of HPA axis function may occur. Reduction in growth velocity may occur when corticosteroids are administered to pediatric patients by any route (monitor growth). Prolonged use may result in fungal or bacterial superinfection. Use may be associated with local sensitization.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Avoid contact with latex-containing products; may damage or reduce effectiveness of latex condoms or diaphragms. If contact occurs, latex product should be disposed. Avoid contact with eyes, face, underarms, or groin area; not for intravaginal use.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1032921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Hypothalamic-pituitary-adrenal (HPA) suppression may occur; acute adrenal insufficiency (adrenal crisis) may occur with abrupt withdrawal after long-term therapy or with stress; withdrawal and discontinuation of corticosteroids should be done carefully. Adverse systemic effects (eg, hyperglycemia, glycosuria, fluid and electrolyte changes) may occur when topical steroids are used in large areas of the body, denuded areas, for prolonged periods of time, with an occlusive dressing, and/or in infants and small children; infants and small children may be more susceptible to HPA axis suppression or other systemic toxicities due to larger skin surface area to body mass ratio; use with caution in pediatric patients. If HPA suppression occurs, consider withdrawal of  prednicarbate, reduction in frequency of application, or substitution with a less potent corticosteroid. Cushing&rsquo;s syndrome and intracranial hypertension have also been reported in pediatric patients. May cause inhibition of bone growth in pediatric patients. Immunosuppression may occur; patients may be more susceptible to infections; avoid exposure to chickenpox and measles. Corticosteroids may activate latent opportunistic infections or exacerbate systemic fungal infections. Prolonged treatment with corticosteroids has been associated with the development of Kaposi's sarcoma (case reports); if noted, discontinuation of therapy should be considered. Allergic contact dermatitis can occur and is usually diagnosed by failure to heal rather than clinical exacerbation, diagnostic patch testing may corroborate observation.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Ointment contains propylene glycol; in neonates large amounts of propylene glycol delivered orally, intravenously (eg, &gt;3000 mg/day), or topically have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use ointment containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F212790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aldesleukin: Corticosteroids may diminish the antineoplastic effect of Aldesleukin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Corticosteroids may diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Corticosteroids may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Corticosteroids may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving corticosteroids (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Corticosteroids may decrease the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Corticosteroids.  Management: Concurrent use of telaprevir and systemic corticosteroids is not recommended.  When possible, consider alternatives.  If used together, employ extra caution and monitor closely for excessive corticosteroid effects and diminished telaprevir effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F212791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F11431693\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no adequate and well-controlled studies using prednicarbate during pregnancy. However, intrauterine growth retardation has been reported with other topical steroids. Avoid use in large amounts for long periods of time during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1032934\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Growth in pediatric patients; assess HPA axis suppression (eg, ACTH stimulation test, morning plasma cortisol test, urinary free cortisol test)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1032930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Controls the rate of protein synthesis, depresses the migration of polymorphonuclear leukocytes and fibroblasts, reverses capillary permeability, and stabilizes lysosomal membranes at the cellular level to prevent or control inflammation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F13143977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Topical corticosteroids are absorbed percutaneously. The extent is dependent on several factors, including epidermal integrity (intact vs abraded skin), formulation, age of the patient, and the use of occlusive dressings. Percutaneous absorption of topical steroids is increased in neonates (especially preterm neonates), infants, and young children.",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1032935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/30/3556?source=see_link\">",
"      see \"Prednicarbate: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use only as prescribed and for no longer than the period prescribed; apply sparingly in a thin film and rub in lightly; avoid contact with eyes; do not apply to the face, underarms, or groin areas; notify prescriber if condition persists or worsens. Wash hands before and after use.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"'Inactive\" Ingredients in Pharmaceutical Products: Update (Subject Review),\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 1997, 99(2):268-78.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7796/abstract-text/9024461/pubmed\" id=\"9024461\" target=\"_blank\">",
"        9024461",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goedert JJ, Vitale F, Lauria C, et al, &ldquo;Risk Factors for Classical Kaposi's Sarcoma,&rdquo;",
"      <i>",
"       J Natl Cancer Inst",
"      </i>",
"      , 2002, 94(22):1712-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7796/abstract-text/12441327/pubmed\" id=\"12441327\" target=\"_blank\">",
"        12441327",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16771 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-4E972C53F8-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7796=[""].join("\n");
var outline_f7_39_7796=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212804\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212805\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032917\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032931\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212795\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212782\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134798\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134778\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032918\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212828\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212827\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032920\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13134777\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032921\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299937\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212790\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F212791\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11431693\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032934\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032930\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13143977\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1032935\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16771\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/16771|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?6/31/6644?source=related_link\">",
"      Prednicarbate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?3/30/3556?source=related_link\">",
"      Prednicarbate: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7797="Anatomy of the parapharyngeal space";
var content_f7_39_7797=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F67251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F67251&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Anatomy of the parapharyngeal space",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 535px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAIXAgYDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiikV1YkKwJHoaAFooooAKKKKACiisifxBZpK0cAmumU4Y26bgp9M9Kmc4wV5OxUYuWyNeis/T9XtL6QxROyTgZMMqlHx9D1/CtCiMlJXixOLi7MKKKKoQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRQehx1oA5WaZ9XuJXkdhYIxjjiUkCTBwWbHUZ6Cmf2XYg5W1iRv7yDaR+I5pNDx/Y9nj/nkv8quSSLEhZ2AUdzXz85ucuZno/D7qIop7/T23QSNeW/eGZvnH+656/Q/nW1p+qWl8MQygSjrE/yuv1U81j/aIvLWQyKEboTxmmT21teKDKiSAfdYdR9CORXRSxU6ej1RnOnGW+h1FNkdI0LyMqIOpY4ArlRY7RiO7vkHoty/9TSf2bbs4acSXDDoZ5Gk/QnFdDx66RM/q67ljUb/APtWQW1mW+wj/XTDgS/7KnuPU/hT440iRUjVURRgKowBS9B7Cq8N5HK4UBwT0yK4alSVWXNI2jFRVkQ618li1yvEtuRKjdwQf8OK6sPXKa9/yCLkf3l2/mQK6JZK6MJU5boirG6RcDA0tVg4pwevRVVM5nEnopgenAg1opJk2FooopiCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDktHGyzMR/5ZSSR/k5FWLiITR7T65FNt12XWop/dunP5hW/9mqevn5rlk0ehe+pT+xgwhD2JxVY2sls/mREg+3Q/WjUBN9oJSR1HGADiprC4eRWjmG5wMg+tGpWpcifzIw2MHuKqG6n8ziJdme/XFOW4JidZQsDfwnNS2gYQjc+/nhs5/WkIQQ+XM0zSNjkkZ4qK2uUknKiIp6N61Xuprl5HVG2oDjAFW7Fd0Yd1AfPanYCLWubEL/eliX85FrbzWJrZxYhuyyxMfoJFraqqfUmWyHBqeHqKit1NozaLKyU8PVTNOD1rGtYlwLqvT1cGqIkqVZK3hWM3At5oqAPT1krdVEyHFklFICDS1pckKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDmpPl1vUl9Wjf80A/9lqWoZv8AkYNR/wB2L+RqavCr/wASXqd8dl6IrXEsQkCOG3eoHFNaMQHzANxHQDvS37SKq+VgMT1xnFV75pnSLazJkZO04yahFInKi5hV5UKlc8dapl7gYER2IvRQM/nUsE1wlrLx5jJgjd6d6ks7gTHEqBW7EdDRsMsIqyqHK4J6023uYZWKRE5X1HWkkMwmVYwBEDzx1pkdp5UwZOxpCHarCbjTrmJfvsh2/XqP1rQtZluLWKZDlZEDj8RUNVdDbyDPp7dYG3R+8bcj8jkfhVU3ZieqNWiiitiAooooAKUGkooEPD09ZKhoq1NoTii2slSq9UAxFSLJW8K5DgXg4NOzVNZKkWSuiNZMycCxRTFfNPBBrZSTJsFFFFMQUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFRXM8dtbyzzHbHGpdj6AUN2Dc5xT5msarIOnnLGP+Aov9SanJAGTwKq6ZHIlrvnGJpmaaQejMc4/Dp+FTyPHnY7AE9ia+fnLmk5dz0LW0COWObcEO7aeeKSRot6o7KGPQd6itZ4GdoocgjnkdadHbr5vmvy4PFIZKqouQMZNQw24Tr2qtNp+6RmznJzmpoLeRI3jLHaRgZPSgB08qSqY4Z1D57NzVW5lntI0RXLOxzlucCnfYOakvYS0kZ6/LimrAWLWRpbdHcYY9ar6iDA8V9GpLwffC9WjP3h+HX8KmjDrbYTG4dM1LDv8ALAlIL98Ug2LkbrLGskbBkYZBHQinVj6c32C7Nk5xBKS9v7Hqyf1H4+lbFbRd1chqzCiiiqEFFFFACgUEUCg0xCUUUUhig05XIplFNNoViyj1KHqkDinh63hWsZuBdV6eDmqayVIr10wrXM3As0VGr08MDWykmQ0LRRRVCCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAK53XJ/t96NPj/wCPeEh7k/3j1VP6n8Kua5qT2wW1sgGvZR8ueRGv99v6eprPtYFtoQisWOSzOxyWY9SfeuDGV7L2cfmdNGFvfY+WRYkLNnA9KrmBLj97z83qKdelmgxGeWPUVUsoZlnUh3255BPFeajoLkNskTbh1q0E+UsSFUDJJ4ArH8S+I9P8N2vmXz+ZcMMxWyH539z6D3/nXjPiPxVq3iCRxdXDR2pPFtESqAdsjv8AU0SlGHxb9ioU5VNtj1zVPGnh3TWKS6gJ5B/BbL5n6jj9ay1+Jvh1n2mPUkH94xJj9GzXjPlUhjrF130SOhYaPVn0Lp2t6Pr0Zi07UIpXYf6o5R/++TgmrsNkIHBDHHp2r5sUMjBkJVgcgg4IrufCvxDv9NdYNYMl9ZnjcxzLH7gn730P51Uayej0InQa+F3PYJHSJMuQq9KqQ3pkmZSoABI96fYXtnq1nHc2UqT278gjsfQjsfai8gzh4wgIPzHpkfWtFYw9R97bLd25jYlTkMjr1Rh0IqXSrxriN4rjat3CdsqjofRh7EVE06QRp57BS3TvUV7A7sl3ZEC6jHynPEi91Psf0pxfKwtdWZsUVXsbuO9txLESOzKeGQ9wR2NWK3M9gooooAKKKKACiiigAooooAKKKKAFBpwamUU02hWJ1kqVXzVOnqxFbQqtbkOBfVqcDmqqycVIr5rrjVRk4k9FMV6eDmtlJMiwUUUUxBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUyWWOGJpJXWONRksxwB+NZEniK1bIsori8b1iTC/99HAqJ1Iw+J2KjCUtkbVY+qauIpGtLALNe45/uRe7H+nWqU1xqV6pEsi2UR/ggO58e7np+A/Gkt4IbSHZCqxxjk/4k1w1sbpan95vCjbWQ20thAHd3aWeQ7pJW6uf6D0Haid28zyyqrGwILFsflSC9tzIEEgLE4HBx+dVZbJpZC75LHvXB6nR6ly2gWFNo5Gc1l+LvEVv4Y0wTuoku5si3h9SP4j7DIrQ1C+t9G0ia+vWPkW6DIHVj0AHuTXgniTXLrxFq0l9eYXI2xxr92NR0AqZT9mr9en+ZdKn7R67Fa/vLnU76a8vpWluJTlnP8AL6e1RqtIlSrzXLvud1rCbRSMlTbeKawosMg8umMlWwOOaY60rAXPDWvXnh6/E9qxaJuJYSflkH+PvXuGk6nZeINLFxZvuibhlP3kb0I9a+f2TNanhXXrjw5qizx5e3f5Zos8Ov8AiO1VCbg/Ixq0ufVbnt91afu4wuSEz+Gas2ilYQp7dKhhuRqFjBdadMGilG5WAzkVFeSXK7FVtpxklR1NdS1OPyJbiCSC5+2WQzL0lizgSr/8UOx/CtCxvIb2IvCxyDhkYYZD6EdjVKxmeSPbLy69/UUXFksswnikeC4HHmRnBI9COhH1pxk4g1fRmrRWT9q1G3OJIIrtP70TbH/75PH61ImtWm4LcGS1c9p0KD8+n61qppk8jNKikVldQyEMp5BByDS1RIUUUUAFFFFABRRRQAUUUUAFFFFACg04ORTKKabQrFhJamV81RzT1cit4VrbkOBfVqeDmqaS+tSq/vXVCqmYuFieimq2adWydyAooopgFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABSEgAknAHU0tc/r9y11OdMt2IXAa5cdkPRB7n+X1rOrUVOPMy4Qc3YpO51i7a5my1khxbxH7rY/5aEd89varo6cUigKoCgADgAdqgvHdU2x8M3f0rw5Sc5XZ2rsifIBwSM1WvUaUBB93qfes0WTSP6se5rRnin/AHflSsAowfc+ppWsMigslU72GSvIWrNqZyWE2PbAxQkbuyvIWVl4wp4P4VBruorpGiXuoPgmCMlAe7nhR+ZFPcHqeW/FXxAdR1YaXav/AKHZnD4PDy9z+HT864lUpASzszEsxOST3qwi1ySk5u56EIqCshiofSp40NSxRZq0kPtQkMrKvagx1eWGneT7U7AZxQ4qNlrTaD2qCSCiwFArUcqZFXGjIqKRODUtAdb8KvEBstQbSbpz9nuTmEk8JJ6fj/MD1r1t0V/vCvmtt0cqvGSrqQQR1BHevoXw9qH9qaJZXvGZowWx/e6N+oNXRl9k5cRCz5kPvJTahfJUFz69hVm2l86FXIwT1FRXaooMshwvTpmqbRC4cPA5KrwCOMV07owNCS5hjk2O+G+hqQ7JE52sp/EGq0iqtt5s67nUc+/pTLS9hICFTGffp+dKwWEksmtf3ul4hkHJi6RyexHY+4rSsbpLy2SZAVzkMrdVI4IP0plUDJ/ZuoNM5xaXOBIe0cnQMfQEcH8KcJWYNc3qbVFFFbmYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAU9XIplFNNoTVy0klSq9UQcU9XIrohXtuZuBoKwNLVRJKnSSuuFVMxcbElFAOaK1JCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACuU02T7RHLdkfNcytJ+GcL/46BXTXbFLWZh1CMR+Vcxo426TZgf88U/kK87Hy+FHTQWjZakcRxs7ZwBniqkt3utWlhjLFTghu3vVlpItxjZ03HjaSM1FbFtsm+EIPrnNeejoIbC8M8hR4grYzkdKS4+0rcMyudvYY4xS26mGQsF4PBqxc3McCgyZOegAyTT6h10HwO0keXXa1cN8Yb4w6JZWSnH2iYu30Qf4sPyru0YMisOhGa8t+Mxb+0tLX+AQMR9Sxz/IVEvhZdJXmjgY0zVuGIkiorfGRWpboOMVzpHcPt7fgZq0sNTQJkVP5daWAriIUvlCrGw0oQ0CuVTFxUMkXtWjs9qY8fFA7mNND1qlMuM1tzR8Gsu5TBNS0BlyrzXsnwumMnhKFD0ildB+e7/2avH58AV698LIjH4TjY9JZncfy/pSpr3jGv8AAdZNGsqbW6VT+029k5iO4tnJwOlX6y7+OOWUMnLfxV0o5EWZY4GcTSSAK4wMtgGonsgp45FMa0LwQ9woI/WnsnEKNLsdeFG7FMY6a5NpFEmwuT74wKsRtHdW+SoKMMFWH6Gop4DNJkjpwKsQxiKMKKTsIg0iRreeXT5GLCNQ8LE5JjPGPwPH0xWrWRdDZqOnzjg+Y0R9wyn+oFa9awd0TLuFFFFWSFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFADlbFSo9QUoNXGbiS1cuo9Sq2aoo9Tq2a66dUxlAs0VGr461ICD0rpUkzNqwUUUVQgooooAKKKKACiiigAooooAKKKKACiiigAooooAjuV328qf3lI/SuX0Zt2kWZ/6YqPyFdZXJaQnl2Qi/wCeckkf5Ow/pXnY9fC/U6aGzK95a7rlmXvzVm4AZoVefy3I6BsZNStLGXZEZTMO1QQ2u2bzXG4jnn1rgudAPfwRylGDkg4JA4p88K3BWRSCuODVZ7be7MRyTmplRUs3WbPlg5o9ALqZ2jPXFcL8XdLe50qzv4lz9lYpJjsrYwfzH611un3UMg8pAyY6Bu9XJo47iCSCdBJDIpVlYcEHtStumOLcZJnzlBkNWvaHOK3fE/gi50mRriy3XNj13Dlo/wDeH9f5VgWwKHmsOVxdmd0ZKSujatxgCrIGapW84GBV+ORSKoBwWnAY7Uu5fWjI9aBDCKY+MVI5AHWqkkgFAyC4I5rIuj1q7dTjmst/MnkWOFGeRzhVUZJPsKljRWWGS6uY4IFLyyMEVR3J6V73oOnrpWjWlkpB8mMBiO7dSfzJrl/AfhBtLYahqag3pH7uPr5QPc/7X8q7irhG2py1qnM7IbI6IhMjBV9SahWJXUMjBlPQiq99E00mD91egpoWS3syseQWbr6VpYxLFyswiVYG2+pHWnQxF40acAyDvWdaebDMG3sVJ+YE5q9cSzpMPLClMdx1pgRym5+0FlYhQeF7Yq8DkA1VvbpoEjKIGZuee1Os7kXCnK7XHUUnsAx83Gr20C/cgHnyfqqj88n8K16ybM+Xr1wrdZoEZPfaSCP1Fa1a09iZhRRRVkhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFPVsUyimnYTQt7P5Vo8g/h5o0O/W8jYA/MtQ3imS0mT+8hH6VzHga6ZdVMLHh1I/r/SuqlUvJCdO8G+x6DRRRXccgUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFcpp8itBNMCBG88rg+xkbBq7rmoNM0mnWDfvSMTyjpCp7f7x7enWqYWEeXZoCFUAAAcYA6V5mNqKTUF0OujBxV31CGKKVxNFzk56d6kmt5WkDrJIg9O1cB428cSadcSaV4f2rNESs1yQG2t3VR0+pP/1642HxV4oik81dXuieuHIZfyIxXnSqwg7O7OuNGcldHurAhDjBbH61Rd7hUCTRrIp+8cY4rnfAfjM6/IbDUY0i1JVLKyDCzAdeOxrq72VobcsgBbOBmrTTV1sZtOLsyg9qFIK52nkGrdmzglHJIxxmmWNw0sb/AGjaNnO7pxTp51W3MlsVc5xnqBTd9heRdVivSsnU/DulaiS09oscp5MkPyN+nB/Gp7G6eQ7JwN3YjvUwvLcnAmTPuaNdgV07o4+78CbSWsb7jsky/wBR/hWRdeHdXtQT9mMqjvEwb9Ov6V6crK4yrBh6g5pahpGirSW547MLq3/18E0X++hX+dRfbD617PVaSxtJTmW1t3P+1Gp/pU8par90ePNeEjGabGl1eHbawTTH/pmhb+VewJplghyllaqfURKP6VbVQowoAA7AU+Uf1jsjzHS/A1/eESajILSI/wAI+Zz/AEH+eK7rR9A03SADZ2yiUDBlb5nP4/4Vq0U0kjGVSUtwpk5cRN5f3+1Ury+dW2W4BI6sf6U+wuHeGRrgqNn8XTiqt1JsRNdywRkSgSSH7vGOPepLK9M7bJVCt2x0NEkAlYyKQytyCKfBahXDHtT0DQephlkYI6lh1Aqwq9ABmoY7eNHDKOa4v4m+K5tJRdJ0pyl7Km+WZesanoB7n17CpbUVzPYcYuT5UdncvbCQQzzwJL2RpAG/KlS3EThulfNr2zyMXcszsclickmux8B+LrnRbqKx1GRpdKkO3DHJhz3X29RWMa93ZqxtLDtK6dz1m9H2iNZ7Nla5tzvj56+qn2I4rSsrlLy1jniPyuOh6g9wfcVWitlgkJX6VBakWWqtHkiG8yyjssgHP5jn8DXTF2djneqNeiiq91dxW6FnYcVsQWKTI9RWfH/aF9GWgiEMXZ5Tt49cVxniD4ieBvDcjxa14vhlulOGgsgZmB9DsDYP1xWkaM57Ilyit2eh7l9RSgg9K8rtviz4Qu1DQ2Hiwwn/AJbrpsrIB68A/wAqtWPxG0XUruK18IyX2t3rFg9lmG2mixjGVuJIic5P3Q3Q5xxnSWFqxV7EqrB7M9KorkV8V6qkxhm8E+IVlHVfOsP/AJJqb/hJtW/6EjxF/wB/9P8A/kqseVou51FFcv8A8JNq3/QkeIv+/wDp/wD8lVoaNq17qE7x3fh7VNLRV3CS7ktmVjn7o8qZznvyAOOtKwXNiivK/AviLVPEEup61q3iWPS7ez1eSyOkyQwrEkaHaFkZgJPMbqCHAz/CRxWYvxvUPqQfRYZ0t9Lm1O3ntbqYw3IjfayBpbeP3+ZQ69s1fs5XshcyPZ6K8l/4Wtq/lWUcnhFLXULqym1RIbrVEWM2saBg4kRG+dskbCBjGSRmsLT/AIn67rGteIry0QRaBD4bGrQwGZEngPls25SYWDMWGMNlQMN833aFSkLnR7vRXzx8RvidqmofDjVbbQ47m1urTSNNv7rUzfeVPG1w0TARiOMByQcMR5Y5OB0B9e8deJb3wxotreWGi3OrvJMsUgi37YEIJMsnlpI+0Y/hRqTptWHzI6mivntvijqEPivV/EdkseqaPF4fhvGsotRlWBf35Rnj3xDL+uUQ8EZ4561/i7LP4nm0zSPC2p6hb20ttHczQpK0kYmUNvCpEybVB53SKT2BHNN0pIXOj1eivGLz4xz3V3d6ZpWn2kjz2V7NY6lb3UrwM8CMx5kt1ViMfwFxngnmue07xv4skvvAOp3TJdTT6Je3k1ql80MN5sjDB5Ase1X+9hQrAHHzcnDVKXUOdH0RXBaXJ9h8TqM4CzlfwzXR+C9fj8U+FNL1yGB7dL6BZvKZgxQnqM9+e9ctr37jxDcEdnDfmAamHuyN6XvXR6xRSIwZVYdCMilr1jzgooooAKKKKACiiigAooooAKKKKACiiigArI12+kh8qztG23U+fn6+Wg6t9ew9z7Vr1yls5ur+/u35LTGFPZEOP55P41y4uq6cLLdm1GCk7voJiPTrZUiXOT3blj3JPc1Yt5AU87ZtYAnB9aqX6xp87gux6LUmnyyzI7ShQM/LgYryVpqdb1R4dY2wkmLzEs7Ekk9zWpPBEsR+UV0uueDbiC4efSgJYWOfKzhk9h6isdtC1ic+WlhOD/tDaPzPFYcljuVSLV7lLwVbn/hNNMeHIKyknHptOf0r2S4TzEK++a5bwZ4XfSJGvL5lN2VKqinIjB68+tb94WmCiHeCpzkcVpBWVjlqyUpaEqW+1HGMhhjFVLADdJCybQxyD9KsmO4khjBkKOM5x3qYoEUvty4GeO5qrmZXm8q1Cu4J5wAoqE2SOoeLlG5HtTjOsxEVyFR8/LjP+RUk7TQJGkCrx1JFMAs7Ywy7hkDHPvUF21w8rBXZFBwAvFTSNPPa8ZjcHnaeoptmJA585iyYz83OPxo8wIoZbmM8uXHo3NXHu1jgEjq2ScbRzzUYvbMtt3j67Tin3UkKRKGUurdNoz+NAC217FcNtUMrejDrUM97IrsscWcHGWNPitlyrofcGp7jCxM4QOwHT1paBoQ2lzJKHDxgMBkYPWnwySShlki2HHXOahs52eXa8ITPQg1HfGczkRuyqOm2nYCVrZVUlsADqTTI5LaWN4EkG5vUEZqVQ1zalJB846+9VJII4iPMYKT0zQMm+zbIGR32RdTzgU2a3fyESOQmPrwauTqJLdhw3GR71nRJcRsCrtgfwnp+VCEjQsQ6QhZCTg8E+leQfEaB/wDhN71pAdriNlPqNgH8wa9bubl4vL2x5JGWz2rK8UeH4dft45FYRXaDEchHUf3T7fyqJx5lYulLlldnl1pZq6AkVX1CxXBCjmupPhfWrdti2yyr03JIuD+ZFbWieEH85J9W24U5EKnOT7n0+lZuF9DrdWKV7nTQ3EsOj2byrumMSBgT/FtGaS/zc6WZohiaLEyezLzj+n41PdNE7LG0iBh/CTT1QQW77vugEn8q26HDe2oXOor9mjeH5mlUMoHuOK5H4h+MNJ+G2gjWPEZF1qkvFnpquA0jevfAHdug9ziui0+4svD3hN/EGtyiO1tLXzSzfwqB29z0H/16+EfiNqvibxj4hk8Q69Z3yJeybLXzInESIT8kcZIwQB6deT3r08PQVlOfyOerOzcYnp0finx58eNXksjef2P4dgwLiKz3KmD0U85kY46E4HXA79Ht8FfDRRZ6Lp8eqa1HxLcSYZkbuDJjg/7KAD1OauazEvw2+GOnaLpeItQvQVlmThiQAZXz6klVB9MjtXlUduzjJ719jl+Xq3NJani1a0WuabtE724+LOsyDENlp0Q9drsf1b+lXLHUNL+JYOl+IbSO01ZB5lnfWpKyIw5yp6gjGcZIOPavPPsfHXmtLQLLU7TVrC/s7O7kSOZWDxxMQcNyMgfUV6dXCR5LSWhzRr0at/ZP3kfQfww8RX3iHw3f6drkqyeKPDU5trpwMG4j6pL/AMCXn6j3r0O0lE0KsO9eOeD7W70z9pG5Zba4Wx1bRf37mNthkRsLk4xnan616poTnyCjdVOK/PcwpKnV0Pfws3OmmzVoooriOgy28PaK2sDV20jTjqo4F6bZPPHGP9Zjd0469KqQeDPC9v53keG9Fi85Gjk2WES71bG5WwvIOBkHris+Lx5YnxdqugXNhfWj6ZB9qur24eBLaOHBIkLeZuwcHqvHfFR+JfiZ4V0Pw5faz/a1pqUFmYxJDp1zFNKTIQFAXeBk8nqOFJ7VdpbE3Rval4d0TVbS2tdT0fTby2tsCCK4tUkSLjHyhgQvHHFF34b0O9uIp7zRtMuJ4oTbRyS2sbskRUqYwSMhSrMCOmCR3qA+LvDgNkG8QaQrXqh7UNexgzgnAKfN83PHGaJ/F3hu3luYp/EOjxS2pYTo97EpiKkBt4LfLgsoOehI9aXvBoF74Q8NX4hF94e0e58mFbeLzrKJ/LiX7qLleFHYDgVb1nQtI1yGKLWtKsNRiiO6NLu3SZUPTIDA4NUz4w8MiymvD4i0b7JDKIZZ/t0WyOQ9EZt2A3B4PPFZ1544s18T+E9L00W+o2mv/ail9b3IZI/IjD8YBD5zjqMe9FpBoa58MaCY5UOiaWUlgFs6m0jw8QORGeOUB529KZe+FPDt9dw3V7oOk3NzCFWKaazjd4wv3QrEZGMcY6VDfeLtJsdfl0q7u7aGSG2N1PLJeW6LAg/voZBIOCDu2bcHrVt/EehoLgvrOmqLeFbiYm6QeVEwysjc8KcjBPBo94NCKz8J+HbG++22WgaTb3uXPnxWcaSZYYY7gM8jg+tFn4T8O2JQ2WgaRblA4XyrONNocYcDA43AAH1xzSWni3w5exxvZ+INIuEknS2Ror2Nw0zDKxghuXIBwvU1kaj4+06DxT4d0mye0vrbVWvElvYbtSlq1tGHYNgEE84IJGKLSYaHV2FnbafZxWlhbQ2trEu2OGFAiIPQKOAK4jxem3XJT/eVT+mP6V0Ft4y8MXVpc3Vt4j0Wa1tQGnmjvomSIE4Bdg2FyTjmuV8Z61pLsupx6pYPpyx7GuluEMQYOVIL5xnPGM9aEnc2otKR6lo8vnaVZydd0Sn9Kt1yXh7xPodp4cBvta0y3+xKq3PnXUaeRuyUD5Py7gMjOMjpVx/GGji609Iry0mtL2Ca5jvo7238ny4hl25kDMB3KKwH8RFerF3imcE1aTR0NFZOjeJdC1uaSHRda0zUZokWR0tLqOZkU9GIUnAPY1rVRIUUUUAFFFFABRRRQAUUUUAFFFFABXK2iG2ubu0fiRJnkA9UZiwI/PH4V1VYmvWKTyQ3HmPDJGcCVOqg+o7j2rkxlPnhp0NqErOzKs8QlAz1FJDEYs+npWbearJpV+bPU4SW2h0mhGVdfXB5Hv1qRNe05hzcbT6MjD+leVKLi7SR2+zlZNLQuJPII3aWIgr0AOc0heWeDMYMbZwc/wBKpya/pyj5ZmkPoiMf6VQn8RyNxaWwUf3pj/Qf40JN7IuFCpP4YmzZ28kTMXdmBHQnNWuB6CuKuNQvbg/vbqRV/uxfIP05/WqN1EIpDI+ZIG53E5KH39ver9lJnUsvm/idj0PI9RS152IomAIVSD3FTwyzW/NtPLHjsGJH5Hij2Minls0tGdubeMybyOc5qvqDXAdRE21MdQM81kab4iYxxtqEYCOP9bGOh9x/UV0UciSxq8bK6MMgqcg1m7xdmcM6cqbtJFG2uZkOJhvX1AwalWSVrooyJ5LZHTnFWiik5IqvdNLHtWGNSMdWoIM57UB2C/dzxXC/Ey/ubHU/CVte311pvhaa7lGp3lvM0BQhAYUaVSDGjNkEgj6ivS8KkAklGDjkAZqLzWlTFqWQ/wAWV5q4ys7hLVWPC/id4o0fTdE0630rXdZur27E0WlSDVJIIUy+PNe4LL5iIRgFmYEdcjkes+H5Lp9C0qZ9Uh1KU2kQku7eQPFO4UBnUjggsCa3LKdvNMMpLt2bGKdctFCfnyzHsOTVSndJWEk0wa5iXYDlXcdQPu5pxZbeMCUtI/61FDLFcybWjZGxxnvVt4lZsmshlK5uWeLbAGQnqfSnW9uZoEMxJYcZPcVaECA8jNPYqiksQqjqTwBRcLiooVQo6AYowOuBWFfeIY1JSxTzm/56Nwg/qaxZrq41CVkuZ2ZQMlF+VB+A/rVRpylsdNLCVKivsjrpruzU7ZbmBSOzSAU0NaTyo0c8bMvA2uDXFCNF4CKB9KjnWJIy7opx7VfsX3Ov+zX/ADHojZ2nb97HFVIFuhMDI+U7jArjrc3FpDF5dxNHIRlgrnH5dKvRa1qEYwZIpf8AfTn9CKTpSRg8BVXw6nRNYqWJJznmjVA80KWUJ/f3Z8pfYfxN+AzXOXviy4srcyzW8LjOAFJBJq3rviqw8DaBFr3iZmOpXgENpYRj947HpGg9eRuJ6flm6VCVSVnsctenPDrmmvQf8QdOt9d1rw14XuAracN+oXMJ5Eqw7FjRh3XfIGx32Vg/E3U9J1X4XWmpQoGs5r2yKB02uhF1GrKR2ZSCCOxBrD8TXXi/Vvj/AL/CcNstro+nx2d812W8lmk/fFAQM7sMnTpjnrg898ZvC/ivUYZ9E01LW1j1W7OqW0Ec2VknjTM0QYgYZsCUDgEpIc5Na1kpYuN5fDZrXtucaT9n63MT4zSyz+LLSGQYihtV2e+WYk/n/KuRUAAAV3NnLbfEzTIi8q2HivTFMF5ZzDadwODkdcZBII6ZINZc3gjxBHJsFgXHZkkQg/rX6hgMRRlSTTR8TmMarkoNPQ5ur/hjwra+IvEcCTWNvMgYSXDvED8gxwTjvjFdNp/w+vyDNq88FhaoNzszhiB/IfUmuc8Y/EbS/Dtg/h/4eE3mo3J8ua/Qb8E8AIR95ueMcDtk1OPx9CnTadmyMFg606icdDrvhd4Y8N+Jvjp4ncaJpM2g6LYrb+R9kjMJnJGWKY2kjEgz7V6LpvhDwb83meFNAcsxwDp0JP0+7UvwD+HNx4K+HTwXwEeu6qfPvWJyYweFTPcqpJ/3mNdxcXOmeHIvKtofOu8Z2Ly592bsP8gV+f4pSqz5k7I+3w0bR5Ers5hfh/4Yl5i8D6Dj1bTIF/mtaGk+CNL0m8S80rwxothdoCFmt7WGN1BGDhlGRkVYbXtSmGVa3hB6BELEfiT/AEoF1qkhz/aEo/3UjH/stYqlHq2zr+r1FvZHH6t8M9d1HX/FeoyarZrFr2mtpjwpZndCmxlRgxlwSN2TwM9tvWsLWPhAlzp15Z3urS2wudDs9G8wWYwGt3RhLnfg5KD5ew/ir1FbrVoTkXrSAdpI0I/QA1Yh8QSplNTtQ0R4MkIJx9VPP5E/Sq5F0diHQmuifoeY678JP+Ej1m61W71q2uJb+CGK9gkt7lbeRosbGVIrpCBwDtZnAPIxmrGpfBuxvtJ8Z27XlsNQ8Q3j3KagbFWltY2dGMQO7LLlPVRznFeoLp9vcxC70idVD8gKcofw7f54qO3uiZTBcIY516qf5isJ+0p7maUXsec33wuvzq2vX+j+KZ9MfVriymdIbdlGy3iKGNmSVHIfOSVZCMdT1pPB/wAJv+Ecv/DNyNa+0DRbm/uAn2Yr5v2pAu3JkYjbjOTuJ9utepUVn7SVrD5UeTeM/BOpeMviJePcWs2n6J/YM+mfbXeJjJJI4IKIrFsDvuC9CPQ1k638HLqTStYludWl1G7uLKytY4rGySI5tmXaxWWcK2QoypZR1wegr1u58Q6LbatFpVzq+nQ6nLgR2clyizPnphCdxz9K1KftJK1hcqZ4fofw08Q6y2paprs8Oj6q/iGDWrUGBZVJhQqPMjSYgBsk7RKSPWtbRvhBNpdxplxF4jZbixuNSuVliswp3XcQQFcucFCNwznPTivWqqnUbJdSXTmvLYag0RnW1Mq+aYwcbwmc7c8ZxjNDqyYcqR47L8D7y7t9bGpeLZLu71TTY9PluZLWR2ykySeYd87cnZt2qVUZyAOlbvjrwtpaaCmg2tnbWlhNavEY7aFYlBPVgq8Zyc/Wu817XdO0GG1m1a4+zx3NzHaRHYz7pXOFX5QcZPc8etYXjv8A4+LT/db+Yo55O1zWlFcxxfhf4Mw3fw/0yA67cDWLfVf7TN/sdfMdB5aqwSRXACgYKyBgckEZrbg+DMcUNgkWqW1sLa01G2KW9rMVc3aBS/72eRgV6kbju/2a7/wN/wAi5B/vP/6Ea369ODvFM46itNpHnXgf4Zr4W8S6Zq66oLk2Xh6LQTELby/MKSB/O3bjjOMbcH616LRRVEBRVHWdX03RLP7XrWo2enWu4J513OsSbj0G5iBng8VUs/FXh69Zlste0m4Zbc3ZEV5G5EIODLwfuA/xdKANmiq9he2uo2cV5p9zBdWky7o5oJA6OPVWHBH0qhL4n0GGG9mm1zS44rGUQXTtdxhbeQnASQ5+Vs8YODQBr0UhYBdxI24znPGKxk8WeHXtLa7TX9Ja1upDFBMLyMpM46qjZwxHcCgDaorm08e+D3tJLtfFegNaxOsbzDUYSiOwYqpbdgEhWIHfafQ1uWF7a6jZxXmn3MF1aTLujmgkDo49VYcEfSgCxRRRQAVXulDRkHkVYqOUZQ1FRXi0VF2ZzeraZHq9n9imcR3UeWtJz1U+nuPUdx9K4YCaCeS2vI/Ku4TiSM/zHqD2NelXESyAq3XOQR1B9aratokGv2ETysYb6MFUuEHIIPQjup9K4oXqe71R62Exv1d2l8L/AAOEKRyoVLGNvUVWuUngCeXNHMzMFC7cH+dW7+xvNLkEepRCMnhZVOY3+h9fY81XjIF9CW6KrN+PA/rUtW0Z70ZKUeeDuh5tZ1UebPGh9FXJ/nTWk8lQis0hPAGOWp08uS0jngc0yyJjDTOP3r9P9kelIdnbURdNYnfNKLYHnZGeT9e1Pa3VR8l2/wDwJQaVmLkljk0lA1F9WNsgUaS2kYNvJeNsYye4/rVi0ubiwkLWr7Rn5o2+634dvqKpTvGw2b/3g5XZywP4VIss7x7praYMOCwThvfHWlKKkrMidOMvdlszsNM1eC+AQnyrjvEx6/Q960q88DRzDgg4P0IP9K04/E/9k2ry6xIDZRjLTngoPVuxHv2rmlSa2PKxGBcPehqjr2AIwRkUKoUfKAKq6bqVnqcCzWNxHPGRkFT2q3WR54xY1DbgoBpGhRiSQM1JRQBGsKKQQvIqSqmo6jaabbtPfXEcESjJLtjisC+1+a6TbYqYIj/y0b75+g7U0nLY1pUZ1XaKNrVNVgsF2n95OekSnn8fQVyV7f3V/IfOSaRc8RIpCD8+v1NR58kGQ55OSxyST70ouwRxMMf71dEKSWsj16GDjS1erIrhLpYtxjEa5GQDl8ewqaGWFYdlvjnliTyT71GjvcE+QAwHWRvuj/Gni0tg26UG4l9TwB9AK2Ot+eo15UTgsM+g5J/CpI7Lz1828LQxj7iZwxPqaWGZY/8Aj1tCD0ysR/nUN1PMI2d4Z8gcZQ0xNt6bD2t8E+RcsT6SDIP9ajWVlk8uZdjnp3DfQ0QSIYFIkDYHJzRaW11r1x9l0mPzCjAvct/q4vx7n2FCV9EOUlTXNJ6FvwzYrq3iITXChtO0395ITyHl/hX3x1/D3rjfGngzW9b+Peha74jvY5fDNlHJfiMgqllFBtba2SQSzFCT354wor07wprPh+WO90zRLyKW30icxXUpYZkm2gsx9Rz19QQOlc18T7u48S6LH4e0KfY2uR7rm6UbjFZZx8o7mU5A7EBj2op1ZKt7OPwrdnzmKm8XO6Xp/X4s4v4M/GjRNS8QeJotduodPlv9Re7tZJ2CK8RAVULHgMFRRz17V6Tq1tq2rQRXM3iLwq9nbTreQOdLnzGyHKtvW8GcdD0BBIIwSK8Gn0f4UaA76bc2st/PCdkk6B5ct0PzblHH+yMelcx43+GWmT+HpvEHgG+a5sYgWnsixZkA64z8wIHO1uo5BNZyoQnVdSErN+Sf57F1ctr06anKN/S/+R2Fr4e1Xx9481nU9D8PeFryKCcIddLahaJcSKoBMax3RHBGMjg4znmofF3iTxV4J1OTT9ai8KxRooJl/tbUpW56DyxcmUH3K4967P8AZ08c+GLr4XxeHtUv7axurZJIJ4pZvJMiMWO5TkHkN1ByDnpxXI/tE+K/CT+Grbwb4Igsp55blJZBp8alFI91+85OPU9c1rRxdeNb2VnZadtO/wDwDzqlKElzNHmniX4jQ6xcCGTQLDVbfjb9ruNSX5vZPtrD/PSvVfCnhqPwT4esPGmsaN4X8O63K3/Et09rK9vLiViBtwkl4ArHPoSoIyQTisjwb4O0P4P6Zb+L/iQUn8R4EumaGrAsjY4eQdiD+C47tgCD4WanrHxX+Penal4hd3isibxYDkJCicoqr2G7b9e+a9GUmzGMUj6QvZfHltYWpm1rw3He3KjdCmjTt5RxlsMbvkL0zjk445rIXSPFUStu13QGdjlmbRpizH1J+18muo1u5MmvSn+CBREv1I3E/qB/wGqcspds1hKWp6uHoWgn3OYksvFkT/8AIc0Haen/ABJ5f/kqkH/CWpkLr2hZ9P7Hm/8AkqugmVpTGgGctWiNPg8rBID1Cu9jokox+I5RB4xK865oX/gnm/8AkqlaLxcRzregn/uDTf8AyVWs+beYxucr2NDzDonzMegFHMyvZR6GLZf8JnY3cklnrWhZxlkOkTBJD7j7V1966CKHxRrkYUeI/DkdwnO06DMsif8Ak5yPcZFEJKqN/Ld6e67irozJIhyjqcMp9QaalpZ7GNXDxnqtH3K0UHjWK4a1uNd8PpIvQnRJjuHqD9rFamnWvimO9ibUtY0S4tAf3kdvpMsLsMdnNy4HOP4TWhaSnW7IpLtXUrXkMBgNnofoccjsR9KlsbjzkKuCsiHaynqCK5KsXB+TOLladnujzfwxoWseHtf8V2954dXWbfWtX+3xaiZoRGsTFSEmV23jysZXajZPp1rn7Pwt48svCt/dTy63qet3N+0YsZ9aZI4LXzGZZYzHLGS2CPlMq5HHGMV7lRS9oxcp4T4e8LfESYeHrTXbrWVsodSv/tkiar5chtWiXyCzJMzH592BuYr3PeneH9G+JttpenNqcV9e3UWgXVvPBNq+wSXZuCYtzxyZ3+VjEgOR0LA817pRR7V9hch88Wng/wCIV4JYdXtryazTWtKv7aO5vVk8lI9xuNu+4mYAHbwXJPUAcgdX8atN1XUfEvhVbCW7j01PtH24290YDtKAJnDAn5umM4r1yuL8cn/T7cekef1NP2jbuaUoLmseU6L4Z+Kd34T8Or9v1ZIEsZophY3KtcRXP2hysjf6VCsn7vaBudx1yhPNdxYeBfGGs+KfE11rviPxLp9obS2j0sW+oiGGSZrQxyyNFG7FCsuGwGA3c5Yc16Z4LXb4btPfcf8Ax41t16UHeKZyVFaTR8+xeG/i5eeCb+6vb65tvEDz2dsLKO/zutIUxK6MsiqssrncTvVsAjcuajvPDXxIXQbWO2ufFN5dwXVxMltc3EVvE6OqbI5JYtR8/ap3FT5jn1U4Bb6GoqiDzz4n6TresfBu90ax0yS71q8so7doIrlSEkwCxMkzruUEEZJLHrg81xXxB8E+JfGGn6RHY6I+l3OmaLIjzXFxDuvZCFX7C3lyH92wViWJx8wwRzXvFFAHHeCfEdzqWp3ejP4f/smLSbS1WZfPRhDO6bvs6qgK4VNp3BujDgV574t8F+Ir74jT+KrLw+stlbajZhtJa4iA1NIlkBu2+faHQyDYrEHCcjoK9zooA57wh4il8RR6tOLA29paX81lbyebvN0IjtaQDACjeGUcn7uc15X4U8G+I9G8f2nimbw7mxvLq+dtIjuYSdI8zYFmTMgQvII/n2k4DcY5Fe60UAfO0nhDxdL8FvGfhv8A4Ra+XVNV1WS6tka6tNpjklEmSwmwNojwR1yy4yMke+aI80mkWbXNrNZzeUoeCYoXjIGMEozL+RNXaKACiiigAppHBp1IaTBGdckJlj0HNcf45+J/hr4cWtrF4kuZRe3KNLHa28ReRl3HnsAM8ckdDXX6qwjjLHHUHHrzXyV8dPHni3w38SNUsNc0zSdW0Uy+ZYRappqTReUVB+R8BvY/N1zXNRglOTNZv3Uegn9qTwVdl4L3RdaNswIO6GJww9131TtPjB8MNQkzBfaropPAS5tDJGPpsLED8ce1eGL408Bak4Ou/DmG3c/el0jUZYPyjbcv608H4O3z4K+NNKJ7gwXCD+RrolBS3HSr1KLvTdj6Ni17w/qkGNM8UeH7kMQNv25InIz02ybTW9FZ3MwHkQ+fn/njIkmP++Sa+X5fB/wpuYw9l8Sru1LdI7vR5HI9iVxTIfh54HkI8n4r6aM8/Pp0yfzNZPDxO+Ob11ukz6nbSdSK4WzuFPr5RNMTQr5v9ZY3UhHd0OPy6V80p4J8MW6YT4yWUajoI7eY/wAmoXwt4aDAN8aIQpPOLW5P9aX1ddy/7Zq/yr8T6fg03UYxth06VPpERUx0zWDybWb8hXyy3hzSLVy9l8arZcdGEd0h/TNTLo0NyQn/AAvC2ORyJZbtR+Zp/V13Jebz/lR9L3Hh/UZWEhsplkH8agZ/H1qlrmg6pcaJqEUelz3LvbyKIcAeYSp+Xkgc9K+eV8LW8T4T43aasmcfLcXGPzBqK48O2yN+8+Nli8h9Jbph+YzS+rx7g84qtW5UVtC8EfGPwjtl0nR9YgTOfLjKyr/3wCcflXpfh/xx8ZbVFXUfAd5eovBPkPEx/E5rzi10eO2LmD42WcJY5YxzXgz78DmtWLw9plxDm9+PC726qGuHH6uP5Vc6FOeskeaqso6Jnr0XxJ8YCIm5+GniJWHUR25cfhzzWHrPxA+KmoZi0D4d6jacf6y6hYfocD9aqeG/EfhXQvh1rnhk/F6W61C+4t794J8WnTITqQDg5ww68e/m83gnS7pfMb4zaRLu/wCe0kwJHuCc1msHST2K9vMsar4L+MXiLWra713RL29iSdJDbPcRpCcEHBG/p7mvo8aVfiJGuLYW7Mu4pJNHuX2OGNfLa/DzStzLD8WPDfod0sqZ/TmmSfC7SHw8nxS8JN25uHJ/lWkqMWktjfD46ph78ut+59Q+XLGdoms1Po95EMf+PVWvI7V9pv8AVtHQA/da+hUfj83NfNMfwq8Mgg3PxS8NxqRkFUdiR+JFa8Xwk+HssKuvxe0kEjo1sq89+DJmp+rxOh5vW7L7v+Ce9HWNBACP4p8NRY42nU4uPyJpkuv+GLVN8vjLw0o/2b9WP6V4BL8LPh7BKfP+LmmGMf8APKyLn9HNMl8A/CiHG/4pu/8A1z0uRv5U/YRIea1/L7j3a68feBrNM3PjjTSAcEW6yTH/AMdFZF58XfhrFHk+JNRum9LewdT/AOPjFeJT+GfhHFIEXx9rEoPV00hsD88GnJoPwagQvceMfEl1j/lnb6cI2b6FgRTVGHYzlmOIf2rfJHqsfxv+Gcd0oXRvEepSMwUGZI/m57KHAP0xXq/iHxZcaboviy70iGK207RbARpEEUEXbDP8PA2ZUEeuea8E+G1j8LGm1PXtE0zxFOfD8aXiXOrTRLF527ESbU6ksCeeMIa774Q6jc/EX4beNbRNCFpFcRMiX7OWe/uWDks2QBwdnA6ZxQ1Z2iUpylRlVrO99Ff72/krL5nzJ8L7H+3/AIj6HpdzPKlvqF7HFcbGI3oWyQfrX09Pqc9xefEa4tozDf2U01hbRqOY4oYAIto7Dl2Huxr5CsL280HXbe+sZGgvrKdZonxyrqcg/pX1JpGtnxxqCeMPAbWc2s3MCRa94clmEUsjoMCaEtwTjI54IwDzRUjzR0M8FWjRrKVTY8p07w+Z4FklYru6Cu++HdmdOv5pdN0KV2EGyd7jXQsLdOdosyR0JAycDPJrp5tK015fNn0PxFayk/NbDTLg4Pp8qEH6qcU/xEthpeiP/wAJXKvhvQCu57FZV/tC+H9xUU/u1PQsTuxx8vWvIw2GxKqNztY+0zLNsDKglTk+byf57njXgfwLpfj7VrqLw94S142sUhE163iCGO1i5P8AEbLOPQAE47V2HgmbQ/h94xfTvDHhi18Qa8wKi/TXTcfZR0JVjZogx/eCn0yelcD4/wDi9qGs2I0Lwzbx6B4XhBSKws/lDL6uR94n/PPNetfBDQrXTfA9lf2yJJf6gvmzTk89TgZ9AO1evUm4q58ZgsKsTU5W9FqyW18Lumvz6tf+HF1nVHPmNcX3iBpShPpiyAH5Vt/CnU7rWPHXiTVPDnhzTxe6dBHp1w9zrrCDaWZv3e2zznKEEnHtWB8XPH1r4U0Cew0+5R9ZuF2qqkEpnq7emB0Fa37J9q9r8JfEmqPnz7q5kG89W2xjBz9XNRSu/eZ1Y1Qp2w9N+p07ap4sk3XDaJomJmaTnV5uNxyB/wAevvikOp+KAuTo+gY/7DMv/wAi10ccXngIhxGvHHerq6dDsAwtTubu0dLnJw6h4sOHXRNCx76xN/8AItSnUfFxOTomhZ/7DM3/AMi10NxCLVP9moCZWIEaA575ovYfLza3/I52W58Vy3CK2iaET/2GJf8A5Fq7HN4ojXA0Hw99f7am/wDkStJoJom81ss3cVOGJAPIoT8gcG9pHOXN54sjfcNF0Lb3A1iY/wDtrSDUvFf3V0XQmJ9NYm/+Ra6CcMy4Xv1q5ZrFFEAFGaAaaW5y9vqnjKyvIrmHQ9ELJkFRrEuHU9V/49vp+IFbIvfFMt1baodG0KOyuWVZjFrEzsvOCdptV5GMYyOR1FacjRsPu80ukTCO6eynP+iXnyf7knYj0z0+oFKUVJcrOatT5lzrdfkcF8Y9UtrLxv4Dhk12406O6vGS8ii1SS2V4MHaXVXUY3cbu/TPaqFr8TvEs+uRweXo62cvii68Oqv2aXzECLlJS3m4J55XAzjgjPHsWnuxg2S/62MlGHuKtVyqatZo5HHXc+afCPxN8R6H8NvD/nXltqd5cX1xbXdze/O+n7Xcqlw0lwgLP/DueMBRj5uM9dofxD8aa94g8N6VYWfhmOW901tQvWa4aeNQlyYn8qSF2VsqMgc4JOTxivaKKbqJ/ZEovueD+H/i94gnHh661eLSlsNWg1R2+y2czSW7WgYhseYd4IA+UYPXkV538QviFfeMvDXiO3u/sctvFZ2k9vPbxLEWVp0yGRZ5gpBPTcCMYIB4r68rgfF7btclH91VH6Z/rTjUje6RdODk7XHeKfFt94R8NeFUshZW0Go3Qt7jVNQRntrFDk7pArL97oMsoz1Ncn8SfjRqHhTYNI1DRNakhtIbqby7Ly4bhHk2loZTd5YYPRElwQdxAzj2/QU8vRbBf+mCfyFXq9GGkUck3eTPDdY+J/jS3n8c3mnaVot3o/hy4+zBMTfaWLBNrkAlSqhmZsYOBwBya57xt8RPE2p6HetY6rYx2Oka7YRHX9LjljtbqKQZbJExwqNgON5DZAytfSdFUSeB33xM1TRtQ8Rm1k02eMaxplh/ac0s72cEc8G5rlkaYqkeegRkHzDJJ5Op8A9RFr4C8balJcRziHXdRuGnt4WdHwFYskYYkg9QoYk9M969oooA+bI/j3rr6X4mubWHSLxbDS4tSsp/s/lB91wkRWSNLmXH3ycF1YY5UVr3viTxrpnxT8ON4j1HTLcXWkTyLp9mZja3cglykKb3UG4ZSqg4OCfukECvfKKAPnHTvjh4puNB1zUZbDQAbTTJLtIPOjE1vMsoUxyQi5aVl2kfMUiIPVQCK2fE/wATfHXhKy0W51vStCuhrltJHYpp6zNtvGwYEcswyGDDIAHIOGFe61k6z4d0vWr/AEq81O1+0XGlzG4tCZHCxyYxu2ggMQOm4HHbFAF+w+1Cxtv7QMJvPLXzzCCIzJgbtoJJAznGSeKnoooAKKKKACg8CiigDJ1zVBpsHmiFHP8AtHFcfq/iPTdatGtNZ0exv7VusU4Ei/kQa7DxDC0unyBMbgMjJxXmzG4DEM0YI7b2P9K5qs5RejPby/DUK1N88bv5nJa18Mvhhqrb/wCwrjTpCME2V4VH5NkfpWN/wo/4bOxIvfEaD0FxCf8A2SvRC1xjHmx4/wCBGlSC4kOFZGPosRP9az9tM7HlmG7W+bPNZfgP8Oyx2ax4kT23wH/2ShfgN8PfLCnV/EpfP3g0H8tteojTdQbH7lyP+vdj/Wj+yb48m0b/AMBT/jT9rMz/ALPwvf8AE8ob9n7wSfua/r6j3iiP9KY/7PPhEnKeJ9YA9Daof6161/ZF70+yce9oaG0e/Xn7Ccf9exFP20xPL8L3/H/gHlA/Z58GhRnxNrRPfFugob9njwcV+TxPrCt/tWyGvUpNPuox+8ttg/2o2H9Kh2MvBtkI9Qf8cUvbzGsrw72b+/8A4B5X/wAM5+GSzY8YX4B+7mwHH1+bmk/4Zw8Of9Drd/8Agu/+yr1UIh625/76/wADR5EZ5CyL/wADYf1o9vIr+yaHd/h/keRH9m7SCx2+OmA7btKb/wCOUrfs16UBkePB/wCCtv8A45XrLCFOC0gP++1IrRdpJv1/wo+sSE8oo93+H+R5Kn7Nemk8+O0A/wCwW3/xdRTfs22a8ReOYW/3tNcfyevX8qThbiX8gf6UBSePNum+kf8A9jR9YkL+yKHd/h/keNL+zhACPM8a2+O+zTpCf/Qqu2f7NmlyyhZfG7YwSdumEYAGScmTgAc16yEQD5hdN9Q/9AKq6y4Swjs4FnE2pMYn5clbdcGQ4PTdwgPu1H1iW5UcnoSaim9fT+tFqcRqXwo0jxvY6dcz+ILjSrK1hFtZWi2fmFYF+VGY5HzMBuPuxPes7/hnHw5/0Ol3/wCC7/7KvTQtuFCx2kwVRgAFgAPTk05fL6LZSc+p/wAWqY1pRVjWvltGtNz1X3aJaJbdEeXN+zn4cC4HjG9LY6jThj/0Ohf2dfDg+/4u1Bj/ALOnqP8A2evVPKB4+x4B9XX/AOKpwgx923iH1cf/AF6r28zL+yaHn9//AADy+L9nnwmufO8Uau/+5aIv8ya0IPgL8O4h/pGq+JJT/vwqP/QK9AaDP/LK0/EZ/wDZauWAhtPOvr1LcWVnE1xPsGCQo4UcdScD8aFXkxSyuhFXs3/XoYGneDfCGgXkfhW0tLiXQox/aGoRztveed0CxxuRjhVy2Onze5r1nSNY0O3tIrSx8qyt4xtjhWLy0QegA4FeV6YLh4ZrzULbzby9ka5mOFYgt0XB5AAwMe1XF8hvlQNE/oCVI/A8fpUxrSTb7m9fLKUoxp3fuq2nfq/v/Cx5v+0P8DJZprzxd4LQTwyZnu7GPkgnq8eOo6kjtzjjgfMEUk9ncLJC8kM8ZyroxVlPqCOlffukatd6TMGjbzLcn5kPT8R2+orzX44/Bqz8VWE3ijwLAseoKC95p6DHm9yyDs/qOjduevTTqqR4WLwM8Pruu/8AmfPEPxH8dTIlrD4p15wRsWNbyQk+w5ya6PRfhR4q8RH7drs7WkT/ADM9y5eZvw/xNdp+zloumDS769kijk1hJzE4kA3RKAMAZ6Z9a9p8mMr/AKR+9Yj1wq/Qf1NZVKzTtE7sHlsJwVSo736HlVp8CPDdvB5d3cX1xNjmTzAoz7ACvJPFWr654D13UfDWia5drpts4CLkZAZQxHTj73avaPiP8VLDwtFJZ2EiahquMKgOVi/3yP5da8f8I+ANe+It9caxfTi3t53Mj3Mi5LnOPlX07UU2/insPFRhdUsKvf627ebPOZ5pbiZ5Z5Hllc5Z3YksfUk190/ACwNt+z3a4XDzxXExHr87Afoor438e+GH8J+KZ9JM3nqoV0k24LK3t+dffPwasfsfwo8NWsqYzYqzKf8Aby3/ALNXRpLY8dqVKdpbplWAhV+XgU8TMD1qC4jGmztaXLhGjOFLnG9exHrxjPvmmLcROf3bh/8Ac+b+Vc22h7itJcyL07+bAQ3pUOnyBYVLcnFVLm7UKItwTd3f5cD8anjwEUKRtxxRcXLpYutMjoQaooDLI6A49DSswAJPApbQ5HmYxmjcEuVaBLazQplWL455pscgYZU1d80t7ist42kuisOR6kUPyCLb3LOTUNy52NsOJANyn0Ycg/nU/wBiutnD/pVHmETiX/WKpP14pFKz2OwkZY9XJX7tzGso+vQ/0q1VfVohC+mP/cBj/Qf4VYHSuasrVGjyIu6QUUUVmUFed+KG3a7dEeqj8lFeiV5tqWbnW7gD+OcqP++sVUdzWju2es2ieVaQx/3EVfyFS0UV655oUUUUAFFFFABRVS51Kxtb60srm8toby83i2gklVZJ9oy2xSctgcnHQVboAKKq2uo2V3dXVra3ltPc2jKtxFHKrPCWGQHAOVJHIz2q1QAUVXv72106zlvNQuYLW0hXdJNPIERB6sx4A+tSwyxzQpLC6yRSKGR0OQwPIIPcUAPooooAKKKKAI541kQhhkVzkllYxTMq2kJbP8eWP6munoAA6AVMopm1KtKnovzObjiVP9TaIvpsgH88VaRbxh8qSgfXbW1RS5CpYhvoY32S7bqP++no+wXR/wCeX4uf8K2aKfKifbyMY2F2Onkn/gZ/wpPsV4Oip+D/AP1q2qKOVB7eRiiC+XojfhIP8aQrej70cp/EH+tbdFHIg9u+yOeeBmOZLXcf9qEN/SofssHexh/GAD+ldPRS5EaLFSRyr21kOXtLdf8AgO3+tMFrprA/6NAfo7f411tIVB6gGl7NFLGT8/vZyf2HTWH/AB6oR7St/jTG0vTD/wAu5H0lNdaYo/8Anmn5Cmm2gOMwxH6oKXskUsdNdX97OTXR9NJ5icDuTLgAetYXha1tNVlutburffFO3k2Ku5Gy2QkKcerHLH61veOz9ojsfD9gBHdatIYpHQANFbqMyt/3z8v/AAKupt7O2toIoIII0ijUIiheFUDAFR7NOVux1vGTp0FJt3ntrsl/m9Pk+5zX2PTe1nB/323+NJ9l07ta2/5n/GurEaL91FH0FOxV+yRx/XJ9397OVS0tMDZZwH/tnmni1hAyLGL/AMBwf6V09FP2aJ+ty/pnNLbRDn7FCPrbgf0rA8RxwX+r6ZoMUESwsRqGoBFChokP7tDj+8/P0WvQLmeK2t5bi4cRwxIXd26KoGST+FcL4WH2qyvdZuov9P1iX7QN45ggAxCv1288f3jWc4r4TswlaVpVn00Xq9vuV36pGrJoumXIysDRH1jcj9DmsbVPDMiozWzC5jHOxhhx9B3/AAq1e66lnMYrZBPMOGJbCqfc+vtVaHxNcRTD7bFC0H8RiyGT3561zT0dtzpo/W4rmjqvP+rnNAtBKYpcmNuBu7f7JrV0q/m0u5Wa3YlD95D0Yeh/xrc8TaUl3bvMozMBlsD76j+o659K5CB2+aKQ5de/qOxpJ21R6FKpDFU9V6o4r46eCbyw3/ET4dvJbTEbtStoBw3rIV6H/aH/AAL1NfPmufFLxbq9u1vPqTQRHhlt18sn8Rz+tfanhzVFsrhop8PZzfJIpGQO2cfz9q+T/wBon4bHwJ4saWxjP9jXxMtqeuznlPqufyIrrpuM9WtTwcXTq4SXs4yfK9jnPhT4Mk8Y+IT9p3f2bbESXUn970XPqa+srC3jsLeKG0hSK18pVVF42AdMD8a5D4T+HE8M+BbeKQbbm5T7ROT/AHmHT8BxV34i+JU8OeBrnUVOJzEIYQevmHgfl1rCpJzlZHsYShHC0eae+7Pnvxzd/wDCV/F+RLUeajXKWkWOc4IX+ea/QjT7WOxsLa1hGIoI1iQegUAD+VfAH7Oumf2v8XtAR/mCXHnnP/TNTJ/7LX33qt/DplhNd3JPlxjoOrHoAPcniuuKUV6HzdSUq079Wx99cWtrD5t7LFFED96UgDP41zd340tU+XT7Wa4x0Z/3SfqN36VyN/dz6leNd3pzKfuIDlYl/ur/AFPeoJJFjXc5wK554h/ZPbw+UQSTrO77dDpJPGd7tYvYWmzHIMrHj8qk0zVNH1CSOPUNOXT5psEPG+EYnoCy4wfqPxrkmWSaWGJoikch5LHBwOTxU92UfeGGUPG3HX2qPbSWsjplgKFrQ93zTZ3GpeGbdYjLBdNCqckTtuj/ABJ5H51gpcRxyNFI8Jx/FFIHQ/iP64rStLe7vILd9Zk80xooWH+HIH3mHdj+Qp+sIsUC3gVS1t8xBGQyfxKfUEZrGWKjze6tDyqdScfdk7lBmA+7TrJ0XLpgkmta/wDDxX97pZGw8+Q54H+6e30PH0rBiHkySRMrpIDlo3GGX8K6mnF6m9OpCrH3WR6vqGvwXKjSdO0y6tymWe61CS3YNk5AVYXBGMc57njjJwr+78V3CFf7D0EO/wC7BGsSk5PA/wCXX1NdKzFqt6Fam+1SMgZgtm3yN2LD7q/XOD+HvTXvaCklTTncg1278aGCAyeH/Dq7ZRgrrkx7H/p0FIl7402j/iQeHf8AweTf/IldbrmPs0YPeQY/I1DH9wVz4lpVNjzafwnM/bfGn/QA8O/+Dyb/AORKPtvjT/oAeHf/AAeTf/IldRRWF12Lscs1/wCM1UsdA8O4Ayf+J5N/8iVwWkXHim51u1KaNorSNMH2tq0oB5zyfsx/lXrWsS+TpV3JnpE2PrjArkvA0Pm+IoWxxGrOfyx/WtaWskrGkdISdzpPt3jj/oXvDf8A4Pp//kOsH4oweIdX+EHiq1vNIt11KW1ZILbTLiS9Mo46ZijO7rwFP1r0iivTPPPA9J8M+IfBHh/V/EdhpcllNdafZ20OjeHAHkEild08gkgIDnJDAROQCep5FLTdc+LWp/YtOWfUtPaXWpbY6lLo3mbbQxBkdw0MQIDZG7ZHk8Edq+iaKAPD31n4kw+LfsbNqUsqa1FarCumKLGbTdg33JuPLO2Qnnbv4PG01zHhDR/EejaVpmnvY6tc3UPjeGS4ivdHSWKG2Z5d1zFIYcDPBMiN8nGNm7n6XooA+d9B/wCEw134peBNS8T2ms/abG+1VbqFtNMVpYRmIrFslEYDhwB8xd+QAMd9H43+L/GXhvUdfuLK8v8AS9ItNNil06a209J4bi4aQBxNK8bhMAnC5TPHUnB93rI1PwxoOq6jDqGqaHpd7fwgLFc3FpHJKgBJAVmBIwSSMHqaAPE/tPijQ9V8balZ6V4hM+p6jpoS5sbYfd+zYeQ7oJt0atw2yNiDxxUmh678UdTi8LW1+dYsHmbVY9Quo9KQH91GGtmbzIcLubIHyru9M9Pf6KAPmDxVqnxH8SeBzp+vWWuwpd+HmbybPRy7Xd75pBSbETGL5BuAHl5J4PQV9F+FopIPDGkRTI8cqWcKujjBUhACCD0NalFABRRRQAV594t+KemeGta1XTrjSdYu20q0S+vJ7VYPLihc4DfPKrNz2UE16DXlXjr4Naf4x8R61rF/fBLi8s4YLRltgXspom3LKrbvmz0K4GR37gA7lfFnh8SafDNrOn291fxpLbW1xcJFNKrjK4jYhjnPTFYnh34peE9cbVxHq1pZ/wBmXzWEhvLmGMSMCAJE+c5jYnCscZIPFcpqvwZl1XXrnVtR1yG9uL9bZr6Oe3uUillgUKsiJDdRhemcNvCnO3A4qXVPg49/aa/p765AdL1bXRrzQyafvdJCwLxlvMAZCFx90Ed80AegP4w8MpJZo/iLRle9UNaqb6IGcE4BT5vmGQRxnmnx+LPDsmr/ANlR6/pL6n5jQ/Y1vIzN5i/eTZnduHcYyK8/8T/Bm11O71tNJ1G30nSdagtbe8so7AN5awNlfs7B1EWccjawzk9ayPDXwr1i58TanPrdytho9v4sbXbSBY1lmutqgRsZRIdi+qldxx1FAHa/Db4maP4z0SK6luNP03UX85m05r5JJUjjdlMhGFO3C5zjA9a27fxv4UubO5u7fxPoctrbbfPmS/iZItxAXcwbC5JAGepNcDofwYfSF8MNbeI2S50NNTCzx2QV3a7VgGGXIUxlsjO7OO1Y158A73UbbWBqnjGS7u9SsIbKW5ltJZGJjuEm8w+ZcNyQm3apVRnIA6EA9ch8X+Gpop5YfEOjyR28RmmdL2IiOMMVLsd3C7gRk8ZGKE8X+GpNQjsI/EOjtfSOIktxexGRnIBChd2ScEce4rzP4ifCiPWfGfg9NB0uLT/D8KSQautr5cMDWyyrOkPlggndKGPC4+Yk1p6l8Ihe6hf3R1oIbrxFba+F+yZ2eUpHlZ385z97t6GgDu08WeHZNYOkJr+ktqocxGyF5GZ946rszuzweMdqji8ZeGJUvXi8R6K62Izdst9ERbjO3MnzfLzxzjmvF7D4W65/wl+l6eLa6i8LWOo6hePd3AgjlInQphWSeRpCeMFkjIHUE8Db0f4IXej2EsOl+KmtL1LI2FpqcUNz9qgiMofZ81yY9vBBCRpycgrzkA7TxD8RNLsbXw/c6LLZa5barrVvo5ltLxWSFpd3z5UMCRt+7xnPUV0eueItF0BYm13WNO0xZiRGb25SEOR1xuIz1rzHSvgvJZypLN4h86QeIbXX3/0aRtzQqwMe6SZ3O4tnczMR710XxJ+H9z4v1GzvdP1aLRr21haGO+hhn+1xBjltkkdxGuCOMMjjrQB0g8XeGzqMenjxDo5v5HWNLb7bF5rMQCFC7skkEED3FPsfFXh7UNUl02w17SbrUoiwktYbyN5UKnDZQHIx344ryOH4Ua5rHizxMNYvvsmhXGrWV+kpiSW4vfIjxkOHxF82c5Qk9sDrqTfBq8v/ABVBq+ueL73UFi+3RhXjkEnk3MTR7FYzGNNgbIKRrnHI6YAPQovGnhaaG7lh8S6JJFZ4+0ut/EVgycDed3y8gjmtTTdRstUsY73TLy2vLOQZSe3lWSNgPRlJBrzC6+E2oXvgvR/Dd34jgFtok8Fxps1rYSW8itFuA84pON+Q3VPLbPIOa63wL4Mt/DHhm60eQ28sd1NLLMbcToHMgAYnzZpXye53/gDQNWvqM8Fg6zqmp+JpRmO4Y2lh7WyH7w/33yfoBXYVDZ2sNlaQ2trGIreFBHGi9FUDAFTVMI8qsbYmsq1RyirLZLslov8Ag+YUUUVRgFFFISACSeKAOS8du2pS6d4agYhtSk3XRU4KWqYMn03cKPqara5M1vpTmDMZdgmV42Ant6egqx4Kzq+o6n4mkyUu2+y2Wf4baMkAj/efc35Vf1eyjDNHIqSQTHOw9QevT0z3rCzknLuevzxoTjh39nf/ABPf7tF8jzqfy0tWQqOmEx1DdsUqwSSOsMbyXFyw4jQAAn39q6aey0eydWmt/NcfdQuzH8icVEt1OgIsIILKM9o0GT9TXK4STsep9c5vgj951MMbR20UZbLooG71IFcP4j082d4JIF+RsvGPb+Jfw/wrUh1LULdsvIJ07qwA/UVo3CQazYERcOeUz1SQdj9Rx+AqVFx0ZwUJSw1Tmls9ziQ+ZFZTmOUZHsR/nNT+O/DqfEX4Y6ho7KG1WzXz7Rz13KOB+Iyv4g1VZGSWS3I2t9+MHjDdx+f861/Dd+LPU7efcRE3yv8A7p9fp1/CtKcuWR6ONoe3otLdao82+FHiePxJ4djguwBqen4huIiccjgNj0OPzrz/APad1SPbpemRt+9ZjcyKDwMDaOPfJ/Kpv2g9O1H4cfE99a8PObWDUQblCo+RiT86EdD83OOwYV4j4j1y+8RatNqWqzebcy4BIGAoHQAdhW8KVp36Hk1cx9ph/Zte8/yPb/2M9KN38Qry/Zf3dlZuwb0diFH6Fq+lvHlwL7UINNVyEgXzpMH+M/d/IAn8RXln7GWlpZ+Dtb1eQAefOsW4joEUsf8A0MV2kVy11dzXs3DzsZmz2B6D8BgfhRWlaNu5OV0eao5v7K/FlWBy0AZ+CMhvqODU1rGqRLdTDdM/Manog/xqqqGS2C9pGy3sCcmrbtuPsOlch9G1fQYHY3fmNnhCAfcn/wCtW14c09ZiL+flFJ8pT046t/hWHGftM6W8BJkkYJkDIH+RXdC3EVokEA2oqhQPauetL7J52YVuVKnHqRvfKJVVF3of41PSm66QNGvc94WH5ipLe1SMEHGTziqXimTZpLp3ldUH55P6A1i+yPLguaSSMSTWdVkfedQmQjosYCqv0GP55q0dfknVE1e0jvY16Sx/u5l9wRx+A21jsoZSp6EYNNt2LxMr/wCsjOD7jsa9BVJLqe9LCUWkuW3podzoun6LqkRmtp7idVOHikkKlD6MBg/nXSwQxW8SxQRpHGvRUGAK8mgup9PuVvbNis0fJAPEi90PqD+ler2dxHd2kNxCcxSoHU+xGRXXRmpLbU8DMcPOjJXleL2M/XGzJaR+rlvyH/16BwBUWpNv1iNM8Rx/qT/9YVNXDXd6jMIK0UFFFFZFGL4vl8vRJFzzI6p+uf6VS+G8G67vJ8fcQIPxOf6Uzx3LiO0iB4JZiPpgD+ZrX+HsHl6NJKRzLKcH2AA/nmujDq8kVUfLRfmdRRRRXonAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVy3xAu5v7Lh0ewfbf6xL9kjI6ohGZX+gTP4kV1Nch4f8A+J54v1PWm+a0sc6dZehIOZnH1bCg+ims6mq5V1OzBpRk60toa/Povv1fkmdJbwwaVpccFumy2tYQiKOyqMAfkK5jVruWJQVObmc/ePYV1WpAmwuAOvlt/KuP1gfvrdz0ww/HilU0VkXhFzycpatmaUEMTyH55MZJPc1aYYCjvjmq16T9nKqMs+FA9zUh+0Hk25z/ALwrA9Nj6dYzC0vATxFNhWPoex/OmKrhf3gUN6A5rF1jXrKxna1uYdUeTaGzb6Zczpz/ALccbL+GaGrqxMrNWexueMrEu8GoRgAucN7OOD+YrnjhJiB92TLD69x/X8a07fxppeoaO9tcWviAs68FdAv2w4+kPcDNcY3imyaJkNrrXnxtkD+xrz7w7f6rjIrJxe50YHER5OST1j+QftFaKfFPwfi1KMbrzRZQX9TG2Fb/ANkP4Gvi4jBxX3VonivRNQ0/U9Iv7XXHtNRt2iYJod655BBwBEexPPtXxJr1jJputXtlMksckEzRlZYmiYYPdWAZfoQDXZSba1PDx1NU6zUdv8z7h+BVmNN/Z8hdRtee3uZjj1ywB/JRTmGYWRTjcMZ9qo/C/wAVadD8E9N0+S11xp/sMseYdDvZYySXxiRIipHPUGs9fFmnMqkW+tcjP/IGvP8A41WNdPQ9PKZxUZpvqb6YIYD+A4P5VHjz5TGSREnMhHU/7IrCg8XacUmCW2tO5kyVXR7skYAH/PKiDxPaPN5MVhrqO5zzot4cepwIiTXO00r2PVlXppNuSO68M26zXjzhAsVuNiADjcev5D+ddDM8qsvlorL3zXK2Xi7RdPs0hS28QBF6s2gX4ye5P7moJPF2nSSmZIfETc5UjQb/AP8AjNcjjKTu0fP1qqqzcjpre3f7YJnJJ5yayvFkwa7srbP95z9cYH/s1Rw+ONNZcyWPiFG9BoF+f/aNchrfjHT7m9uJ0t9a+Vhszo14OF/7Zcd/zqoQk5K6NcHaVVNvY2uhxUDyrBcBm6SKV47kdKypfFenFgwt9awwz/yBbz/41UcPinTXvkd7bWisQLf8gW8PJ6f8sq6uV3PcdaFr3X3m8bbKh7sZY8rH2X6+prvvAc6yaEIAfmtpGjP0J3D8MMB+FeTSeLtPdyxt9ayf+oNef/Gq6DwP43021v7yKS214rLGrgJoV85ypIJwISf4hzW1G6mefmXLUw7d9Vqd0D5msXb/AO1tH4DFXa4qz8b6UZ53+y+IDukY8aBfnv8A9cau/wDCcaT/AM+niL/wntQ/+M1yNSbbseNdLQ6iiuX/AOE40n/n08Rf+E9qH/xmj/hONJ/59PEX/hPah/8AGaXK+wXRmeMp/N1fyx0iQL+J5/qK7zwvAbbQLKM9Sm8/8COf614tP4ssNQ1d2FvrZE0vGNGvCcE8cCLPSvUU8daOiKi2fiQKowB/wjmo9P8AvxXbhotXbDEySjGKOsorzX4r+Mdb8O+EbbxH4bexFs8sMLW2p6bOspMkgTdzJGyYz91kyfUVPrnxIt/Cc0+m63DdavqVhZf2hqM+lWixQ28BfarFJZiemPlVnPBOAOK6zjPQ6K8zm+M3h5L2eNLPVprOG8trKS/jijMKtcKGib7+8qQeoXI9OlQ6j8YtIYeJbbTYrmO60aO4Mks4t2wYVyxFsbhJ3XsDtUH+8OtAHqVFebfD7xZqWvfEDxDZ3N15mmQ6Zpt3bReQsexpo2ZzxlueOCzY7HvXpNABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAGB431WbS9Bk+xc6jdOtpZr6zOcKfw5b8Kv+HtLh0TRLPTbbmO2jCbu7Hux9ycn8awIP8AifePpZvvWGgoYk9GupB8x99qYHsWNdfWcfek5fI7a/7qlGj1fvP57L5LX5sQgEEEZB7Vz17ZCFlimCyRnJQn29ffmuirJ1tGE1tJ/wAsxuQ/U4x/I1U1oY0JNSsciYlS9mO7cI2wg/u08ux6k02+SS2umULuaZiyHt17/nUf2WNgftMjux6hTgCuY9pWaTCGQy72/gzhT6j1qOOVTdSqCW6dBkZqVbaI4QySsuPuZA4qU4UbEUKo7CkO5d0KUpcSwg43fvE/3h1/z7VleLrQWmqpeQriC5AJ9m//AF/zqeOUwTxTD+Bsn6d/0rc1mzF/plxbEZYDzY/6j/PrWUlrYyjU9hXU+j0ZxFjcNYakksfADCVB/wChD/PrXg37XXhX7B41tvEtmn+g6zCrswHAlUBSPxG0/ia9vw7xFT/r4Tn6/wD6xU/jHw5H8Q/hZqGioobULUfabMnruGSB+OWX8RWtCVnY1zajzQVRdPyNP9nG5F58HdEVsExedEw+kjf0IrLu4m05ri1YfPbuYgD3/u/mMH8ayv2RdQMvgfVNMl/11le7sHsroMfqjV3nxA0vbd2+qIp8viObHQN/Ax/MjP8Au1pVjzQT7HFldf2dZwf2vzOdQm3t4reEFnOBhersa6vRtNWwh3OQ9y4+d/6D2rI8L2olvJrpxkRfImf7x5J/LH510zuqDLsF+pxXlVZuTsdWNrXl7NbIrXaR3JEW9d6nO3NRESWkSpCASWyQfSmQXatIxeIJJztOeM+9XrcuyfvlG8dx3qNjh2G3s4trKac/8s0LfpXCRg+UA3JI59z3rqvFMoXTPK7zOqj6A5P8q5mtaK3Z62Ww91zI1lCWEe48plfyOKljUwwbW/1r/M5/pUFrCDcTSOciNgVXtkjrUxJJJPU10HoJa2GRNvi3EYZWKmtrwc+zxNb5P34pE/k3/stYULBZp48jJIYD8K0dEk8nXtMk9Jwv/fQK/wDs1VB2kmZYqPNRmvJnW6Uu1px3EjD9TWjVGD91ql7F/wBNC358/wBavVg1ZtHzT11CqGu3H2bSLqUHB2bR9TwP51frmfHFzstYLZTzI28/Qf8A1z+lCKgrySM3wLa/aNejcjKQKZD9eg/n+lem1x/w5tSlldXTD/WuEX6L/wDr/Suwr0qEbQMMTLmqPyMrxN4e0vxPpZ07XLX7VZ+Ykvl+YyfMjBlOVIPBA71m+JfAfhzxLfm91nT2muWg+zSPHcyw+dDu3eXII2USJnna2RXT0Vsc5yVx8OfClx9t8zSVxeXMF5MqTSIGlhGIiAGAUKOwwPUGo774beF9Qu57nUrK7vp5oZbcveajczlI5QRIse+Q+WCCR8mOK7GigDE0Twto2iajcX2l2fkXVxbwWsj+a7bo4V2xrhiQMA4yOT3zW3RRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAVwPx5v7zTPhF4lvNNurizvIYFaOe3kMciHzFGQwwRwe1d9RQB4Naax4j8EaNrniLUZtTsNCnjso7C31eU6rKJmAEkh/wBIAjRj03TKATk46VT0z4xeMNYsNMt9MsfD/wDbF1r1zo2+4Di3YRxK6Sfu5Hx97nazg44POa+haKAPCrf4w6r/AMLH0/w8Rp11BJqD6bdhbU28kEqpnK7rhndc5wzQoCBwc5xyrfFrXPGHgO9tbxNGuU1Pw3qlxeRafFIsmmtGsip5pMjjDgDAIU/MOo6/TzAMCD0NZnhfw/pnhbQrXRtCtvsum224RQ+Yz7dzFj8zEk8sTye9AHhvhf4mal4Y8LjTtTayFlpvhbTdRtbmCwkldBIEj2SR+cA/UfMGjHc1HY/GjxdqQgstMs/D8mpTa4mlRzShhBIjxF0f91NKAcgZKu4x0r6KooA8Yi+IXjSD4k23gfUNO0g6rPNb3AuoIZfs/wBhMTNO4y+dyuuxScAk8isfw18YfFN4fDlxe6fpV3BrNvqrpa2cEscyyWasygM0jBt+AMYHJ69q9qj8P6ZH4mm8QLbf8TiW2Fm1w0jt+5DbggUnaozzwBk9a05EEkbI24BgQdrEH8CORQB876f8bvEkkNzLHaaLrEi+HDrP2XTopFkt5vtCxGGQmRs7FYs3Cnjt3s2Xxp1g6Fc3OoTaJC5u7aC0uLVILlJBKjllmRb7bbkMvDSTAEA/LnO32HQfB2i6FqtxqdjBcPqU8Qgku7y8mu5TGDkIHldiFzzgEDNdBQB88+C/F17438f/AAy1nVLaC2vmt9XhmS3z5e5Nq5XJOOg7n611Xi/4lanonxQtfDytpa6bNLbwL5Kpe3jyScsHhW4jkiUL0by5ByD3xXrlFAHz/wCHfjRrV9q1nFcjR7iOWXUUurSxtZXubKK3BKTsBK25WxjbtXJ6Hnippfx1126g8Qva6fY6slnpceo2klvB5JIaZY2MkaTzEBQxYjcHAU5Uda928N+HtL8Nae9jolr9mtXme4ZPMZ8u5yxyxJ5PbpWrQB4V4r+LGtaPBpCaTqXhfXEvmnD6taosdnA6RqywN5l2FDktklpVOCMITwfUvDOs6hrPgSz1Y2tp/alxaeZ5FvcpNCZcHhZFYqVJ7gnjvXR0UDTs7nn/AIVPiXQtFisz4YM85ZpZ5zqMQMsrHczHj1P5AVr/ANteJv8AoU//ACpRf4V1NFZqm0rKT/D/ACO2pjY1Zuc6UbvX7X/yRy39teJv+hT/APKlF/hTJtW8RzRNHJ4RDKwwR/aUX+FdZRT5H/M/w/yI+s0/+fMfvn/8keZ3uq6k0Eck3hm4CofvLqMWfx+WqUmt3Ma5bw7cD/uIxH/2WvQtSsvKLzRjMTcumOnv9K5a9tVspjLEg8l+4H3T/hWEoSXX8v8AI9ShiaU1b2a++X/yRiQ63cKzSJ4cu2Zx/wA/8ZIHp9yp01S/kGR4Zux/vahEP/Za0PtK4++Kb57yttgR5m9FGajXv+R0c8P+fa++X/yRmzardqh3+HLnHr/aMX/xFb0es66iRuPC0h2DIzqMWSMd/lqxp+juzrLfkcciIcj8T/St2sJz10f5HJXxFJ6Kmn85f/JHm2r3FzaXIuLrw3dxeaAw2ajEVIJ4/gPrSaT4gm0q9Elt4fuwzhjtbUItpBPI+5612mtWX23TpoNu6SHMkY9UP3l/z7VwoQtG0WczRHKH1/8A1iqTe6f5Ho4arSxFK04Ls9Zf/JDvAemXHhj4sX6tpM+mWHiC1acI06zJ9oRyxCsoAUbWY7Tk/h09gmijnieKZFeNwVZWGQR6EVzHh2/GoaNE/wB+5smDD1K/47ciupRldFdCCrDII7iu6m7o+bxUHTqtWtbtf9bv8TlNOtorN722gXYkdwwC5JwMAjr7EUt5BGwMsucKPrUsg2a9qaHjeY5R7goF/mtQ33nlwIiPLI5GM5rxaitUa8zoTbs2RxJFcJmIEbeCGHNXogVRQeoqs6Sx7DbhRn72RmrdQwZyviebzdSjhH3YUyf95v8A6w/Wsukurjzpp7puVkkJz6LnA/TFHvXVTVon0OFhyUkhtufmuf8AeUfpT6ihYCNGP/LaQ4/kP5U9yEUluAOtaG6Io4YppJ2kBGCoVh1BxViwLxavp8UhyTcwlHH8Q3r+tMhUpapuGGcl2H1q7oqedrmmREZH2gOPbaC39KqO6RjWdqcpeTO2u02a65H8cSsf1H9KsVHqH/IZT/riP5mpKzqq02fLx+FBXnnia6+16zNt5WP90v4df1zXd6jcizsZrhv4FJHuew/OuG8K2n27X7ZXBZFbzXz7c8/jilCPM7G9P3U5voekaJZ/YNKtrbHzIg3f7x5P6mr1FFeqlZWPObu7sKKKKYgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAOtZF1prhj5Cq0R/gPGPp7Vr0Umrlwm4O6OYbSkjVpHskRVGSSFqC9vINPtw7gjJwkaDlj6AVva1Jtgij/wCejgH8Bn+grz7XLwnVJySNsIEafXGT+Jzj8KwqNQ2PUwcJYl+8Xl8S30iJOkNskLf8s23Fv++un6V0Ok6hFqVr50SshVtro3VT/kivPVR4Y03PlnYkx9SCT0Hv7V3HhqwksLFvPwJpn8xlB+7wAB+QrhkkjqxtCjTppx0ZpybkZZUGWTnHqO4ri/FViLO9W8tx/o8vzAjsD1/I/wA67iqN5aJdRSWUwHly5aI/3X7j8acH9k48LX9hPm6dTkPDt9/ZWtxuxxbTZBx2z1H4HBr0exHlNJB/Ap3Rn/ZPb8OR9MV5NJFJG0ls/E0J+XPf0/wrufDOpm70mOYkmWz+Vx3MZ/qMf+O100Z20OrNaHNFVY/12/yLfiGPyNSsbwfcfNtIfryv6gj8aK09XtBqGmTwK2Gdco3ow5U/mBWLY3AurSKYDG9ckeh7j8DXJjYctTm7nmUpXjbsVYYZ0ugzSMeeeeDT9buPs2lXEinDbdq/U8D+dT3zXKWkrWEMM10B+7jmlMSMfQsFYge+01wnifUPFpitoJtE0JNzl/k1iZs7R3/0UeormUXI6Ka55qJJEo4Qj5SNpHtVNGLp9nDfOCUZvQA9axpL7xRv8tNI0XzCM5Gqynb7n/R6WCTxLCpC6PouScknVpck/wDgNXdY+i515/czeusLGhUYVCuPwNPnAln8nqpO5vpXO3d34nEDZ0fRu3TVZSev/XvU/m+KYFYPo+iGSQ5Y/wBrS/l/x7UWE6iWmv3M33bc5NbPgqDzvESPj5YIXf6E4UfoWrhhdeKD/wAwfRc/9haX/wCRq6rwM/jGOK8uoNB0BxKyx5k1qZOFGeMWhzyx/KtKUbzRx5hWUcPJLrpszuLpt+tuB0SNV/mf61NXGw33jKW/u5hoPh4ln2n/AInc2Bjjj/RParX23xp/0APDv/g8m/8AkSsJ+9Js8FaJITxvebYYbRTy58x/oOn6/wAqvfDyx8u0nvXHzSnYn+6Ov6/yrzTVdS8U6lqruuj6MWdgiKuqykegwfs3+c16Rp8njSxsobaLw94bKRKFz/b0/Pv/AMeddGHp63fQqvLlpqK6nZ0Vyv27xx/0L3hv/wAH0/8A8h1y37ReiXniL4cR6da2V1dSzahaiWO0jaR1Tf8AOwwM4Azziu04j1Oivm7TfC3jPwr8Sn1nWjqOu3kfh24hS60yHcFCbUhRWkXZ5xClyGByzHAboZbDxV8UZ7LWkc6pZqTZyWU97o880qBg3nRAxWS/MNv3jAyrwMnIJAPoyivna0j8V6j448B+JdSs/FFo/wBiurd/PtYpmWXzSUSby7ceXHICoLNGhCjOVILGWw1r4j6lpV9BqNnqd602hag2o2l9oyJDbXQDiCO3zEBcBvlG0mUEHn0oA951TUrHSbNrvVLy2srVSFaa5lWNAScAFmIHJIA+tF7qVjYS2sd9eW1tJdSeTbpNKqGaT+4gJ+ZvYc18x+OB451rwfJol9putRW0On6M1jp9ho37md9sbXBkZIj5TRsCBGCmAPukV6j8dbO9uL7wLc2dvqjxWetLPcT6dZvcyW6BGHmbFR+nupHsaAPVqK+fU8SfE9tE0x9Tj1yxgkgvnW7s9ISe8llUn7Mk0IicRhhjJ2L9V60uq658WHtL+UJqVjd23h63vI4LTTY5o5b0yASR5MbEkpyUU5HbpyAfQNFeDnxH8UJfHcUdxE+n6cLq1KwnTp5bee2Zf3gLR20hSTJ6tMgXHK45r3igAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAo6vEz26uiljG27AGSR0P8AOuRu9Diurx51neMOQWUAHnGMgnpXdsQoJJAA5JNfPnjLxFceI/EMz20jrYxkxwqpIBUfxH3PX8qwrWS1PTy72kpNQdrdTv7i70Pw+jSTTo1wvq2+U/h2/QVZ8MeJrPXFf7KWjnj+9DJjdj1HqK8pg0/Iy1OgS40y9ivLJ9k0ZyD/AEPtWPP0toelLCqad5XZ7yjh1yKSVN6EZweoPofWue8Ma9DrFr5kY2XEeBLEex9vaujRgy5FYVKfLqtjypwcHZnK+MLPIi1OFMMPlmC9j3/x/KqHhu+Gnawjlh9muOHHbnr/AEP512U9ukwlgk/1dwNpPo3Y157PayWtxNaSDDxtlP8AD+n4iqjLaSPUwU1WpOjPp+X/AAD1WwxGr2+STCcDP908r+nH4VgzRfYNZmgxiC5zPD6Bv41/r+Jp/h2+F1ptnd7vmj/0ebP93+En6cfma19YsPt9psR/LnRg8UmM7WH9OoPsa3q0/bU7LdbHitOhVcZehm1yHiucnVo4oxvkWIBV9yf8AK6nbqMY2zadI7jq0MiFT9MkH9K4qeSVtWvp7hNk/mGLbnO0Lxj9K86FKSl7yselgI81W66FRLc2t26u25nUNu9afO22Fz3xge5qW9OYop+8Rw30NMtgJX89/wDUp9wf3j6/Suk9xS01GzJt+zoezoDVm6OZjVa5JZo2PXzF/nU8pzI31oBLUrs4jldm6CIkfmK9N0S3OkeHIUm4eKIySf7xyzD8ya4rwzpY1PXIWcZhsyJpPc/wr+Yz/wAB967TxJPi1S2X78zYx/sjk/0ren7kHUZ4ea1eecaK9WUdF3G23N1PJqPxLe/YtKkKnEkn7tPx6n8s1ftIxHCAK4zxlei41BYEOUgGD/vHr/SuKKOOC5pEvgTT/ter+e65ithv9t3b+p/CvSaw/Bth9h0OIuuJZv3rfj0/TFblepRjyxOXET55sKKKK1MQooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigDn/iBetp/g3VbiM4fyfLB9C5C5/8AHq8J0KAFdxr2n4rKW8Banj/pl/6NSvE7CbyIAScVy1/iPeytfuZNd/0R0OFAqGXaR2rDn1XHQ1UbVWLdaxuegqbN+0u59Jvku7I4deqnow7g16r4e1mDVbJbm2OD0kjJ5Q+hrxCPUg3DkVoaZqdxptyLmwl2t/Ev8LD0IpqS2exlXw3tV5nvB2yxkZ4P6Vg+LNPa4tl1GBczw/LMF7gd/wAv6U3wz4httatvMtzsnT/WwseV/wAR710lo6NMUYZSZcEe4/yaSp8srdGeSpTw0+Zbo5TwS3mz39k3+qniLfQ/5JrrPD9+b+xHmf6+I7JB7+tV7e2hspN0cUcbxvtZlUDcp6E1kXEjaL4kkkAP2eU7mA7qev5HNatujZvbZkYmccTUcoq1/wBDsq8u1+Mw6/qMZGP3u8e4YBs/mSPwr09HWRFdGDKwyCOhFcv410aS6VL+yjL3ES7JI1HMidePUg5475PtWtaPNHQeWV1Rre9s9DiNvnzCHJVCN0hHZfT8alkYMQFGEXgAdhVe2cM1ww6l9n4Af4k1NXEfTpXdyGXmWBfVwfwHNTpHLcXEcFsnmTyttRM9T/gOpPpUFuslxqBito2mmA2rGgyST39h05PFekeG9Aj0mLzZSst84w8mOFH91fQfz/lpTpub8jkxmMjho95PZFnQtLi0bThCGDOSZJpTxubufoOg9hWVG/8AaOoSXfPlD5Ywf7o/x61Y8S3jSMun2zfM/MxHZfT8f5fWpLOEQQqgHQUsTUTfs47I+djzO9SW7G6ldLY2E1w3PlrkD1PYfnXCaDZNq+tRxy5ZWYySn26n8+n41r+Nr7LRWUbdPnkx+g/r+Va3w+08wWEt5IuHnOEz/dH+J/lU0Yc0jZv2dNy6s6wAAYAwKKKK9I84KKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAOY+Ju3/AIQbVd3TYn571xXgKbpIwFr3j4rPs8Bap6ny1H/fxa8X0W33qCwrlr/Ee/lTtRb8/wBEV4dJaXlqnbw78uRmukt1jjI3FfpWlHNEVAIFZKJ1yrvoebX2jSwDcmeKq21w8cgRutek6hBE6FlxXFazp3lSefGOO4pNWNadXn3JtM1GbSdRgv7f70Z+ZezL3Br3OzuVubSK4tWysiLLGf1FeAKwlgP0r1v4aXRuPCtqGOTA7RH6A5H6EVUdU4nJj6acVI7mYrOIpB92ZSh9vSs3X4PPsIZ2HzwnY/4//Xx+dN1e7e10C6MTYkjkwhHbPP8AU1zvhy9mlvJrGeVmjul4LnOGxwfzFVOaqQ5X1R51HCylTdVP4f6/I6Dw7f8A2X/Rblv3TH92x6KfQ+1dPXI2MAntyrj5hwfY1ft7+exAjnQzQjgMPvAf1rPD4jlXLM5atPmd4l7UNE03UHL3dpE8p/5aL8r/APfQwf1rOHg7SN2Slzt/u/aHx/PNakWrWMg/4+EQ+j/L/OnPqdigybqI/Rs/yrrbpvXQUateC5Yya+8XTtOtNOiMdjbxwqeWKjlvqep/GmarfCzg+QBp34jT1PqfaqU+uBzssImlb++4wo/qaigt2aQz3LGSZupPb2FY1cRFLlgJU5SfNMh02zaMtNMxeZzuZj3NXbiVIIHlkOERSxPsKkrl/Gt/shSyjPzSfM/07D8/5VwpHRFczsc/bxza1rKp/wAtLiTJP90d/wAhXrNvCkEEcMQ2pGoVR6AVx3w90zCy6jKOTmOLP6n+n512tejh4csb9zHFTvLlWyCiiiug5gooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA4L4y3Aj8KxQdTcXKL+ABb+grgNAtN6qMcV0PxnufN1nSbIHiONpSP944H/oJqj4fUI659RWHxVD1W3SwSt1f9fkdAnhpHjXekePQiornwmgBNvmM/7DEVvXokNlvibDBc1iWXiRom8q9XDDow6Gtzy02tjHutGv7Rc585P7rDB/OsW8jWRHVlKtjDKw5FekabfnUZXVo/3OOGNcl4rgSG9OwfdOD9DWU6aaujuwuMnCajJ3R51GvlXLxHpXpvwpbGkXsX9243fmo/wrzq/j2alx3FehfCwEW2o+nmJ/I1zU/iPbxetK513iRc6VJj+KdB/wCOmuNtpjBd2k6H5gMj8CCK7HxM2NLjHrcL+imuIQ5jtPXB/kKz2SFl6vR17nocGE1O7Rfult4+jDP9avMoYcjNZ1rzdRP3e3iY/wDfNaVZTVpM8Rq2hXezhfqg/Kmixg/uCrVFRYV2RxwpGMKoFSUUUwGSyJDE8kjBUQFiT2FeczNNrOsHYMyTvhR6DoPyFdF41v8Ay4Eso2+aT5pMf3ew/E/yqb4faXjzNRlXrlIs/qf6fnWtKHM7Gifs4ObOws7aOztYreEYjjUKKmoor1Njzm7hRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUjMFUsxAAGST2oA8M+Id0b7x7cr/DbhIV/AZP6k1a0uMlsZwciuas5m1TXLu9PW4meT6ZJNdRZExXO1uOhrmpO82z2sfDkoRh2sdzbBnssP021xuuwAShgO9dpbOJdPIiwTjtWEuj3N8Xa4PlJ/CD1NdJ4preH1C2QOMYrkvFcolnuSBjArp9Fkmgla0uYznGVcDhhXMeKGUTzqvVjtFA0m3ZHA6pn+0V+lej/DBMaZeSD+KYD8lH+NeZ6o5OoNjtxXrHw1hKeGYnI/10rv8Art/pXDDc+nxbtSNXxY+2ztF9ZHf8gBXIJwlquOQrH9FrpPGkmRAmfu27v+JJ/wABXPKha6hQf888D8W/+tWbNMCuWjG/9as7u14u40/uW8S/+O1pVTiUf2ndEdAQg/AAf0q5WU/iZ4Ld9QoooqRBUV3cJa20k8pwiDJqWuQ8Z6luZbGJuB80uPXsP6/lQlcqEeZ2MZFn1vWAo/1s7/go/wAAK9WsbWOytIreEYjjXaPf3rl/h/pZhtnv5lw8vyx5HIXufx/pXX16OHhyxv3McTU5pcq2QUUUV0HMFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXPfEG/Om+DNVuFOH8kxqR2LfKP510NeafG69I0mx01Gw1xN5jAf3V/+uf0qJu0WzowtP2laMfM8+8JxeWiO1b15MPN3KTuHQAE/wAqpaZD5Vsir1PFdPpulu0DS4+QfrWNKF9T0swxCi+S17lLS9ca1OCSAezcV0EWvg4LAEe1VLLTba/jkUYLocMpFZ19oCRMdjvGf9lv6V0nim/c+IIliJjQ764vUbg3Nwz/AMK5LH39KS6tZLTBld5Is4YkkEVX1WRLeyIQbeKyqzsrHoYHDqpNTvscncEPcsx7mvdPDVt9h0KxhYYMcILfUjJ/U14roVp/aOt2VrjIllAb/d6n9Aa9+hQOyp2Zgv4Z5rlXwtnpZhOyUTkvGDZ1KSP+4scX6An+tVtDi+0a9bpjgOgP0HzGma1MbrVXkHKvK8g+g4H86teFsi/nuf8Ankkjj8to/mKWnMdetLDeaX42/wAzq9OPmGab+/IzfmavVU0xNlog9qt1zb6nz73CiiigCpql6mn2UlxJztGFH95uwrhdFsZNZ1hI3YkOxklf0HU/4fjVrxbqJu7828ZzDAccd27n+ldh4N0n+ztOEsq4ubgBmz/COwrehT5maSl7KnfqzejRY41SNQqKAAB2FOoor0jzgooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvEviLdHUfHMsQYNFaIsS46Zxk/qT+Vey6hdxWNjcXU5xFDG0jH2AzXz/AKe8l3cz3s/+snkaVvqTmsK70SPUyyHvSqPob+nQ+ZKABwtdxaAQadtPGa5/w7aZAZuAPmarWq6skT7B91RxWsVyqxwVqntJuRiS309hrM4tOfM7Vt6JaXdxP5t65YHovYVkaDa/bdSe4l6E8ZrvCy2lq0mBwOBVGRy/i+GGG3lAAHyHivOtfl/0eJCeSBn8q7DxVdm4Co33pTjHt3rgNal868IHQcVz13sj2Mpg7yl0Ol+Flh5+ty3bDKW0eAf9puP5bq9WuZPs1nNcHjy4mYf7x4X+dcx8ONO+x+HonYYkumMp+nQfoM/jWp4ruBFYRx5wJnLH/dT/AOuT+VYvRJfM1q/v8Qo9L/gt/wBTkw4M8jn7kYC/kMn+dbfh6Dy9GuGYfNK8cIP/AI838hWCB/orbh80hx+LHP8ALNdjp8Oy102DHJVrh/8AgRwv6Csm7Js7cfPlpcvd/wDBNu3XbEo9qkpAMAClrE8IKyfEmo/2fp52HE8vyx+3qfwrVZgqlmICgZJPavO9avn1bU8xBmTPlxL3P/1zTSuXTjzPUt+ENK/tPUw8y5tofnfP8R7CvT6zfD2mjS9LitzjzfvSEd2P+cfhWlXp0ockTlr1PaS8gooorUxCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA5r4gQXF54dls7QHdOQrn/ZHJ/pXnMWjTWlphkII4r2iRA/UZFU7rToZ1IZB+VZzp8zudtDFeyhyW0OB0a7RISD36ir8Frp8sjOyBnbru7VY1PwmrkvA7xt6pxWHcaZqdgflbz09GGD+daHG7X0N2w05YLyR4iBE2CAOxqfxBMI7HZnkmuXi1uW3+SQMjj+Fqp6nrL3EZBbfIRhUBzQCTbsjG1a83STTn7qDYn9f8+1ctpccmp6nHCgy8sgQfiau+JLjybdIFbnHNbXwl0zztTlvHXKW68E/wB5uB+ma4pPnmfTUYLDYfzPWbWIQQJHCuFjUIg/QCuV8WTefqQt0OY4/wB0D/sr978ya62WYWts85x+6Uyc+vRR+ZFefbjLI0pJLOwVc+nr/M/jUTd22Y5fDmm6j6aDkiae8t4I+Sece5OB/Wu8twr38zp/q0xEn0XiuX8MIDqM94RmO2VnGe5HyqPz5rq9Li8u2UHrjk1lPZInMal5qPb9S5RWJd6jd/2kEtoJQkIfzIpU2/aPu8xt3IG4479/UaTXsC2H2zzAbcp5gb1BHFZXuebZmL4x1HyLUWkZ/eTD5vZf/r/41B4A0oT3D6hMuUiO2PPQt3P4f1rARbjW9YVRzNO/4KP8AK9WsLSKxs4raAYjjGB7+9dmHp3d30KrS9nDkW7LFFFFdxwBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAEA1DLAjjDKDU1FAHOat4et7tSdi7hyDiudu/DXkQu0KAEjoBivRSM0x4kYYI4qZR5jajWdJ6HzT4g0e+fUCWibYD6V6v4C0o6Z4eto3XbNMfNf8en6Yrr7jRrWdvnjUjPPFTtaLg7MA4wPasfZON2juq5h7WChY5XxTchLGO3B+a4bew/2BwPzOTXJySCLcVHMS7V/327fyrr9f0uW4u3nwdigBVHZR0Fc2mk3El1bwEHe8m5v949PyyawlBrQ9TBzpxpJX82b2gWoh0eCP+K5fe3+4vA/XJrU1eWW2s1NuJBlwHeNQzRp1LAHrjHv9D0MsECLMTH/q4wIo/ovH+J/GsIyPYDULxWY38DPLPC74E8QJKkemEwAR3GDXNUep5NSftZufcN1/qf2KE3AhVg88NwgDPIqsu1iMAISrDpnOTwOlUfFN2kSQ6VaZWC3UBuc5IHA98Ctu4e20fT5r2O28mefpGzZwx5xwSAOpIHHWuX0HT5Na1YJIWKEmSZ/bv+JopxbY4WXvPZHV+A9I+z2xv51/eTDEYPZPX8a62kRQihVACgYAHQClr1oRUFZHn1JucuZhRRRVEBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQA1kVhggGofskQk8xVAfGAfSrFFKw1JrYqfZQqgIMAVTurCGcobiCKUodyl0DbT6jPStemugZSD3rCeGjLYtVGjzDxXePeX+xAfIh+Vfc9zXa+EdL/szSk8xNtzN88nqPQfgP61ONFtjdJMyA7DuAx37Vq0UqPI7s0q1uaKjEKKKK6DnCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooA8/8AiRqV/L4i8L+F9Ov5dNXWJJWuLuE7ZFjiTcURuzN0z24rN1yaX4dwwJ4evbzWb3Vr+Cxis9SvGmSFsMWIPVc5TOfUHpXc+JvDGj+J7aGDXLFLpIW3xksyMh9VZSCO3Q9qrWXgvw9ZDTha6ZGn9nytPbfOxKSNjcxJPzE4HJz0r2aGNw8KUKck7K/NGytJ3bTbvfsrW2Ts+hyypTcm18n2/rU43VPHHiiC61HTorPRYdQ0mwfUNQkleR4VXJKRpjBLFNpLHjJPHHNPWPibrcNjod5Fp1tp2n3til1NqF7bzTwJIxwI/wB3yvY5OeCOK73XfBPh3XtSF/q2mR3F3sEZfzHUOoOQrhSAwz2YGotT8A+GdUv2u77TFllYIGUTSLGwQAKDGGCEAADBFbUsZly5eek/Oy6+V5a66q600VnuTKlX1tL+vuON1n4geIrLxBBp7waVp9vIkCxXl3BPJb3krqCwjkQ4UA5A3Z98c12XxF13VPD3h77ZoemtqN2ZVjKBGkESHOZCq/MwGAMD1oHgLw1/a/8AaR0wNdib7SN00jRiTOd4jLbM/hxWh4i8N6X4iSBNXt3mEDFoik0kTISMHBRga56mJwTqUnGD5Y/Fpv8Aj+b+VtC1Cqoyu9Xt/VjziT4oajHoemNbjTtT1LVLySC2eytrjy4441QuXi5kLgtjaOo5zUtn8RPEkltYadc6JDbeItQ1CW0tWuYpbeBokVWMxR/nxhh8vU+vGK7O48BeGZ9GtdLk0mEWVrIZYVR3R0c9WDghsnuc84FJceAvDVxpVvp02mBra3lM8R86QSI56t5gbfk8Z55wPSun65llreye76Lzts15Xjs9dSPZV/5v66/8OcR4s1Pxu3irwnocd5pMV/PNLdObRpUikSLkLICSdpAIIyeeKgj8d3kWva1LY2kU99d6tFodlvnl8jzEGJJGUkgKPl+6ATnvXoUngnw9Jd6XdNpw+0aYAtq4mkUoAd2Dhvm5yfmznJ9abP4E8Nz6UdNk0tPsn2k3gUSOrCY9XDhtwP0NOOY4LljCdN7Wdkl9pu/xa/Z09dROjVu2n/VrdvU4e5+JmtWOja2lxZ6dPrNjqsWlwNAHEE7vnjBJYEBWyM+ldL4A8T6zrXiLxNpetW+np/ZMsUay2RcqSwYlSW6kYHOB9K2IPBnh6C0sLaHS4UgsbkXkCgt8sw6SE5yze7ZrQ0rRtP0qa+l0+2WGW9mNxcMCSZJD1Jyf0HFc2IxeClSnGlStJ7PtrHz00T07vyNIU6qknKWn/D/18jRooorxzpCiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7797=[""].join("\n");
var outline_f7_39_7797=null;
var title_f7_39_7798="Ferrous fumarate: Drug information";
var content_f7_39_7798=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ferrous fumarate: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2373?source=see_link\">",
"    see \"Ferrous fumarate: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20709?source=see_link\">",
"    see \"Ferrous fumarate: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F170762\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Femiron&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferretts&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferro-Sequels&reg; [OTC];",
"     </li>",
"     <li>",
"      Ferrocite&trade; [OTC];",
"     </li>",
"     <li>",
"      Hemocyte&reg; [OTC];",
"     </li>",
"     <li>",
"      Ircon&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F170763\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Palafer&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F170792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F170767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     19-50 years: Males: 8 mg/day; Females: 18 mg/day; Pregnant females: 27 mg/day; Lactating females: 9 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &ge;50 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Doses expressed in terms of elemental iron; elemental iron content of ferrous fumarate is 33%.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of iron deficiency:",
"     </b>",
"     Oral: Usual range: 150-200 mg elemental iron/day in divided doses; 60-100 mg elemental iron twice daily, up to 60 mg elemental iron 4 times/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of iron deficiency:",
"     </b>",
"     Oral: 60-100 mg elemental iron/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     To avoid GI upset, start with a single daily dose and increase by 1 tablet/day each week or as tolerated until desired daily dose is achieved",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F170780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20709?source=see_link\">",
"      see \"Ferrous fumarate: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Dietary Reference Intake: Dose is RDA presented as elemental iron unless otherwise noted:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0-6 months: 0.27 mg/day (adequate intake)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7-12 months: 11 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1-3 years: 7 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4-8 years: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     9-13 years: 8 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     14-18 years: Males: 11 mg/day; Females: 15 mg/day; Pregnant females: 27 mg/day; Lactating females: 10 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">",
"     <b>",
"      Doses expressed in terms of elemental iron; elemental iron content of ferrous fumarate is 33%.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of severe iron-deficiency anemia:",
"     </b>",
"     Oral: 4-6 mg elemental iron/kg/day in 3 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Treatment of mild-to-moderate iron-deficiency anemia:",
"     </b>",
"     Oral: 3 mg elemental iron/kg/day in 1-2 divided doses",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Prophylaxis of iron deficiency:",
"     </b>",
"     Oral: 1-2 mg elemental iron/kg/day",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F170768\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;text-align:justify;display:inline\">",
"     Lower doses (15-50 mg elemental iron/day) may have similar efficacy and less GI adverse events (eg, nausea,constipation) as compared to higher doses (eg, 150 mg elemental iron/day) (Rimon, 2005).",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F170746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 324 mg [elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Femiron&reg;: 63 mg [elemental iron 20 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferretts&reg;: 325 mg [scored; elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrocite&trade;: 324 mg [contains tartrazine; elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hemocyte&reg;: 324 mg [elemental iron 106 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ircon&reg;: 200 mg [elemental iron 66 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, timed release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferro-Sequels&reg;: 150 mg [contains sodium benzoate; elemental iron 50 mg; with docusate sodium]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F170733\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F170749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be administered with water or juice on an empty stomach. Administer 2 hours prior to or 4 hours after antacids.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F170748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron-deficiency anemias",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F170790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Constipation, dark stools, nausea, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea, heartburn, staining of teeth",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Discoloration of urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Contact irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F170752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iron salts or any component of the formulation; hemochromatosis, hemolytic anemia",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F170737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Gastrointestinal disease: Avoid in patients with peptic ulcer, enteritis, or ulcerative colitis.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Blood transfusion recipients: Avoid in patients receiving frequent blood transfusions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly:  Anemia in the elderly is often caused by &ldquo;anemia of chronic disease&rdquo; or associated with inflammation rather than blood loss. Iron stores are usually normal or increased, with a serum ferritin &gt;50 ng/mL and a decreased total iron binding capacity. Hence, the &ldquo;anemia of chronic disease&rdquo; is not secondary to iron deficiency but the inability of the reticuloendothelial system to reclaim available iron stores.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Premature infants: Avoid use in premature infants until the vitamin E stores, deficient at birth, are replenished.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Administration of iron for &gt;6 months should be avoided except in patients with continuous bleeding or menorrhagia.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299322\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F170742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F170760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Cereals, dietary fiber, tea, coffee, eggs, and milk may decrease absorption.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6789285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron deficiency anemia in pregnancy. Treatment of iron deficiency anemia in pregnant women is the same as in nonpregnant women and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F6789287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6789288\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron-fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F170754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Should be taken with water or juice on an empty stomach; may be administered with food to prevent irritation; however, not with cereals, dietary fiber, tea, coffee, eggs, or milk.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elemental iron content of ferrous fumarate: 33%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323149\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferrimin 150 Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     150 mg (120): $15.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferrocite Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 mg (100): $22.25",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Ferrous Fumarate Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     29 mg (100): $4.64",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     90 mg (100): $2.30",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Hemocyte Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     324 mg (30): $10.05",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F170747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Serum iron:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Males: 75-175 mcg/dL (SI: 13.4-31.3 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Females: 65-165 mcg/dL (SI: 11.6-29.5 micromole/L)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Total iron binding capacity: 230-430 mcg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Transferrin: 204-360 mg/dL",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Percent transferrin saturation: 20% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Iron levels &gt;300 mcg/dL can be considered toxic, should be treated as an overdose",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F170755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Ercofer (SE);",
"     </li>",
"     <li>",
"      Ferraton (EC);",
"     </li>",
"     <li>",
"      Ferrobet (AT);",
"     </li>",
"     <li>",
"      Ferrokapsul (DE);",
"     </li>",
"     <li>",
"      Ferroklinge (BR);",
"     </li>",
"     <li>",
"      Ferronat (BG, CZ);",
"     </li>",
"     <li>",
"      FerroTab (NZ);",
"     </li>",
"     <li>",
"      Ferrum Hausmann (BE, CH, DE, LU);",
"     </li>",
"     <li>",
"      Fersaday (GB, IE);",
"     </li>",
"     <li>",
"      Ferumat (BE, LU, NL);",
"     </li>",
"     <li>",
"      Ferval (MX);",
"     </li>",
"     <li>",
"      Fumafer (FR, PT, VE);",
"     </li>",
"     <li>",
"      Fumiron (DE);",
"     </li>",
"     <li>",
"      Heferol (HR);",
"     </li>",
"     <li>",
"      Hema F (TW);",
"     </li>",
"     <li>",
"      Hierro (AR);",
"     </li>",
"     <li>",
"      Neo-Fer (NO);",
"     </li>",
"     <li>",
"      Rulofer N (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F170736\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replaces iron found in hemoglobin, myoglobin, and enzymes; allows the transportation of oxygen via hemoglobin",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F170751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Hematologic response: Oral, parenteral iron salts: ~3-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: Reticulocytosis: 5-10 days; hemoglobin values increase within 2-4 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Iron is absorbed in the duodenum and upper jejunum; in persons with normal serum iron stores, 10% of an oral dose is absorbed, this is increased to 20% to 30% in persons with inadequate iron stores. Food and achlorhydria will decrease absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: To serum transferrin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, sweat, sloughing of intestinal mucosa, and menses",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lipschitz DA, &ldquo;The Anemia of Chronic Disease,&rdquo;",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 1990, 38(11):1258-64.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/2123218/pubmed\" id=\"2123218\" target=\"_blank\">",
"        2123218",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Little DR, &ldquo;Ambulatory Management of Common Forms of Anemia,&rdquo;",
"      <i>",
"       Am Fam Physician",
"      </i>",
"      , 1999, 59(6):1598-604.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/10193599/pubmed\" id=\"10193599\" target=\"_blank\">",
"        10193599",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Marx JJM, &ldquo;Normal Iron Absorption and Decreased Red Cell Iron Uptake in the Aged,&rdquo;",
"      <i>",
"       Blood",
"      </i>",
"      , 1979, 53:204-11.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/760850/pubmed\" id=\"760850\" target=\"_blank\">",
"        760850",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rimon E, Kagansky N, Kagansky M, et al, &ldquo;Are We Giving Too Much Iron? Low-Dose Iron Therapy is Effective in Octogenarians,&rdquo;",
"      <i>",
"       Am J Med",
"      </i>",
"      , 2005, 118(10):1142-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/16194646/pubmed\" id=\"16194646\" target=\"_blank\">",
"        16194646",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Swain RA, Kaplan B, and Montgomery E, &ldquo;Iron Deficiency Anemia,&rdquo;",
"      <i>",
"       Postgrad Med",
"      </i>",
"      ,  1996, 100(5):181-93.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7798/abstract-text/8917332 /pubmed\" id=\"8917332 \" target=\"_blank\">",
"        8917332",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8442 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-9DBBEBA25B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7798=[""].join("\n");
var outline_f7_39_7798=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170762\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170763\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170792\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170767\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170780\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170768\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170746\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170733\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170749\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170748\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170790\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170752\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170737\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299322\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170742\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170760\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789285\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789287\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6789288\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170754\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323149\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170747\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170755\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170736\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F170751\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8442\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8442|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?2/20/2373?source=related_link\">",
"      Ferrous fumarate: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/14/20709?source=related_link\">",
"      Ferrous fumarate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7799="Loratadine: Drug information";
var content_f7_39_7799=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Loratadine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34932?source=see_link\">",
"    see \"Loratadine: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/5/8278?source=see_link\">",
"    see \"Loratadine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F190023\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alavert&reg; Allergy 24 Hour [OTC];",
"     </li>",
"     <li>",
"      Alavert&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Children's Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; Liqui-Gels&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Claritin&reg; RediTabs&reg; 24 Hour Allergy [OTC];",
"     </li>",
"     <li>",
"      Loradamed [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F190024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Apo-Loratadine&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg;;",
"     </li>",
"     <li>",
"      Claritin&reg; Kids",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F190068\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist",
"     </li>",
"     <li>",
"      Histamine H;",
"      <sub>",
"       1",
"      </sub>",
"      Antagonist, Second Generation",
"     </li>",
"     <li>",
"      Piperidine Derivative",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F190027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Seasonal allergic rhinitis, chronic idiopathic urticaria: Oral: 10 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F190047\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/5/8278?source=see_link\">",
"      see \"Loratadine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: Seasonal allergic rhinitis, chronic idiopathic urticaria: Oral: 5 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F190028\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F190029\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &le;30 mL/minute:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: 5 mg every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adults: 10 mg every other day.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F190030\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Elimination half-life increases with severity of disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children 2-5 years: 5 mg every other day.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;6 years and Adults: 10 mg every other day.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F190002\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid gel, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Liqui-Gels&reg; 24 Hour Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral: 5 mg/5 mL (120 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral: 5 mg/5 mL (120 mL, 240 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg/5 mL (60 mL) [dye free, ethanol free; contains propylene glycol, sodium benzoate; fruit flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg/5 mL (60 mL, 120 mL) [dye free, ethanol free, sugar free; contains propylene glycol, sodium 6 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; 24 Hour Allergy: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Loradamed: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, chewable, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; Children's Allergy: 5 mg [contains phenylalanine 1.4 mg/tablet; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, orally disintegrating, oral: 10 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; Citrus Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Allergy 24 Hour: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; mint flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Children's Allergy: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; Citrus Burst&trade; flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Alavert&reg; Children's Allergy: 10 mg [dye free, gluten free, sucrose free; contains phenylalanine 8.4 mg/tablet; bubblegum flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Claritin&reg; RediTabs&reg; 24 Hour Allergy: 10 mg [mint flavor]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F189988\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Excludes capsule, chewable tablet",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be administered without regard to meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F190004\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis; treatment of chronic idiopathic urticaria",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F6699703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&reg; may be confused with clarithromycin",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Claritin&reg; (loratadine) may be confused with Claritin&trade; Eye (ketotifen)",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Lorcaserin hydrochloride may be confused with lorcaserin hydrochloride",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - varies based on comorbidity; Strength of recommendation - varies based on comorbidity)",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F190066\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Headache (12% adults), somnolence (8% adults), nervousness (4% ages 6-12 years), fatigue (4% adults; 3% ages 6-12 years, 2% to 3% ages 2-5 years), malaise (2% ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Rash (2% to 3% ages 2-5 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Xerostomia (3% adults), stomatitis (2% to 3% ages 2-5 years), abdominal pain (2% ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Hyperkinesia (3% ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (2% ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Wheezing (4% ages 6-12 years), epistaxis (2% to 3% ages 2-5 years), pharyngitis (2% to 3% ages 2-5 years), dysphonia (2% ages 6-12 years), upper respiratory infection (2% ages 6-12 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Flu-like syndrome (2% to 3% ages 2-5 years), viral infection (2% to 3% ages 2-5 years)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     &lt;2% (Limited to important or life-threatening): Abnormal hepatic function, agitation, alopecia, altered lacrimation, altered micturition, altered salivation, altered taste, amnesia, anaphylaxis, angioneurotic edema, anorexia, arthralgia, back pain, blepharospasm, blurred vision, breast enlargement, breast pain, bronchospasm, chest pain, confusion, depression, dizziness, dysmenorrhea, dyspnea, erythema multiforme, hemoptysis, hepatic necrosis, hepatitis, hypotension, impaired concentration, impotence, insomnia, irritability, jaundice, menorrhagia, migraine, nausea, palpitation, paresthesia, paroniria, peripheral edema, photosensitivity, pruritus, purpura, rigors, seizure, supraventricular tachyarrhythmia, syncope, tachycardia, tremor, urinary discoloration, urticaria, thrombocytopenia, vaginitis, vertigo, vomiting, weight gain",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F190007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to loratadine or any component of the formulation",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F189992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; dosage adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: May be inappropriate in older adults depending on comorbidities (eg, dementia, delirium) due to its potent anticholinergic effects (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Phenylalanine: Some products may contain phenylalanine.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F190063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2D6 (minor), CYP3A4 (minor), P-glycoprotein;",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C8 (weak), CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F189997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amiodarone: May increase the serum concentration of Loratadine. Management: Due to reported QT interval prolongation and Torsades de Pointes with this combination, consider an alternative to loratadine when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphetamines: May diminish the sedative effect of Antihistamines.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzylpenicilloyl Polylysine: Antihistamines may diminish the diagnostic effect of Benzylpenicilloyl Polylysine.  Management: Suspend systemic H1 antagonists for benzylpenicilloyl-polylysine skin testing and delay testing until systemic antihistaminic effects have dissipated. A histamine skin test may be used to assess persistent antihistaminic effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: Antihistamines may diminish the therapeutic effect of Betahistine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Hyaluronidase: Antihistamines may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving antihistamines (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F190020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: May increase CNS depression; monitor for increased effects with coadministration. Caution patients about effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Increases bioavailability and delays peak.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease loratadine levels.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12881433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of loratadine has not been associated with an increased risk of major malformations. The use of antihistamines for the treatment of rhinitis during pregnancy is generally considered to be safe at recommended doses. Although safety data is limited, loratadine may be the preferred second generation antihistamine for the treatment of rhinitis or urticaria during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F12881440\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Small amounts of loratadine and its active metabolite, desloratadine, are excreted into breast milk.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F190011\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May be taken without regard to meals. Some products may contain phenylalanine and/or sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F190009\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Claritin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (24): $23.16",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Chewable",
"     </b>",
"     (Claritin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (10): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Claritin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (120 mL): $10.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Wal-itin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (120 mL): $8.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Alavert Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (18): $7.80",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Claritin Reditabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (10): $10.19",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, orally-disintegrating",
"     </b>",
"     (Wal-itin Allergy Reditabs Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (30): $17.49",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Alavert Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (15): $9.60",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Claritin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (5): $5.93",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (KLS AllerClear Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (300): $12.69",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Loratadine Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg (100): $82.50",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F190012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aerotina (AR);",
"     </li>",
"     <li>",
"      Albatrina (MX);",
"     </li>",
"     <li>",
"      Alerfast (PE);",
"     </li>",
"     <li>",
"      Alergit (EC);",
"     </li>",
"     <li>",
"      Alernitis (ID);",
"     </li>",
"     <li>",
"      Alledine (AU);",
"     </li>",
"     <li>",
"      Allereze (AU);",
"     </li>",
"     <li>",
"      Allergyx (IL);",
"     </li>",
"     <li>",
"      Allerta (PH);",
"     </li>",
"     <li>",
"      Allertyn (HK, SG);",
"     </li>",
"     <li>",
"      Allohex (ID);",
"     </li>",
"     <li>",
"      Alloris (SG);",
"     </li>",
"     <li>",
"      Ambrace (HK);",
"     </li>",
"     <li>",
"      Ardin (SG);",
"     </li>",
"     <li>",
"      Bonalerg (GT);",
"     </li>",
"     <li>",
"      Caradine (TH);",
"     </li>",
"     <li>",
"      Carin (MY);",
"     </li>",
"     <li>",
"      Carinose (TH);",
"     </li>",
"     <li>",
"      Civeran (ES);",
"     </li>",
"     <li>",
"      Clalodine (TH);",
"     </li>",
"     <li>",
"      Claratyne (AU, NZ);",
"     </li>",
"     <li>",
"      Clarid (TH);",
"     </li>",
"     <li>",
"      Clarihist (PH);",
"     </li>",
"     <li>",
"      Clarin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Clarinese (ZA);",
"     </li>",
"     <li>",
"      Claritin (BR, ID, PH);",
"     </li>",
"     <li>",
"      Claritine (AE, BB, BE, BF, BG, BH, BJ, BM, BS, BZ, CH, CI, CY, CZ, EE, EG, ET, GH, GM, GN, GY, HR, HU, IQ, IR, JM, JO, KE, KW, LB, LR, LU, LY, MA, ML, MR, MU, MW, NE, NG, NL, OM, PK, PL, PT, QA, RU, SA, SC, SD, SL, SN, SR, SY, TN, TR, TT, TZ, UG, YE, ZM, ZW);",
"     </li>",
"     <li>",
"      Clarityn (AT, DK, FI, GB, IE, IT, NO, SE);",
"     </li>",
"     <li>",
"      Clarityne (AR, CL, CN, CO, CR, DO, ES, FR, GR, GT, HK, HN, KP, MX, MY, PA, PE, PY, SV, TH, TW, UY, VE);",
"     </li>",
"     <li>",
"      CPLoradine (HK);",
"     </li>",
"     <li>",
"      Cronitin (ID);",
"     </li>",
"     <li>",
"      Curyken (MX);",
"     </li>",
"     <li>",
"      Dimegan (MX);",
"     </li>",
"     <li>",
"      Dymaten (MX);",
"     </li>",
"     <li>",
"      Efectine (MX);",
"     </li>",
"     <li>",
"      Erolin (BB, BM, BS, BZ, GY, JM, SR, TT);",
"     </li>",
"     <li>",
"      Ezede (SG);",
"     </li>",
"     <li>",
"      Finska (TW);",
"     </li>",
"     <li>",
"      Frenaler (CN);",
"     </li>",
"     <li>",
"      Fristamin (IT);",
"     </li>",
"     <li>",
"      Genadine (TW);",
"     </li>",
"     <li>",
"      Halodin (TH);",
"     </li>",
"     <li>",
"      Inigrin (MX);",
"     </li>",
"     <li>",
"      J-Tadine (KP);",
"     </li>",
"     <li>",
"      Klarihist (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Klinset (ID);",
"     </li>",
"     <li>",
"      Laredine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Laritol (MX);",
"     </li>",
"     <li>",
"      Laura (ZA);",
"     </li>",
"     <li>",
"      Lertamine (MX);",
"     </li>",
"     <li>",
"      Lisino (DE);",
"     </li>",
"     <li>",
"      Lobeta (DE);",
"     </li>",
"     <li>",
"      Lodain (KP);",
"     </li>",
"     <li>",
"      Lora (TW);",
"     </li>",
"     <li>",
"      Lora-Lich (DE);",
"     </li>",
"     <li>",
"      Lora-Tabs (NZ);",
"     </li>",
"     <li>",
"      Lorabasics (DE);",
"     </li>",
"     <li>",
"      Loraclar (DE);",
"     </li>",
"     <li>",
"      Loraclear Hayfever Relief (NZ);",
"     </li>",
"     <li>",
"      Loraderm (DE);",
"     </li>",
"     <li>",
"      Loradin (HK);",
"     </li>",
"     <li>",
"      Lorahist (PH);",
"     </li>",
"     <li>",
"      Loralerg (DE);",
"     </li>",
"     <li>",
"      Lorano (DE, PH, ZA);",
"     </li>",
"     <li>",
"      Lorastine (IL);",
"     </li>",
"     <li>",
"      Lorastyne (AU);",
"     </li>",
"     <li>",
"      Loratadura (DE);",
"     </li>",
"     <li>",
"      Loratan (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Loraton (HK);",
"     </li>",
"     <li>",
"      Loratrim (IL);",
"     </li>",
"     <li>",
"      Loratyne (PH);",
"     </li>",
"     <li>",
"      Loremix (BR);",
"     </li>",
"     <li>",
"      Lorfast (BF, BJ, CI, ET, GH, GM, GN, IN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Loridin (BF, BJ, CI, ET, GH, GM, GN, KE, LR, MA, ML, MR, MU, MW, NE, NG, SC, SD, SG, SL, SN, TN, TZ, UG, ZM, ZW);",
"     </li>",
"     <li>",
"      Lorihis (ID);",
"     </li>",
"     <li>",
"      Lorimox (MX);",
"     </li>",
"     <li>",
"      Lorin (IN);",
"     </li>",
"     <li>",
"      Lorita (TH);",
"     </li>",
"     <li>",
"      Lotan (MX);",
"     </li>",
"     <li>",
"      Lotarin (TW);",
"     </li>",
"     <li>",
"      Mosedin (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Nasaler (PE);",
"     </li>",
"     <li>",
"      Neoalexil (MX);",
"     </li>",
"     <li>",
"      Noseling (TW);",
"     </li>",
"     <li>",
"      NT-Alergi (HK);",
"     </li>",
"     <li>",
"      Nufalora (ID);",
"     </li>",
"     <li>",
"      Optimin (ES);",
"     </li>",
"     <li>",
"      Pylor (ID);",
"     </li>",
"     <li>",
"      Restamine (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Ridamin (SG);",
"     </li>",
"     <li>",
"      Rinityn (PH, SG);",
"     </li>",
"     <li>",
"      Rityne (TH);",
"     </li>",
"     <li>",
"      Rotifar (HK, MY);",
"     </li>",
"     <li>",
"      Sanelor (LU);",
"     </li>",
"     <li>",
"      Sensibit (MX);",
"     </li>",
"     <li>",
"      Talorat (NI);",
"     </li>",
"     <li>",
"      Tidilor (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, OM, QA, SA, SY, YE);",
"     </li>",
"     <li>",
"      Tinnic (ID);",
"     </li>",
"     <li>",
"      Tricel (EC);",
"     </li>",
"     <li>",
"      Velodan (ES);",
"     </li>",
"     <li>",
"      Vincidal (MX)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F189991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Long-acting tricyclic antihistamine with selective peripheral histamine H",
"     <sub>",
"      1",
"     </sub>",
"     -receptor antagonistic properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F190006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: 1-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peak effect: 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &gt;24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP2D6 and 3A4 to active metabolite",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 12-15 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (40%) and feces (40%) as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clissold SP, Sorkin EM, and Goa KL, &ldquo;Loratadine: A Preliminary Review of Its Pharmacodynamic Properties and Therapeutic Efficacy,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 1989, 37(1):42-57.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crumb WJ, &ldquo;Loratadine Blockade of K(+) Channels in Human Heart: Comparison With Terfenadine Under Physiological Conditions,&rdquo;",
"      <i>",
"       J Pharmacol Exp Ther",
"      </i>",
"      , 2000, 292(1):261-4.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/10604956/pubmed\" id=\"10604956\" target=\"_blank\">",
"        10604956",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Crumb WJ, &ldquo;Rate-Dependent Blockade of a Potassium Current in Human Atrium by the Antihistamine Loratadine,&rdquo;",
"      <i>",
"       Br J Pharmacol",
"      </i>",
"      , 1999, 126(3):575-80.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/10188966/pubmed\" id=\"10188966\" target=\"_blank\">",
"        10188966",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Delpon E, Valenzuela C, Gay P, et al, &ldquo;Block of Human Cardiac Kv1.5 Channels by Loratadine: Voltage-, Time-, and Use-Dependent Block at Concentrations Above Therapeutic Levels,&rdquo;",
"      <i>",
"       Cardiovasc Res",
"      </i>",
"      , 1997, 35(2):341-50.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/9349397/pubmed\" id=\"9349397\" target=\"_blank\">",
"        9349397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lin CC, Radwanski E, Affrime M, et al, &ldquo;Pharmacokinetics of Loratadine in Pediatric Subjects,&rdquo;",
"      <i>",
"       Am J Ther",
"      </i>",
"      , 1995, 2:504-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/11850699/pubmed\" id=\"11850699\" target=\"_blank\">",
"        11850699",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Luck JC and Evrard HM, &ldquo;Atrial Fibrillation Associated With Loratadine Use,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1995, 95(2):282.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Lutsky BN, Klose P, Melon J, et al, &ldquo;A Comparative Study of the Efficacy and Safety of Loratadine Syrup and Terfenadine Suspension in the Treatment of 3 to 6 Year Old Children With Seasonal Allergic Rhinitis,&rdquo;",
"      <i>",
"       Clin Ther",
"      </i>",
"      , 1993, 15(5):855-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/8269452/pubmed\" id=\"8269452\" target=\"_blank\">",
"        8269452",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Simons FE, &ldquo;Loratadine, a Nonsedating H",
"      <sub>",
"       1",
"      </sub>",
"      -Receptor Antagonist (Antihistamine),&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1989, 63(4):266-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7799/abstract-text/2572187/pubmed\" id=\"2572187\" target=\"_blank\">",
"        2572187",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9572 Version 47.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-61.234.146.186-93025ABAAB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7799=[""].join("\n");
var outline_f7_39_7799=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190023\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190024\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190068\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190027\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190047\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190028\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190029\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190030\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190002\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189988\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803166\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190004\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6699703\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190066\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190007\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189992\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190063\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189997\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190020\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12881433\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12881440\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190011\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190009\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190012\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F189991\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F190006\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9572\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9572|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/7/34932?source=related_link\">",
"      Loratadine: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?8/5/8278?source=related_link\">",
"      Loratadine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7800="Lipid lowering with fibric acid derivatives";
var content_f7_39_7800=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Lipid lowering with fibric acid derivatives",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7800/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7800/contributors\">",
"     Robert S Rosenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7800/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7800/contributors\">",
"     Mason W Freeman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7800/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7800/contributors\">",
"     David M Rind, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/39/7800/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lipid altering agents encompass several classes of drugs that include HMG CoA reductase inhibitors or statins, fibric acid derivatives, bile acid sequestrants, and nicotinic acid. These drugs differ with respect to mechanism of action and to the degree and type of lipid lowering. Thus, the indications for a particular drug are influenced by the underlying lipid abnormality. Conventional dosing regimens and common adverse reactions are described in a table (",
"    <a class=\"graphic graphic_table graphicRef77498 \" href=\"UTD.htm?28/1/28701\">",
"     table 1",
"    </a>",
"    ), and the range of expected changes in the lipid profile are listed in another table (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"UTD.htm?21/47/22268\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Lipid lowering is beneficial in patients with dyslipidemias for both primary and secondary prevention of coronary heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=see_link\">",
"     \"Clinical trials of cholesterol lowering for primary prevention of coronary heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The mechanisms of benefit seen with lipid-lowering are incompletely understood. Regression of atherosclerosis occurs in only a minority of patients; furthermore, the benefit of lipid lowering is seen in as little as six months, before significant regression could occur. Thus, other factors must contribute; these include plaque stabilization, reversal of endothelial dysfunction, and decreased thrombogenicity. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=see_link\">",
"     \"Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The characteristics and efficacy of the fibric acid derivatives will be reviewed here. Other lipid lowering drugs and dietary supplements are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=see_link\">",
"     \"Lipid lowering with drugs other than statins and fibrates\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link\">",
"     \"Statins: Actions, side effects, and administration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=see_link\">",
"     \"Lipid lowering with diet or dietary supplements\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FIBRATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three fibrates are currently available in the United States:",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    , and clofibrate. Clofibrate should not be used since it has been associated with cholangiocarcinoma and other gastrointestinal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/1\">",
"     1",
"    </a>",
"    ]. Other fibrates that are available worldwide include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    and ciprofibrate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Mechanism/Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major effects of the fibrates are to lower serum triglycerides by 35 to 50 percent and raise serum high density lipoprotein cholesterol (HDL-C) by 5 to 20 percent (",
"    <a class=\"graphic graphic_table graphicRef75715 \" href=\"UTD.htm?21/47/22268\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. Increases in HDL-C of as much as 20 percent are seen in patients with very high triglyceride levels (&gt;500",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [5.7",
"    <span class=\"nowrap\">",
"     mmol/L]),",
"    </span>",
"    while increases of 5 percent are more typical with fibrate monotherapy in patients with lower triglyceride levels. Lipid effects are mediated at least in part by activation of peroxisome proliferator-activated receptors (PPARs), transcription factors belonging to the nuclear hormone receptor superfamily [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/3,7\">",
"     3,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Two factors contribute to the fibrate-induced fall in triglycerides (",
"    <a class=\"graphic graphic_figure graphicRef64734 \" href=\"UTD.htm?42/40/43651\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Reduced hepatic secretion of VLDL",
"     </li>",
"     <li>",
"      Facilitated clearance of triglyceride-enriched lipoproteins by stimulation of lipoprotein lipase activity, an effect that may be mediated in part by downregulation of apolipoprotein C-III gene expression (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H8#H8\">",
"       \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Apolipoproteins'",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three mechanisms contribute to the fibrate-induced elevation in high density lipoprotein (HDL) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Direct stimulation of the synthesis of HDL apolipoproteins A-I and A-II [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/7-9\">",
"       7-9",
"      </a>",
"      ]. The direct effect on apo A-I results from stabilization of apo A-I mRNA transcripts, leading to translation and secretion of more apo A-I containing HDL particles which mediate reverse cholesterol transport [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/8,9\">",
"       8,9",
"      </a>",
"      ]. Similar effects have been demonstrated on apo A-II mRNA and secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/7\">",
"       7",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Increased transfer of apo A-I and other surface components in conjunction with diminished cholesterol transfer from HDL to VLDL.",
"     </li>",
"     <li>",
"      Less inhibition by VLDL (due to the reduction in concentration) on hepatic apo A-I synthesis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Fibrates also reduce low density lipoprotein (LDL) particle concentration despite a lesser reduction in LDL cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/10\">",
"     10",
"    </a>",
"    ]. The mechanism for this is that accelerated clearance of triglyceride-enriched lipoproteins reduces cholesteryl ester transfer protein mediated lipid exchange, which results in less triglyceride incorporation into LDL particles and subsequent hydrolysis of triglyceride-enriched LDL by hepatic lipase.",
"   </p>",
"   <p>",
"    This mechanism is responsible for the conversion of small cholesterol-depleted LDL particles to large-cholesterol-enriched LDL particles. The absolute numbers of small LDL particles are reduced to a much larger extent than the increase in large LDL particles, leading to a reduction in total LDL particles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Large LDL particles are removed from the circulation by the apo",
"    <span class=\"nowrap\">",
"     B/E",
"    </span>",
"    receptor more efficiently than small LDL particles.",
"   </p>",
"   <p>",
"    The fibrates have a variable effect on serum Lp(a). In one study, as an example,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    reduced serum Lp(a) by approximately 26 percent overall and by 39 percent in patients with values above 30",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/13\">",
"     13",
"    </a>",
"    ]. The effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    on Lp(a) may vary with the lipid disorder: in one report, a 17 percent reduction in patients with type IIa hyperlipoproteinemia (p = 0.04) versus no change in those with type IIb hyperlipoproteinemia (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"UTD.htm?20/51/21307\">",
"     table 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with type IIb hyperlipoproteinemia, Lp(a) forms complexes with VLDL. These complexes are cleared by remnant receptors, resulting in a net fall in serum Lp(a). Since fibrates reduce VLDL (enhanced clearance, decreased production), less Lp(a) is cleared via",
"    <span class=\"nowrap\">",
"     Lp(a)/VLDL",
"    </span>",
"    complexes and serum Lp(a) may rise. An additional possible mechanism for the lack of Lp(a) lowering with fibrates in this disorder is the reduced need for VLDL-associated apo B, resulting in more substrate availability for Lp(a) formation.",
"   </p>",
"   <p>",
"    The newer fibric acid derivatives appear to differ from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    in their effect on the plasma fibrinogen concentration. They lower fibrinogen levels, while gemfibrozil has no effect. However, gemfibrozil may normalize impaired endogenous fibrinolysis by reducing plasminogen activator inhibitor type-1 levels in patients with hypertriglyceridemia or (possibly) type 2 diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In addition,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    reduces serum uric acid levels, whereas no effect is observed with gemfibrozil [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/17-19\">",
"     17-19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An additional difference among the fibric acid derivatives is the effect on serum homocysteine. They increase with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     bezafibrate",
"    </a>",
"    , a potentially undesirable effect, but are unchanged with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=see_link\">",
"     \"Overview of homocysteine\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite their favorable effects on lipids, there is evidence that fibrates as a group have less favorable effects on clinical outcomes. A meta-analysis of 10 randomized trials (36,489 patients; both primary and secondary prevention trials) found that treatment with fibrates showed a trend toward increased all-cause mortality (odds ratio [OR] 1.07, 95% CI 0.99-1.15), an increase in noncardiac mortality (OR 1.16, CI 1.05-1.29), and no effect on cardiovascular mortality (OR 0.98, CI 0.89-1.08) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/22\">",
"     22",
"    </a>",
"    ]. A subsequent meta-analysis of 18 trials (45,058 patients) found no effect on all-cause mortality (relative risk [RR] 1.00, CI 0.93-1.08) or cardiovascular mortality (RR 0.97, CI 0.85-1.02), and a trend toward increased noncardiovascular mortality (RR 1.10, CI 0.995-1.21) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike statins, which have demonstrated clinical efficacy across a broad range of LDL-cholesterol levels, fibrates have primarily shown reductions in cardiovascular events in subsets of patients with high triglycerides (above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.2",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/24,25\">",
"     24,25",
"    </a>",
"    ], or low HDL-cholesterol (below 40",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.0",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    and multiple characteristics of the metabolic syndrome including a borderline elevated triglyceride level [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Uses",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Gemfibrozil",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     Gemfibrozil",
"    </a>",
"    and other fibrates are effective for the treatment of hypertriglyceridemia and combined hyperlipidemia with or without hypoalphalipoproteinemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/2\">",
"     2",
"    </a>",
"    ]. At a dose of 600 mg twice daily, gemfibrozil increases HDL cholesterol levels by an average of 11 percent. However, the Helsinki Heart Study showed a more prominent elevation in HDL cholesterol in the lower range of plasma HDL levels (ie, in those at greatest cardiovascular risk) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/24\">",
"     24",
"    </a>",
"    ]. Subgroup analysis found that gemfibrozil was particularly effective in preventing heart disease in patients with high serum triglyceride concentrations (&gt;202",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    plus either low HDL cholesterol (&lt;42",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [1.1",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    or a high",
"    <span class=\"nowrap\">",
"     LDL/HDL",
"    </span>",
"    cholesterol ratio (&gt;5.0).",
"   </p>",
"   <p>",
"    An unexpected outcome of this and some other trials has been the association of lipid lowering with an enhanced risk of noncardiac death, particularly due to accidents, violence, or suicide [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/26\">",
"     26",
"    </a>",
"    ]. However, more recent larger trials (primarily conducted with statins) did not confirm a relation between lowering of cholesterol and an increase in noncardiovascular deaths (due, as an example, to suicide) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\", section on 'Safety of cholesterol lowering'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Fenofibrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    can be prescribed as a nanocrystal formulation (145 mg daily taken without regard to meals), as micronized capsules (200 mg daily taken with dinner), or as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/16/20742?source=see_link\">",
"     fenofibric acid",
"    </a>",
"    (also called choline fenofibrate; 135 mg daily without regard to meals) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/29\">",
"     29",
"    </a>",
"    ]. Dose reduction is warranted in patients with renal disease, and fenofibrate should be avoided in patients with severe renal impairment. The choice among",
"    <span class=\"nowrap\">",
"     fenofibrate/fenofibric",
"    </span>",
"    acid preparations can be made based on cost and ease of dosing.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     Fenofibrate",
"    </a>",
"    is approved for triglyceride-lowering in subjects with types IV and V hyperlipoproteinemia (",
"    <a class=\"graphic graphic_table graphicRef54329 \" href=\"UTD.htm?20/51/21307\">",
"     table 3",
"    </a>",
"    ). One study randomly assigned 84 patients with combined hyperlipidemia to fenofibrate or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/30\">",
"     30",
"    </a>",
"    ]. Fenofibrate was more effective in reducing serum triglycerides and VLDL-cholesterol, while atorvastatin was more effective in lowering LDL-cholesterol, apo B, and total cholesterol.",
"   </p>",
"   <p>",
"    In a randomized trial in 731 patients with type 2 diabetes, micronized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    decreased angiographic progression of coronary heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/31\">",
"     31",
"    </a>",
"    ]. This may have been partially due to fenofibrate increasing the size of LDL particles [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/32\">",
"     32",
"    </a>",
"    ], and presumably an associated reduction in LDL particle concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, in the randomized FIELD trial of 9795 patients with type 2 diabetes, patients who received micronized",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    (200 mg per day) had nonsignificantly lower rates of coronary events, but had nonsignificantly higher rates of coronary death and all-cause mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/6\">",
"     6",
"    </a>",
"    ]. Analyses of secondary outcomes from the FIELD trial raise the possibility of some improvements in microvascular outcomes in diabetic patients treated with fenofibrate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Similarly a substudy of the ACCORD study found that combination treatment with fenofibrate and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    reduced a measure of progression of diabetic retinopathy more than simvastatin alone, but did not reduce the risk of vision loss [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H30#H30\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'FIELD trial'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=see_link&amp;anchor=H31#H31\">",
"     \"Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents\", section on 'ACCORD Lipid trial'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    An important drug interaction is that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    increases the clearance of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    . In one series of 43 heart transplant recipients, as an example, fenofibrate therapy led to a 30 percent reduction in cyclosporine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/36\">",
"     36",
"    </a>",
"    ]. Five of these patients had an episode of acute rejection that was associated with decrease in cyclosporine levels on the visit before the episode. A small elevation in the plasma creatinine concentration of 0.34",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (30",
"    <span class=\"nowrap\">",
"     &micro;mol/L),",
"    </span>",
"    which did not become apparent for at least six months, was also noted.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Bezafibrate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/40/12933?source=see_link\">",
"     Bezafibrate",
"    </a>",
"    can be prescribed in doses of 200 mg. three times daily or a sustained-release daily dose of 400 mg. daily [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/37\">",
"     37",
"    </a>",
"    ]. Bezafibrate is primarily excreted by the kidneys; as a result, the dose and dosing interval should be reduced in patients with renal insufficiency according to the following schedule to avoid myositis:",
"   </p>",
"   <p>",
"    &nbsp;Creatinine clearance",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;40 to 60",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    - 400",
"    <span class=\"nowrap\">",
"     mg/day",
"     <br/>",
"    </span>",
"    &nbsp; &nbsp;15 to 40",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    - 200 mg daily or every other day",
"    <br/>",
"    &nbsp; &nbsp;Dialysis - 200 mg every third day",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Toxicity and drug interactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fibrates have been associated with muscle toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/38\">",
"     38",
"    </a>",
"    ], an effect that is more pronounced in patients also treated with a statin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. This effect may be mediated by competitive inhibition of CYP3A4, leading to a reduction in statin metabolism (",
"    <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"     table 4",
"    </a>",
"    ).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"     Pravastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"     fluvastatin",
"    </a>",
"    are",
"    <strong>",
"     not",
"    </strong>",
"    extensively metabolized by the CYP3A4; as a result, they may be safer when combination therapy is required with a fibrate, but this is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=see_link\">",
"     \"Statin myopathy\"",
"    </a>",
"    .) Glucuronidation, which is an important pathway for renal excretion of lipophilic statins, appears to be significantly inhibited by",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    but not",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/42\">",
"     42",
"    </a>",
"    ]. In clinical studies, serum levels of statins increase 1.9- to 5.7-fold in gemfibrozil treated subjects but are unchanged in fenofibrate treated subjects. In the randomized trial of fenofibrate discussed above (see",
"    <a class=\"local\" href=\"#H6\">",
"     'Fenofibrate'",
"    </a>",
"    above), there was a low incidence of myopathy whether or not patients were also taking a statin [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, fenofibrate is the preferred fibrate in patients who require combined therapy with a statin and fibrate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/43,44\">",
"     43,44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Fibrates also interfere with the metabolism of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/39\">",
"     39",
"    </a>",
"    ]. As a result, the warfarin dose should be reduced by 30 percent in patients treated with this drug.",
"   </p>",
"   <p>",
"    In randomized trials, fibrates have been shown to increase creatinine levels, and a population-based study found an association between new fibrate use in older patients and nephrologist consultations and hospital admissions for a rise in creatinine level [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/45\">",
"     45",
"    </a>",
"    ]. However, although the rise in creatinine levels seen with fibrates may prompt clinical concern and interventions, it is uncertain that the changes in creatinine reflect renal injury. In the FIELD trial, the increase in serum creatinine with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"     fenofibrate",
"    </a>",
"    was reversible on discontinuation, and at the end of the trial fenofibrate treatment appeared to have slowed loss of renal function and reduced proteinuria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/46\">",
"     46",
"    </a>",
"    ]. As discussed above, the action of fibrates is mediated, at least in part, through modulation of peroxisome proliferator-activated receptors (PPARs). A study that examined the effects of fenofibrate, as well as a more potent experimental agonist of PPAR-alpha, found that both drugs increased serum creatinine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/47\">",
"     47",
"    </a>",
"    ]. It is unclear whether this is a class effect of PPAR-alpha agonists.",
"   </p>",
"   <p>",
"    Although fibrates are frequently administered to patients with severe hypertriglyceridemia in an attempt to reduce the risk of pancreatitis, in patients with normal triglyceride levels they may increase this risk (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H301366#H301366\">",
"     \"Approach to the patient with hypertriglyceridemia\", section on 'Fibrates'",
"    </a>",
"    ). A meta-analysis of seven randomized trials of fibrate therapy in patients with normal or mildly elevated triglyceride levels (N = 40,162) found a trend toward higher rates of pancreatitis with fibrate therapy (relative risk 1.39, 95% CI 1.00-1.95) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7800/abstract/48\">",
"     48",
"    </a>",
"    ]. The absolute risk appears to be quite small. In these trials, over a mean follow-up of 5.3 years, only 0.36 percent of patients developed pancreatitis; 935 such patients would need to be treated with fibrates for five years to cause one case of pancreatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/28/20930?source=see_link\">",
"       \"Patient information: High triglycerides (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=see_link\">",
"       \"Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=see_link\">",
"       \"Patient information: High cholesterol treatment options (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23262669\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The major effects of the fibrates are to lower serum triglycerides (by 35 to 50 percent) and raise serum high density lipoprotein (by 5 to 20 percent) (",
"      <a class=\"graphic graphic_table graphicRef75715 \" href=\"UTD.htm?21/47/22268\">",
"       table 2",
"      </a>",
"      ). These effects are mediated at least in part by activation of peroxisome proliferator-activated receptors (PPARs), transcription factors belonging to the nuclear hormone receptor superfamily. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism/Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Despite their favorable effects on lipids, there is evidence that fibrates as a group have less-favorable effects on clinical cardiovascular outcomes than statins or niacin. Meta-analyses of fibrate therapy have generally found no benefit, or even harm, on the outcome of all-cause mortality, due to an increase in noncardiovascular mortality. Unlike statins, which have demonstrated clinical efficacy across a broad range of LDL-cholesterol levels, fibrates have primarily shown reductions in cardiovascular events in subsets of patients with high triglycerides (above 200",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [2.2",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      or low HDL-cholesterol (below 40",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [1.0",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      and multiple characteristics of the metabolic syndrome including a borderline elevated triglyceride level. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism/Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Fibrates can be beneficial in patients with hypertriglyceridemia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=see_link&amp;anchor=H301366#H301366\">",
"       \"Approach to the patient with hypertriglyceridemia\", section on 'Fibrates'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Certain fibrates such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"       gemfibrozil",
"      </a>",
"      have been associated with muscle toxicity, particularly when used in patients also treated with a statin. This effect may be mediated by competitive inhibition of CYP3A4, leading to a reduction in statin metabolism (",
"      <a class=\"graphic graphic_table graphicRef76992 \" href=\"UTD.htm?9/45/9950\">",
"       table 4",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/27/25016?source=see_link\">",
"       Pravastatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/4/8264?source=see_link\">",
"       fluvastatin",
"      </a>",
"      are",
"      <strong>",
"       not",
"      </strong>",
"      extensively metabolized by the CYP3A4; as a result, they may be safer when combination therapy is required with a fibrate, but this is uncertain. Glucuronidation, which is an important pathway for renal excretion of lipophilic statins, appears to be significantly inhibited by gemfibrozil but not",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/23/17784?source=see_link\">",
"       fenofibrate",
"      </a>",
"      . In clinical studies, serum levels of statins increase 1.9- to 5.7-fold in gemfibrozil treated subjects but are unchanged in fenofibrate treated subjects. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Toxicity and drug interactions'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/1\">",
"      WHO cooperative trial on primary prevention of ischaemic heart disease with clofibrate to lower serum cholesterol: final mortality follow-up. Report of the Committee of Principal Investigators. Lancet 1984; 2:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/2\">",
"      Fruchart JC, Brewer HB Jr, Leitersdorf E. Consensus for the use of fibrates in the treatment of dyslipoproteinemia and coronary heart disease. Fibrate Consensus Group. Am J Cardiol 1998; 81:912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/3\">",
"      Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 1998; 98:2088.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/4\">",
"      Birjmohun RS, Hutten BA, Kastelein JJ, Stroes ES. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2005; 45:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/5\">",
"      Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999; 341:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/6\">",
"      Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366:1849.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/7\">",
"      Vu-Dac N, Schoonjans K, Kosykh V, et al. Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor. J Clin Invest 1995; 96:741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/8\">",
"      Berthou L, Duverger N, Emmanuel F, et al. Opposite regulation of human versus mouse apolipoprotein A-I by fibrates in human apolipoprotein A-I transgenic mice. J Clin Invest 1996; 97:2408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/9\">",
"      Jin FY, Kamanna VS, Chuang MY, et al. Gemfibrozil stimulates apolipoprotein A-I synthesis and secretion by stabilization of mRNA transcripts in human hepatoblastoma cell line (Hep G2). Arterioscler Thromb Vasc Biol 1996; 16:1052.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/10\">",
"      Rosenson RS, Wolff DA, Huskin AL, et al. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 2007; 30:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/11\">",
"      Otvos JD, Collins D, Freedman DS, et al. Low-density lipoprotein and high-density lipoprotein particle subclasses predict coronary events and are favorably changed by gemfibrozil therapy in the Veterans Affairs High-Density Lipoprotein Intervention Trial. Circulation 2006; 113:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/12\">",
"      Rosenson RS. Fenofibrate: treatment of hyperlipidemia and beyond. Expert Rev Cardiovasc Ther 2008; 6:1319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/13\">",
"      Bimmermann A, Boerschmann C, Schwartzkopff W, et al. Effective therapeutic measures for reducing lipoprotein(a) in patients with dyslipidemia. Lipoprotein(a) reduction with sustained-release bezafibrate. Curr Ther Res 1991; 49:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/14\">",
"      Jones PH, Pownall HJ, Patsch W, et al. Effect of gemfibrozil on levels of lipoprotein[a] in type II hyperlipoproteinemic subjects. J Lipid Res 1996; 37:1298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/15\">",
"      Avellone G, DiGarbo V, Cordova R, et al. Effects of gemfibrozil treatment on fibrinolytic system in patients with hypertriglyceridemia. Curr Ther Res 1992; 52:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/16\">",
"      Nordt TK, Kornas K, Peter K, et al. Attenuation by gemfibrozil of expression of plasminogen activator inhibitor type 1 induced by insulin and its precursors. Circulation 1997; 95:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/17\">",
"      Farnier M, Bonnefous F, Debbas N, Irvine A. Comparative efficacy and safety of micronized fenofibrate and simvastatin in patients with primary type IIa or IIb hyperlipidemia. Arch Intern Med 1994; 154:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/18\">",
"      Giral P, Bruckert E, Jacob N, et al. Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia. Atherosclerosis 2001; 154:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/19\">",
"      Insua A, Massari F, Rodr&iacute;guez Moncalvo JJ, et al. Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study. Endocr Pract 2002; 8:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/20\">",
"      Dierkes J, Westphal S, Luley C. Serum homocysteine increases after therapy with fenofibrate or bezafibrate. Lancet 1999; 354:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/21\">",
"      Westphal S, Dierkes J, Luley C. Effects of fenofibrate and gemfibrozil on plasma homocysteine. Lancet 2001; 358:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/22\">",
"      Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J 2007; 154:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/23\">",
"      Jun M, Foote C, Lv J, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010; 375:1875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/24\">",
"      Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317:1237.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/25\">",
"      Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000; 102:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/26\">",
"      Manninen V, Tenkanen L, Koskinen P, et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992; 85:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/27\">",
"      Hebert PR, Gaziano JM, Chan KS, Hennekens CH. Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/28\">",
"      Muldoon MF, Manuck SB, Mendelsohn AB, et al. Cholesterol reduction and non-illness mortality: meta-analysis of randomised clinical trials. BMJ 2001; 322:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/29\">",
"      Adkins JC, Faulds D. Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs 1997; 54:615.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/30\">",
"      Ooi TC, Heinonen T, Alaupovic P, et al. Efficacy and safety of a new hydroxymethylglutaryl-coenzyme A reductase inhibitor, atorvastatin, in patients with combined hyperlipidemia: comparison with fenofibrate. Arterioscler Thromb Vasc Biol 1997; 17:1793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/31\">",
"      Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 2001; 357:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/32\">",
"      Vakkilainen J, Steiner G, Ansquer JC, et al. Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS). Circulation 2003; 107:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/33\">",
"      Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/34\">",
"      Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007; 370:1687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/35\">",
"      ACCORD Study Group, ACCORD Eye Study Group, Chew EY, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010; 363:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/36\">",
"      Boissonnat P, Salen P, Guidollet J, et al. The long-term effects of the lipid-lowering agent fenofibrate in hyperlipidemic heart transplant recipients. Transplantation 1994; 58:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/37\">",
"      Monk JP, Todd PA. Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987; 33:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/38\">",
"      Magarian GJ, Lucas LM, Colley C. Gemfibrozil-induced myopathy. Arch Intern Med 1991; 151:1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/39\">",
"      Miller DB, Spence JD. Clinical pharmacokinetics of fibric acid derivatives (fibrates). Clin Pharmacokinet 1998; 34:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/40\">",
"      Pierce LR, Wysowski DK, Gross TP. Myopathy and rhabdomyolysis associated with lovastatin-gemfibrozil combination therapy. JAMA 1990; 264:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/41\">",
"      Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol 1997; 80:608.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/42\">",
"      Ballantyne CM, Davidson MH. Possible differences between fibrates in pharmacokinetic interactions with statins. Arch Intern Med 2003; 163:2394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/43\">",
"      Rosenson RS. Current overview of statin-induced myopathy. Am J Med 2004; 116:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/44\">",
"      Goldberg AC, Bays HE, Ballantyne CM, et al. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 2009; 103:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/45\">",
"      Zhao YY, Weir MA, Manno M, et al. New fibrate use and acute renal outcomes in elderly adults: a population-based study. Ann Intern Med 2012; 156:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/46\">",
"      Davis TM, Ting R, Best JD, et al. Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study. Diabetologia 2011; 54:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/47\">",
"      Nissen SE, Nicholls SJ, Wolski K, et al. Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials. JAMA 2007; 297:1362.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7800/abstract/48\">",
"      Preiss D, Tikkanen MJ, Welsh P, et al. Lipid-modifying therapies and risk of pancreatitis: a meta-analysis. JAMA 2012; 308:804.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4563 Version 14.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-AF04787F30-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7800=[""].join("\n");
var outline_f7_39_7800=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23262669\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FIBRATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Mechanism/Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Uses",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Gemfibrozil",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Fenofibrate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Bezafibrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Toxicity and drug interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23262669\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PC/4563\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4563|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/40/43651\" title=\"figure 1\">",
"      Metabolic effects fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PC/4563|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/1/28701\" title=\"table 1\">",
"      Types of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?21/47/22268\" title=\"table 2\">",
"      Effects of lipid altering drugs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/51/21307\" title=\"table 3\">",
"      Fredrickson classification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/45/9950\" title=\"table 4\">",
"      Inhibitors and inducers of cytochrome P450 3A4",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/47/35578?source=related_link\">",
"      Approach to the patient with hypertriglyceridemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/50/19240?source=related_link\">",
"      Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43626?source=related_link\">",
"      Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/51/28474?source=related_link\">",
"      Lipid lowering with diet or dietary supplements",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42217?source=related_link\">",
"      Lipid lowering with drugs other than statins and fibrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/2/32?source=related_link\">",
"      Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/37/19034?source=related_link\">",
"      Overview of homocysteine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?6/4/6212?source=related_link\">",
"      Patient information: High cholesterol and lipids (hyperlipidemia) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/6/43108?source=related_link\">",
"      Patient information: High cholesterol treatment options (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/28/20930?source=related_link\">",
"      Patient information: High triglycerides (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33802?source=related_link\">",
"      Statin myopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7801="Heparin: Pediatric drug information";
var content_f7_39_7801=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Heparin: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"    see \"Heparin: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?0/20/325?source=see_link\">",
"    see \"Heparin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block spa drugH1Div\" id=\"F15793684\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Special Alerts",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Heparin Product Label Change",
"     </span>",
"     <span class=\"collapsible-date\">",
"      December 2012",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       The Food and Drug Administration (FDA) has issued a notice about changes to some heparin product labels to reduce the risk of miscalculations that may result in medication errors. Effective May 1, 2013, manufacturers of Heparin Lock Flush Solution, USP and Heparin Sodium Injection, USP will be required to clearly state the strength of the entire container of heparin followed, in parentheses, by the amount of the medication contained in 1 mL. Heparin carton labeling will also be revised to comply with the new format. As the labeling is transitioned to the new requirements, users should be aware that both current and revised heparin container labels will be available. The FDA suggests users separate heparin stock according to &ldquo;current&rdquo; and &ldquo;revised&rdquo; labeling and use all &ldquo;current&rdquo; labeling supplies before transitioning to the &ldquo;revised&rdquo; labeling supply.",
"      </p>",
"      <p style=\"text-indent:0em;margin-top:2em;\">",
"       Further information can be found at",
"       <a href=\"file://www.fda.gov/Drugs/DrugSafety/ucm330695.htm\" target=\"_blank\">",
"        file://www.fda.gov/Drugs/DrugSafety/ucm330695.htm",
"       </a>",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F11443864\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F178752\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Hep-Lock;",
"     </li>",
"     <li>",
"      HepFlush&reg;-10",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F178753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Hepalean&reg;;",
"     </li>",
"     <li>",
"      Hepalean&reg; Leo;",
"     </li>",
"     <li>",
"      Hepalean&reg;-LOK",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1053161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Anticoagulant",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F11442594\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Many concentrations of heparin are available and range from 1-20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of I.V. devices and is not to be used for anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Line flushing:",
"     </b>",
"     When using daily flushes of heparin to maintain patency of single and double lumen central catheters, 10 units/mL is the concentration used in neonates. Capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6-8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater) or may be standardized according to specific NICU policy (eg, 0.5-1 mL/flush). Dose of heparin flush used should not approach therapeutic unit per kg dose. Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      TPN:",
"     </b>",
"     Heparin 0.5-1 unit/mL (final concentration) may be added to TPN solutions, both central and peripheral. (Addition of heparin to peripheral TPN has been shown to increase duration of line patency). The final concentration of heparin used for TPN solutions may need to be decreased to 0.5 units/mL in small neonates receiving larger TPN volumes in order to avoid approaching therapeutic amounts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arterial lines:",
"     </b>",
"     Heparinize with a usual final concentration of 1 unit/mL; range: 0.5-1 units/mL; in order to avoid large total doses and systemic effects, use 0.5 unit/mL in low birth weight/premature newborns and in other patients receiving multiple lines containing heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peripheral arterial catheters",
"     <i>",
"      in situ",
"     </i>",
"     : Continuous I.V. infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Umbilical artery catheter (UAC) prophylaxis: Low-dose heparin continuous I.V. infusion via the UAC with a heparin concentration of 0.25&ndash;1 unit/mL (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis for cardiac catheterization via an artery:",
"     </b>",
"     I.V.: Bolus: 100-150 units/kg; for prolonged procedures, further doses may be required (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     <b>",
"      Systemic heparinization:",
"     </b>",
"     I.V. infusion: Initial loading dose: 75 units/kg given over 10 minutes; then initial maintenance dose: 28 units/kg/hour; adjust dose to maintain APTT of 60-85 seconds (assuming this reflects an antifactor Xa level of 0.35-0.7 units/mL); see table",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PROTOCOL FOR SYSTEMIC HEPARIN ADJUSTMENT",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To be used after initial loading dose and maintenance I.V. infusion dose (see above) to maintain APTT of 60-85 seconds (assuming this reflects antifactor Xa level of 0.35-0.7 units/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obtain blood for APTT 4 hours after heparin loading dose and 4 hours after every infusion rate change",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obtain daily CBC and APTT after APTT is therapeutic",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         APTT*",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (seconds)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage Adjustment",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time to Repeat APTT",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         *Adjust heparin rate to maintain APTT of 60-85 seconds, assuming this reflects antifactor-Xa level of 0.35-0.7 units/mL (reagent specific)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Modified from Monagle P, Chalmers E, Chan A, et al, &ldquo;Antithrombotic Therapy in Neonates and Children,&rdquo;",
"         <i>",
"          Chest",
"         </i>",
"         , 2008, 133 (6):887S-968S.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Give 50 units/kg bolus and increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-85",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Keep rate the same",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Next day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         86-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         96-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 30 minutes and decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 60 minutes and decrease infusion rate by 15%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1053153\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"      see \"Heparin: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Many concentrations of heparin are available and range from 1-20,000 units/mL. Carefully examine each prefilled syringe, bag, or vial prior to use to ensure that the correct concentration is chosen. Heparin lock flush solution is intended only to maintain patency of I.V. devices and is not to be used for anticoagulant therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Line flushing:",
"     </b>",
"     When using daily flushes of heparin to maintain patency of single and double lumen central catheters, 10 units/mL is commonly used for younger infants (eg, &lt;10 kg) while 100 units/mL is used for older infants, children, and adults. Capped polyvinyl chloride catheters and peripheral heparin locks require flushing more frequently (eg, every 6-8 hours). Volume of heparin flush is usually similar to volume of catheter (or slightly greater) or may be standardized according to specific hospital's policy (eg, 2-5 mL/flush). Dose of heparin flush used should not approach therapeutic unit per kg dose. Additional flushes should be given when stagnant blood is observed in catheter, after catheter is used for drug or blood administration, and after blood withdrawal from catheter.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      TPN:",
"     </b>",
"     Infants and Children: Heparin 1 unit/mL (final concentration) may be added to TPN solutions, both central and peripheral. (Addition of heparin to peripheral TPN has been shown to increase duration of line patency.) The final concentration of heparin used for TPN solutions may need to be decreased to 0.5 units/mL in small infants receiving larger TPN volumes in order to avoid approaching therapeutic amounts.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Arterial lines:",
"     </b>",
"     Infants and Children: Heparinize with a usual final concentration of 1 unit/mL; range: 0.5-2 units/mL; in order to avoid large total doses and systemic effects, use 0.5 unit/mL in patients receiving multiple lines containing heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Peripheral arterial catheters",
"     <i>",
"      in situ",
"     </i>",
"     : Infants and Children: Continuous I.V. infusion of heparin at a final concentration of 5 units/mL at 1 mL/hour (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Prophylaxis for cardiac catheterization via an artery:",
"     </b>",
"     Infants and Children: I.V.: Bolus: 100-150 units/kg; for prolonged procedures, further doses may be required (Monagle, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Systemic heparinization:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Infants &lt;1 year: I.V. infusion: Initial loading dose: 75 units/kg given over 10 minutes; then initial maintenance dose: 28 units/kg/hour; adjust dose to maintain APTT of 60-85 seconds (assuming this reflects an antifactor Xa level of 0.35-0.7 units/mL); see table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Children &gt;1 year:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Intermittent I.V.: Initial: 50-100 units/kg, then 50-100 units/kg every 4 hours (",
"     <b>",
"      Note:",
"     </b>",
"     Continuous I.V. infusion is preferred):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V. infusion: Initial loading dose: 75 units/kg given over 10 minutes, then initial maintenance dose: 20 units/kg/hour; adjust dose to maintain APTT of 60-85 seconds (assuming this reflects an antifactor Xa level of 0.35-0.7 units/mL); see table.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      PROTOCOL FOR SYSTEMIC HEPARIN ADJUSTMENT",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     To be used after initial loading dose and maintenance I.V. infusion dose (see above) to maintain APTT of 60-85 seconds (assuming this reflects antifactor Xa level of 0.35-0.7 units/mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obtain blood for APTT 4 hours after heparin loading dose and 4 hours after every infusion rate change",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Obtain daily CBC and APTT after APTT is therapeutic",
"    </p>",
"    <table border=\"1\" frame=\"border\" rules=\"all\">",
"     <col align=\"center\" width=\"100\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <col align=\"center\" width=\"200\">",
"     </col>",
"     <thead valign=\"middle\">",
"      <tr>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         APTT*",
"        </p>",
"        <p style=\"text-indent:0em;\">",
"         (seconds)",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Dosage Adjustment",
"        </p>",
"       </th>",
"       <th align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Time to Repeat APTT",
"        </p>",
"       </th>",
"      </tr>",
"     </thead>",
"     <tfoot valign=\"top\">",
"      <tr>",
"       <td align=\"left\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         *Adjust heparin rate to maintain APTT of 60-85 seconds, assuming this reflects antifactor-Xa level of 0.35-0.7 units/mL (reagent specific)",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\" colspan=\"3\">",
"        <p style=\"text-indent:0em;\">",
"         Modified from Monagle P, Chalmers E, Chan A, et al, &ldquo;Antithrombotic Therapy in Neonates and Children,&rdquo;",
"         <i>",
"          Chest",
"         </i>",
"         , 2008, 133 (6):887S-968S.",
"        </p>",
"       </td>",
"      </tr>",
"     </tfoot>",
"     <tbody valign=\"top\">",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &lt;50",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Give 50 units/kg bolus and increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         50-59",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Increase infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         60-85",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Keep rate the same",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Next day",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         86-95",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         96-120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 30 minutes and decrease infusion rate by 10%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         &gt;120",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         Hold infusion for 60 minutes and decrease infusion rate by 15%",
"        </p>",
"       </td>",
"       <td align=\"center\">",
"        <p style=\"text-indent:0em;\">",
"         4 h after rate change",
"        </p>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis (low dose heparin): SubQ: 5000 units every 8-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Intermittent I.V.: Initial: 10,000 units, then 50-70 units/kg/dose (5000-10,000 units) every 4-6 hours (",
"     <b>",
"      Note:",
"     </b>",
"     Continuous I.V. infusion is preferred)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     I.V. infusion: Initial loading dose: 80 units/kg; initial maintenance dose: 18 units/kg/hour with dose adjusted according to APTT; usual range: 10-30 units/kg/hour",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults:",
"     <i>",
"      Chest",
"     </i>",
"     , 2008 Recommendations (Goodman, 2008; Harrington, 2008; Kearon, 2008):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prophylaxis of DVT and PE: SubQ: 5000 units every 8 or 12 hours or adjusted low-dose heparin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Treatment of DVT and PE:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     I.V.: Initial (loading dose): I.V. bolus: 80 units/kg (or alternatively 5000 units); follow with continuous I.V. infusion of 18 units/kg/hour (or alternatively 1300 units/hour). Adjust dosage to achieve and maintain therapeutic APTT as determined by correlating APPT results with a therapeutic range of heparin levels as measured by antifactor Xa assay (0.3-0.7 units/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     SubQ:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Monitored dosing regimen: Initial: 17,500 units (or 250 units/kg) then 250 units/kg/dose every 12 hours. Adjust dosage to achieve and maintain therapeutic APTT as determined by correlating APPT results with a therapeutic range of heparin levels as measured by antifactor Xa assay (0.3-0.7 units/mL) when measured 6 hours after injection.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Unmonitored dosing regimen: Initial: 333 units/kg; followed by 250 units/kg/dose every 12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Unstable angina or Non-ST-elevation myocardial infarction (NSTEMI): Initial loading dose: I.V. bolus: 60-70 units/kg (maximum: 5000 units), then initial maintenance dose: I.V. infusion: 12-15 units/kg/hour (maximum: 1000 units/hour); adjust dose to maintain therapeutic APTT of 50-75s",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     STEMI after thrombolytic therapy (full dose alteplase, tenecteplase, or reteplase): Initial loading dose: I.V. bolus: 60 units/kg (maximum: 4000 units), then initial maintenance dose: I.V. infusion: 12 units/kg/hour (maximum: 1000 units/hour); adjust dose to maintain therapeutic APTT of 50-70s for 48 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in renal impairment:",
"     </b>",
"     No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosage adjustment in hepatic impairment:",
"     </b>",
"     No dosage adjustment required; adjust therapeutic heparin according to aPTT or anti-Xa activity",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F178727\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in 1/2 NS, as sodium [porcine intestinal mucosa source]: 25,000 units (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in D",
"     <sub>",
"      5",
"     </sub>",
"     W, as sodium [porcine intestinal mucosa source]: 10,000 units (250 mL); 12,500 units (250 mL); 20,000 units (500 mL); 25,000 units (250 mL, 500 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS, as sodium [porcine intestinal mucosa source]: 1000 units (500 mL); 2000 units (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infusion, premixed in NS, as sodium [porcine intestinal mucosa source, preservative free]: 1000 units (500 mL); 2000 units (1000 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [lock flush preparation; porcine intestinal mucosa source]: 10 units/mL (1 mL, 2 mL, 3 mL, 5 mL, 10 mL); 100 units/mL (1 mL, 2 mL, 3 mL, 5 mL, 10 mL, 30 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hep-Lock: 100 units/mL (1 mL) [contains benzyl alcohol]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [lock flush preparation; porcine intestinal mucosa source, preservative free]: 1 units/mL (2 mL, 3 mL, 5 mL); 2 units/mL (3 mL); 10 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 6 mL, 10 mL); 100 units/mL (1 mL, 2 mL, 2.5 mL, 3 mL, 5 mL, 10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     HepFlush&reg;-10: 10 units/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [porcine intestinal mucosa source]: 1000 units/mL (1 mL, 10 mL, 30 mL); 5000 units/mL (1 mL, 10 mL); 10,000 units/mL (1 mL, 4 mL, 5 mL); 20,000 units/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sodium [porcine intestinal mucosa source, preservative free]: 1000 units/mL (2 mL); 5000 units/mL (0.5 mL); 10,000 units/mL (0.5 mL)",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F178711\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1053166\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Parenteral: Continuous I.V. infusion is preferred vs I.V. intermittent injections; I.V. bolus should be administered over 10 minutes; heparin lock flush solutions are intended only to maintain patency of I.V. devices and are",
"     <b>",
"      not",
"     </b>",
"     for systemic anticoagulation. Do not administer I.M. due to pain, irritation, and hematoma formation.",
"    </p>",
"   </div>",
"   <div class=\"block uicn drugH1Div\" id=\"F14472659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     Maintenance of line patency: 0.5 unit/mL",
"    </p>",
"   </div>",
"   <div class=\"block uicp drugH1Div\" id=\"F14472658\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Usual Infusion Concentrations: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Premixed solutions available",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      I.V. infusion:",
"     </b>",
"     100 units/mL",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F178803\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in dextran 6% in dextrose, dextran 6% in NS, D",
"     <sub>",
"      5",
"     </sub>",
"     LR, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      4",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, D",
"     <sub>",
"      25",
"     </sub>",
"     W, fat emulsion 10%,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS, Ringer's injection;",
"     <b>",
"      variable stability (consult detailed reference)",
"     </b>",
"     in D",
"     <sub>",
"      5",
"     </sub>",
"     NS, D",
"     <sub>",
"      5",
"     </sub>",
"     W, D",
"     <sub>",
"      10",
"     </sub>",
"     W, LR, peritoneal dialysis solutions, TPN.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Acetaminophen, acyclovir, alcohol (ethyl), allopurinol, amifostine, aminophylline, ampicillin, ampicillin/sulbactam, anidulafungin, atracurium, atropine, aztreonam, betamethasone sodium phosphate, bivalirudin, bleomycin, caffeine citrate, calcium gluconate, cefazolin, cefotaxime, cefotetan, ceftazidime, chlorpromazine, cimetidine, cisplatin, cladribine, clindamycin, cyanocobalamin, cyclophosphamide, cytarabine, daptomycin, dexamethasone sodium phosphate, dexmedetomidine, digoxin, docetaxel, dopamine, doripenem, doxorubicin liposome, edrophonium, enalaprilat, epinephrine, eptifibatide, ertapenem, esmolol, estrogens (conjugated), ethacrynate, etoposide phosphate, famotidine, fenoldopam, fentanyl, fluconazole, fludarabine, fluorouracil, foscarnet, furosemide, gallium nitrate, gemcitabine, gold sodium thiosulfate, granisetron, hetastarch in lactate electrolyte injection (Hextend&reg;), hydralazine, hydrocortisone sodium succinate, insulin (regular), isoproterenol, kanamycin, leucovorin calcium, lidocaine, linezolid, lorazepam, magnesium sulfate, melphalan, meperidine, meropenem, methotrexate, methyldopate, methylergonovine, metoclopramide, metronidazole, micafungin, midazolam, milrinone, minocycline, mitomycin, morphine, nafcillin, neostigmine, nitroprusside, norepinephrine, ondansetron, oxacillin, oxaliplatin, oxytocin, paclitaxel, palonosetron, pancuronium, pemetrexed, penicillin G potassium, pentazocine, phytonadione, piperacillin, piperacillin/tazobactam, potassium chloride, procainamide, prochlorperazine edisylate, propofol, propranolol, pyridostigmine, ranitidine, remifentanil, sargramostim, scopolamine, sodium bicarbonate, tacrolimus, teniposide, terbutaline, theophylline, thiotepa, ticarcillin/clavulanate, tigecycline, tirofiban, trimethobenzamide, vasopressin, vecuronium, vinblastine, vincristine, warfarin, zidovudine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Alteplase, amiodarone, amphotericin B cholesteryl sulfate complex, amsacrine, caspofungin, diazepam, doxycycline, ergotamine, filgrastim,  haloperidol, idarubicin, levofloxacin, methotrimeprazine, nesiritide, phenytoin, reteplase.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Aldesleukin, amikacin, antithymocyte globulin (rabbit), ceftriaxone, ciprofloxacin, cisatracurium, dacarbazine, diltiazem, diphenhydramine, dobutamine, doxapram, doxorubicin HCl, droperidol, drotrecogin alfa, erythromycin lactobionate, fentanyl, gentamicin, hydromorphone, labetalol, methylprednisolone sodium succinate, metoprolol, nicardipine, nitroglycerin, pantoprazole, promethazine, quinidine gluconate, succinylcholine, telavancin, tenecteplase, thiopental, tobramycin, TPN, vancomycin, vinorelbine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Aminophylline, amphotericin B, ampicillin, atropine, bleomycin, buprenorphine, caffeine citrate, cefazolin, cefotaxime, cefoxitin, chloramphenicol, cisplatin, clindamycin, clonidine, cyclophosphamide, digoxin, dobutamine, dopamine, epinephrine, etomidate, fentanyl, fluorouracil, furosemide, hyaluronidase, iohexol, iopamidol, iothalamate meglumine 60%, ioxaglate meglumine 39.3% and ioxaglate sodium 19.6%, leucovorin calcium, lidocaine, lincomycin, methotrexate, metoclopramide, mitomycin, nafcillin, naloxone, neostigmine, nitroglycerin, nitroprusside, pancuronium, phenobarbital, piperacillin, ranitidine, succinylcholine, sulfamethoxazole/trimethoprim, verapamil, vincristine.",
"     <b>",
"      Incompatible:",
"     </b>",
"     Amiodarone, diazepam, doxorubicin hydrochloride, droperidol, erythromycin lactobionate, gentamicin, haloperidol, hydromorphone, kanamycin, levofloxacin, meperidine, methotrimeprazine, midazolam, pantoprazole, pentazocine, promethazine, streptomycin, tobramycin, vancomycin, warfarin.",
"     <b>",
"      Variable (consult detailed reference):",
"     </b>",
"     Amikacin, ceftriaxone, chlorpromazine, cimetidine, dimenhydrinate, morphine, vinblastine.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1053165\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prophylaxis and treatment of thromboembolic disorders [Injection: FDA approved in pediatric patients (age not specified) and adults];",
"     <b>",
"      Note:",
"     </b>",
"     Heparin lock flush solution is intended only to maintain patency of I.V. devices and is not to be used for systemic anticoagulant therapy (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F178805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Heparin may be confused with Hespan&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      High alert medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      National Patient Safety Goals:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The Joint Commission (TJC) requires healthcare organizations that provide anticoagulant therapy to have a process in place to reduce the risk of anticoagulant-associated patient harm. Patients receiving anticoagulants should receive individualized care through a defined process that includes standardized ordering, dispensing, administration, monitoring and education. This does not apply to routine short-term use of anticoagulants for prevention of venous thromboembolism when the expectation is that the patient&rsquo;s laboratory values will remain within or close to normal values (NPSG.03.05.01).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Administration issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       The 100 unit/mL concentration should not be used to flush heparin locks, I.V. lines, or intra-arterial lines in neonates or infants &lt;10 kg (systemic anticoagulation may occur). The 10 unit/mL flush concentration may inadvertently cause systemic anticoagulation in infants &lt;1 kg who receive frequent flushes.",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Other safety concerns:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Heparin sodium injection 10,000 units/mL and  Hep-Lock U/P 10 units/mL have been confused with each other. Fatal medication errors have occurred between the two whose labels are both blue.",
"       <b>",
"        Never rely on color as a sole indicator to differentiate product identity.",
"       </b>",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Heparin lock flush solution is intended only to maintain patency of I.V. devices and is",
"       <b>",
"        not",
"       </b>",
"       to be used for anticoagulant therapy.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F178802\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Immunologically mediated heparin-induced thrombocytopenia (HIT) occurs in a small percentage of patients and is and is marked by a progressive fall in platelet counts and, in some cases, thromboembolic complications (skin necrosis, pulmonary embolism, gangrene of the extremities, stroke, or MI).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Cardiovascular: Allergic vasospastic reaction (possibly related to thrombosis), chest pain, hemorrhagic shock, shock, thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia (delayed, transient), bruising (unexplained), cutaneous necrosis, dysesthesia pedis, erythematous plaques (case reports), eczema, urticaria, purpura",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Adrenal hemorrhage, hyperkalemia (suppression of aldosterone synthesis), ovarian hemorrhage, rebound hyperlipidemia on discontinuation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, hematemesis, nausea, tarry stools, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Frequent or persistent erection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bleeding from gums, epistaxis, hemorrhage, ovarian hemorrhage, retroperitoneal hemorrhage, thrombocytopenia (see note)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Liver enzymes increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Local: Irritation, erythema, pain, hematoma, and ulceration have been rarely reported with deep SubQ injections; I.M. injection (not recommended) is associated with a high incidence of these effects",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy, osteoporosis (chronic therapy effect)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Conjunctivitis (allergic reaction), lacrimation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Hematuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Asthma, bronchospasm (case reports), hemoptysis, pulmonary hemorrhage, rhinitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Allergic reactions, anaphylactoid reactions, heparin resistance, hypersensitivity (including chills, fever, and urticaria)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1053170\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to heparin or any component (unless a life-threatening situation necessitates use and use of an alternative anticoagulant is not possible); severe thrombocytopenia, uncontrollable active bleeding (unless secondary to disseminated intravascular coagulation); use when appropriate blood coagulation tests cannot be obtained at appropriate intervals (applies to full-dose heparin only).",
"     <b>",
"      Note",
"     </b>",
"     : Some products contain benzyl alcohol as a preservative; their use in neonates, infants, or pregnant or nursing mothers is contraindicated; use preservative-free heparin in these patients.",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1053152\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution as hemorrhage may occur; bleeding may occur at any site including internal sites such as GI bleeding, urinary tract bleeding, adrenal hemorrhage, ovarian (corpus luteum) hemorrhage, and retroperitoneal hemorrhage; risk factors for hemorrhage include: I.M. injections; intermittent I.V. injections (vs continuous I.V. infusion); increased capillary permeability; menstruation; recent surgery or invasive procedures; severe renal, hepatic, or biliary disease; indwelling catheters; subacute bacterial endocarditis; congenital or acquired bleeding disorders; active ulcerative or angiodysplastic GI diseases; continuous GI tube drainage; severe uncontrolled hypertension; history of hemorrhagic stroke; concomitant treatment with platelet inhibitors; recent GI bleeding; thrombocytopenia or platelet defects; hypertensive or diabetic retinopathy; and patients &gt;60 years of age (especially women). Discontinue if bleeding occurs; severe hemorrhage or overdosage may require reversal of heparin with protamine.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     High dosage requirements to maintain a therapeutic APTT (heparin resistance) may occur in patients with antithrombin deficiency, increased heparin clearance, elevations in heparin-binding proteins, and elevations in factor VIII and/or fibrinogen; heparin resistance is frequently encountered in patients with fever, thrombosis, thrombophlebitis, infections with thrombosing tendencies, MI, cancer, and in postsurgical patients; measurement of anticoagulant effects using antifactor Xa levels may be beneficial.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Heparin does not possess fibrinolytic activity and, therefore, cannot lyse established thrombi.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1053151\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Some products contain benzyl alcohol as a preservative; use of these products is contraindicated in neonates, infants, or pregnant or nursing mothers",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites. Some preparations contain sulfites which may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     May cause thrombocytopenia; monitor platelet count closely. Patients who develop heparin-induced thrombocytopenia (HIT) may be at risk of developing a new thrombus [heparin-induced thrombocytopenia and thrombosis (HITT)]. Discontinue therapy and consider alternatives if platelets are &lt;100,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     and/or thrombosis develops. HIT or HITT may be delayed and can occur up to several weeks after discontinuation of heparin. Thrombocytopenia may be more common with bovine lung heparin compared to porcine mucosa heparin; however, if a patient receiving bovine lung heparin experiences severe thrombocytopenia, it is not recommended to switch to porcine mucosa heparin because a similar reaction may occur.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Confirm the concentration of all heparin injection vials prior to administration; do not use heparin injection as a &ldquo;catheter lock flush&rdquo; as the injection is supplied in various concentrations including highly concentrated strengths. Fatal hemorrhages have occurred in pediatric patients when higher concentrations of heparin injection were confused with lower concentrations of heparin lock flush.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F178720\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     5-ASA Derivatives: May enhance the adverse/toxic effect of Heparin. Specifically, the risk for bleeding/bruising may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticoagulants: May enhance the anticoagulant effect of other Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aspirin: May enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Collagenase (Systemic): Anticoagulants may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and/or bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticorelin: Heparin may enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dasatinib: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: Anticoagulants may enhance the adverse/toxic effect of Deferasirox. Specifically, the risk for GI ulceration/irritation or GI bleeding may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Drotrecogin Alfa (Activated): Heparin may enhance the adverse/toxic effect of Drotrecogin Alfa (Activated). Bleeding may occur.  Management: Potential benefits of therapeutic heparin doses should be weighed against an increased risk of bleeding in patients who receive drotrecogin alfa.  In patients receiving prophylactic heparin doses consider continuing this during drotrecogin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Anticoagulants. Bleeding may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ibritumomab: Anticoagulants may enhance the adverse/toxic effect of Ibritumomab. Both agents may contribute to an increased risk of bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nitroglycerin: May diminish the anticoagulant effect of Heparin. Nitroglycerin may decrease the serum concentration of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nonsteroidal Anti-Inflammatory Agents: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omacetaxine: Anticoagulants may enhance the adverse/toxic effect of Omacetaxine. Specifically, the risk for bleeding-related events may be increased.  Management: Avoid concurrent use of anticoagulants with omacetaxine in patients with a platelet count of less than 50,000/uL.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Omega-3 Fatty Acids: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Palifermin: Heparin may increase the serum concentration of Palifermin.  Management: Avoid coadministration of heparin with palifermin, and flush any heparin-maintained intravenous line with saline prior to administration of palifermin via that line.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentosan Polysulfate Sodium: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pentoxifylline: May enhance the anticoagulant effect of Heparin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prostacyclin Analogues: May enhance the adverse/toxic effect of Anticoagulants. Specifically, the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: Anticoagulants may enhance the anticoagulant effect of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salicylates: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thrombolytic Agents: May enhance the anticoagulant effect of Anticoagulants. Management: See full drug monograph for guidelines for the use of alteplase for acute ischemic stroke during treatment with oral anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May enhance the anticoagulant effect of Anticoagulants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tositumomab and Iodine I 131 Tositumomab: Anticoagulants may enhance the adverse/toxic effect of Tositumomab and Iodine I 131 Tositumomab. Specifically, the risk of bleeding-related adverse effects may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin E: May enhance the anticoagulant effect of Anticoagulants. Vitamin E may also increase the overall risk for bleeding.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F178723\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F6481836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Increased resorptions were observed in some animal reproduction studies. Heparin does not cross the placenta. Heparin may be used for the prevention and treatment of thromboembolism in pregnant women; however the use of low molecular weight heparin (LMWH) is preferred. Twice-daily heparin should be discontinued prior to induction of labor or a planned cesarean delivery. In pregnant women with mechanical heart valves, adjusted-dose LMWH or adjusted-dose heparin may be used throughout pregnancy or until week 13 of gestation when therapy can be changed to warfarin. LMWH or heparin should be resumed close to delivery. In women who are at a very high risk for thromboembolism (older generation prosthesis in mitral position or history of thromboembolism), warfarin can be used throughout pregnancy and replaced with LMWH or heparin near term; the use of low-dose aspirin is also recommended. When choosing therapy, fetal outcomes (ie, pregnancy loss, malformations), maternal outcomes (ie, VTE, hemorrhage), burden of therapy, and maternal preference should be considered (Guyatt, 2012).",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Some products contain benzyl alcohol as a preservative; their use in pregnant women is contraindicated by some manufacturers; use of a preservative free formulation is recommended.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1053160\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Platelet counts, signs of bleeding, hemoglobin, hematocrit, APTT; for full-dose heparin (ie, nonlow dose), the dose should be titrated according to APTT (see table). For intermittent I.V. injections, APTT is measured 3.5-4 hours after I.V. injection.",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1053164\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Venous thromboembolism: Heparin: 0.3-0.7 unit/mL anti-Xa activity (by chromogenic assay) or 0.2-0.4 unit/mL (by protamine titration); APTT: 1.5-2.5 times control (usually reflects an APTT of 60-85 seconds) (Hirsh, 2008; Kearon, 2008)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     When used with thrombolytic therapy in patients with MI, a lower therapeutic range corresponding to an antiXa level of 0.2-0.5 units/mL by chromogenic assay; APTT: 1.5-2 times control (or approximately an APTT of 50-70 seconds) is recommended (Goodman, 2008)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1053150\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Potentiates the action of antithrombin III and thereby inactivates thrombin (as well as activated coagulation factors IX, X, XI, XII, and plasmin) and prevents the conversion of fibrinogen to fibrin; heparin also stimulates release of lipoprotein lipase (lipoprotein lipase hydrolyzes triglycerides to glycerol and free fatty acids)",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1053168\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Anticoagulation effect: Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     SubQ: 20-60 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.V.: Immediate",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1053169\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: SubQ, I.M.: Erratic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Does not cross the placenta; does not appear in breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Believed to be partially metabolized in the reticuloendothelial system",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Mean: 90 minutes; range: 60-120 minutes; affected by obesity, renal function, malignancy, presence of pulmonary embolism, and infections; half-life has been reported to be dose-dependent: I.V. bolus: 25 units/kg: 30 minutes; 100 units/kg: 60 minutes; 400 units/kg: 150 minutes (Hirsh, 2008)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Renal; small amount excreted unchanged in urine;",
"     <b>",
"      Note:",
"     </b>",
"     At therapeutic doses, elimination occurs rapidly via nonrenal mechanisms. With very high doses, renal elimination may play more of a role; however, dosage adjustment remains unnecessary for patients with renal impairment (Hirsh, 2008).",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1053158\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/20/325?source=see_link\">",
"      see \"Heparin: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Limit alcohol",
"    </p>",
"   </div>",
"   <div class=\"block adi drugH1Div\" id=\"F1053171\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Additional Information",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     To reverse the effects of heparin, use protamine. Heparin is available from bovine lung and from porcine intestinal mucosa sources",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration of heparin therapy (pediatric):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     DVT and PE: At least 5-10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Oral anticoagulation should be started on day 1 of heparin; oral anticoagulation should be overlapped with heparin for 5 days (or more, if INR is not &gt;2)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;text-align:justify;\">",
"     Updates to the United States Pharmacopeia (USP) heparin monograph were made in response to over 200 deaths linked to contaminated heparin products in 2007-2008. Serious adverse effects (including hypersensitivity reactions) were associated with a heparin-like contaminant (oversulfated chondroitin sulfate). At the time, the available quality assurance tests did not test for oversulfated chondroitin sulfate. Effective October 1, 2009, a new reference standard for heparin and a new test to determine potency (the chromogenic antifactor IIa test) were established by USP. The updated USP heparin monograph also harmonized the USP unit with the WHO international standard (IS) unit (ie, international unit). The new standard may result in a 10% reduction in potency for heparin marketed in the United States. The FDA has requested that all manufacturers differentiate (from \"old\" heparin products) heparin products manufactured by the new standards. The labels of products manufactured according to the new standard will have an \"N\" in the lot number or following the expiration date. Additionally, products manufactured by Hospira may be identified by the number \"82\" or higher (eg, 83, 84) at the beginning of their lot numbers. For therapeutic use, practitioners may or may not notice that larger doses of heparin are required to achieve \"therapeutic\" activity of anticoagulation. The impact of this change in potency should be less significant when heparin is administered by subcutaneous injection due to low and variable bioavailability. Heparin dosing should always be individualized according to the patient-specific clinical situation. Appropriate clinical judgment is essential in determining heparin dosage (Smythe, 2010).",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Andrew M, Marzinotto V, Massicotte P, et al, &ldquo;Heparin Therapy in Pediatric Patients: A Prospective Cohort Study,&rdquo;",
"      <i>",
"       Pediatr Res",
"      </i>",
"      , 1994, 35(1):78-83.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/ 8134203 /pubmed\" id=\" 8134203 \" target=\"_blank\">",
"        8134203",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goodman SG, Menon V, Cannon CP, et al, \"Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):708S-775S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574277 /pubmed\" id=\"18574277 \" target=\"_blank\">",
"        18574277",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Harrington RA, Becker RC, Cannon CP, et al, \"Antithrombotic Therapy for Non-ST-Segment Elevation Acute Coronary Syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):670S-707S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574276 /pubmed\" id=\"18574276 \" target=\"_blank\">",
"        18574276",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsh J, Bauer KA, Donati MB, et al, \"Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):141S-159S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574264/pubmed\" id=\"18574264\" target=\"_blank\">",
"        18574264",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hirsh J, Guyatt G, Albers GW, et al, \"Executive Summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):71-109.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574259/pubmed\" id=\"18574259\" target=\"_blank\">",
"        18574259",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Institute for Safe Medication Practices (ISMP), \"Standard Concentrations of Neonatal Drug Infusions,\"",
"      <i>",
"       ISMP",
"      </i>",
"      , 2011.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Kearon C, Kahn SR, Agnelli G, et al, \"Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      , 2008, 133(6 Suppl):454S-545S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574272/pubmed\" id=\"18574272\" target=\"_blank\">",
"        18574272",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Monagle P, Chalmers E, Chan A, et al, \"Antithrombotic Therapy in Neonates and Children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition),\"",
"      <i>",
"       Chest",
"      </i>",
"      ,  2008, 133(6 Suppl):887S-968S.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/18574281 /pubmed\" id=\"18574281 \" target=\"_blank\">",
"        18574281",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newall F, Johnston L, Ignjatovic V, et al, \"Unfractionated Heparin Therapy in Infants and Children,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2009, 123(3):e510-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/19221154 /pubmed\" id=\"19221154 \" target=\"_blank\">",
"        19221154",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Phillips MS, \"Standardizing I.V. Infusion Concentrations: National Survey Results,\"",
"      <i>",
"       Am J Health Syst Pharm",
"      </i>",
"      , 2011, 68(22):2176-82.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/22058104/pubmed\" id=\"22058104\" target=\"_blank\">",
"        22058104",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Smythe MA, Nutescu EA, and Wittkowsky AK, \"Changes in the USP Heparin Monograph and Implications for Clinicians,\"",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2010, 30(5):428-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?7/39/7801/abstract-text/20411994/pubmed\" id=\"20411994\" target=\"_blank\">",
"        20411994",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13349 Version 44.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-200.215.4.194-785DB895A1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7801=[""].join("\n");
var outline_f7_39_7801=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15793684\">",
"      Special Alerts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11443864\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178752\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178753\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053161\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11442594\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053153\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178727\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178711\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053166\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472659\">",
"      Usual Infusion Concentrations: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14472658\">",
"      Usual Infusion Concentrations: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178803\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053165\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178805\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178802\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053170\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053152\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053151\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299438\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178720\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F178723\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6481836\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053160\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053164\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053150\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053168\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053169\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053158\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1053171\">",
"      Additional Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13349\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13349|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=related_link\">",
"      Heparin: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?0/20/325?source=related_link\">",
"      Heparin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7802="Treatment of beta thalassemia";
var content_f7_39_7802=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of beta thalassemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Edward J Benz, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/39/7802/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/39/7802/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 11, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In normal subjects, globin chain synthesis for hemoglobin is very tightly controlled, such that the ratio of alpha to non-alpha chains is 1:1. Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one of the globin chains of hemoglobin. Specifically, beta thalassemia is due to impaired production of beta globin chains, which leads to a relative excess of alpha globin chains. Excess alpha globin chains are unstable, incapable of forming soluble tetramers on their own, and precipitate within the cell, leading to a variety of clinical manifestations. The degree of alpha globin chain excess determines the severity of subsequent clinical manifestations, which are profound in patients homozygous for impaired beta globin synthesis and much less pronounced in heterozygotes, who generally have minimal or mild anemia and no symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of beta thalassemia will be reviewed here [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The clinical manifestations of this disorder are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain clinical terms are used to describe the phenotypic expression of beta thalassemia (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta (0) thalassemia",
"      </strong>",
"      &mdash; Beta (0) thalassemia refers to mutations of the beta globin locus that result in the",
"      <strong>",
"       absence",
"      </strong>",
"      of production of beta globin. Patients homozygous or doubly heterozygous for beta (0) thalassemic genes cannot make normal beta chains and are therefore unable to make any hemoglobin A.",
"     </li>",
"     <li>",
"      <strong>",
"       Beta (+) thalassemia",
"      </strong>",
"      &mdash; Beta (+) thalassemia refers to mutations that result in",
"      <strong>",
"       decreased",
"      </strong>",
"      production of beta globin. Patients homozygous for beta (+) thalassemic genes are able to make some hemoglobin A, and are generally less severely affected than those homozygous for beta (0) genes.",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia major",
"      </strong>",
"      &mdash; Beta thalassemia major is the term applied to patients who have either no effective production (as in homozygous beta (0) thalassemia) or severely limited production of beta globin. These are the patients originally described by Cooley (Cooley's anemia). Starting during the first year of life, they have profound and life-long transfusion-dependent anemia.",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia minor",
"      </strong>",
"      &mdash; Beta thalassemia minor (beta thalassemia trait) is the term applied to heterozygotes who have inherited a single gene leading to reduced beta globin production. Such patients are asymptomatic, may be only mildly anemic, and are usually discovered when a blood count has been obtained for other reasons.",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia intermedia",
"      </strong>",
"      &mdash; Beta thalassemia intermedia is the term applied to patients with disease of intermediate severity, such as those who are compound heterozygotes of two thalassemic variants (",
"      <a class=\"graphic graphic_table graphicRef69490 \" href=\"UTD.htm?27/53/28507\">",
"       table 1",
"      </a>",
"      ). These patients have a later clinical onset and a milder degree of anemia, which may or may not require transfusional support.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Management of beta thalassemia varies with the type of disease, which will be described below for each of the three beta thalassemia variants listed above.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Beta thalassemia minor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subjects with beta thalassemia minor (beta thalassemia trait) are not symptomatic from this condition, may have only mild degrees of anemia, and require no specific therapy. Transfusions are occasionally required in pregnant women who may develop a more severe \"physiologic\" anemia of pregnancy. It is important that this condition be diagnosed properly, as it is often confused with iron deficiency anemia and does not respond to treatment with iron. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H21#H21\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Beta thalassemia minor'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, patients with thalassemia minor share the same general risk as normal individuals for development of iron deficiency anemia from other causes. They should not be denied iron when true iron deficiency and beta thalassemia trait coexist. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=see_link\">",
"     \"Treatment of anemia due to iron deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Beta thalassemia intermedia",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Anemia and transfusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with beta thalassemia intermedia must be monitored closely for progression of their anemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the development of worsening evidence of the complications of hemolysis or extramedullary erythropoiesis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/3\">",
"     3",
"    </a>",
"    ]. In the majority of these patients, chronic transfusion therapy will ultimately have to be implemented, occasionally as late as the third or fourth decade of life. Symptoms usually develop when the hemoglobin level falls below 7",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    and transfusion may be required during periods of rapid growth, infection-associated aplastic crises, and pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. However, in some settings, severe degrees of anemia can be well tolerated, such as in those with hemoglobin",
"    <span class=\"nowrap\">",
"     E/beta",
"    </span>",
"    thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/6\">",
"     6",
"    </a>",
"    ]. Accordingly, the patient&rsquo;s activity limitations, growth, development, and the early appearance of skeletal changes or other disease-related complications are the factors that need to be taken into consideration when considering a transfusion program [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Earlier transfusion may be reasonable in order to maintain growth and increase well being in the child with thalassemia. In addition, the risk of developing alloimmunization may be lessened by earlier transfusion. In one study, for example, the prevalence of alloimmunization to red cell transfusions was 21 versus 48 percent in thalassemic subjects who received their first transfusion before or after the age of three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Institution of transfusion therapy can be delayed by splenectomy if anemia or other symptoms worsen significantly (",
"    <a class=\"graphic graphic_picture graphicRef76666 \" href=\"UTD.htm?26/29/27089\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Splenectomy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14176389\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Splenectomy in patients with thalassemia intermedia is generally indicated for growth retardation, poor health, leukopenia, thrombocytopenia, increased transfusion need, or symptomatic splenomegaly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/9\">",
"     9",
"    </a>",
"    ]. However, a high incidence of thromboembolic complications, both arterial and venous, has been noted following splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/10-12\">",
"     10-12",
"    </a>",
"    ], leading to the suggestion that splenectomy be avoided in this population if at all possible [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/7\">",
"     7",
"    </a>",
"    ], even if this choice entails a greater need for red cell transfusion and the subsequent need for iron chelation because of transfusional iron overload and its consequences [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, splenectomized patients with thalassemia intermedia who developed a documented thromboembolic event were more likely to have a nucleated red cell count &ge;300",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    a platelet count",
"    <span class=\"nowrap\">",
"     &ge;500,000/microL,",
"    </span>",
"    to be transfusion na&iuml;ve, or to have evidence for pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/14\">",
"     14",
"    </a>",
"    ]. Subjects with any of the first three of these four characteristics also had a shorter time to thrombosis following splenectomy.",
"   </p>",
"   <p>",
"    While this and other studies have suggested the use of",
"    <span class=\"nowrap\">",
"     antiplatelet/anticoagulant",
"    </span>",
"    therapy in high-risk patients with thalassemia intermedia (eg, major surgery, pregnancy, post-splenectomy), controlled studies indicating the safety and utility of this approach are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/5,10,15-17\">",
"     5,10,15-17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Iron overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with beta thalassemia intermedia eventually develop iron overload even without the use of blood transfusions, because of the increased iron absorption associated with high rates of erythropoiesis and red cell destruction. Thus, iron stores in these patients should be monitored on a regular basis. Magnetic resonance imaging (MRI) appears to be superior to measurement of serum ferritin for estimating total body iron burden in these patients, especially those who are being regularly transfused [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/18-21\">",
"     18-21",
"    </a>",
"    ]. As an example, when compared to subjects with beta thalassemia major, serum ferritin levels in those with thalassemia intermedia tend to",
"    <strong>",
"     underestimate",
"    </strong>",
"    the degree of iron loading as reflected in liver iron concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because the tannins in tea chelate iron in the intestinal tract and prevent or reduce the absorption of dietary iron, regular consumption of tea is encouraged, although evidence for its efficacy is incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Iron chelation therapy may be indicated if serum ferritin concentrations are excessive (variably stated as either &gt;400 or &gt;1000",
"    <span class=\"nowrap\">",
"     mcg/L)",
"    </span>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    if imaging and other studies suggest the presence of iron loading in critical organs such as the liver and heart [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/7,25-27\">",
"     7,25-27",
"    </a>",
"    ]. The general subject of iron chelation is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cardiopulmonary complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with beta thalassemia intermedia may suffer from the complications of chronic hypoxia, such as high cardiac output, increased pulmonary vascular resistance, pulmonary hypertension, and resulting heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. Although physical examination can be used to screen for the presence of right-sided cardiac changes, it has been suggested that serial screening via Doppler echocardiography (eg, Doppler tricuspid gradient measurement) may be the best noninvasive technique for establishing the presence of these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=see_link\">",
"     \"Clinical features and diagnosis of pulmonary hypertension in adults\"",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H18530051\">",
"     'Pulmonary hypertension'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Initiation of transfusion-chelation therapy is warranted if cardiopulmonary complications are seen in patients with thalassemia intermedia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/30\">",
"     30",
"    </a>",
"    ], although it would appear preferable to initiate transfusion therapy in these patients in order to prevent, rather than palliate, such complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H16\">",
"     'Chronic hypertransfusion therapy'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Other complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thalassemia intermedia are prone to develop many of the complications seen in patients with beta thalassemia major (eg, leg ulcers, osteoporosis, extramedullary hematopoiesis, hypogonadism, gallstones, aplastic crisis, secondary",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    deficiencies). The effect of various treatments (eg, transfusion,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    , splenectomy) on the risk of these complications is unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/7,31\">",
"     7,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of enlargement of the facial bones secondary to extramedullary hematopoiesis, surgical correction of the maxilla may be needed, as are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    supplementation and close monitoring for biliary tract disease secondary to the presence of bilirubin-rich gallstones. Patients who become transfusion-dependent should be managed in a manner similar to patients with beta thalassemia major.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Beta thalassemia major",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642333\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prior to the advent of hypertransfusion regimens in the 1960s, beta thalassemia major was a disease fatal in infancy. Observational studies have shown that hypertransfusion regimens transformed this disorder into a more chronic disease, with subjects usually dying in their second decade of life from the complications of transfusional iron overload. Iron chelation therapy, begun in the 1970s, transformed this into a chronic disease permitting prolonged survival. Hematopoietic cell transplantation, begun in the 1980s, is a curative regimen, although not all patients are candidates for this procedure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Accordingly, the mainstays of therapy for beta thalassemia major are chronic hypertransfusion combined with iron chelation, and supportive measures directed at the complications of the expanded erythron and iron overload [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Emerging therapies include the wider use of allogeneic bone marrow transplantation, the only curative modality, pharmacologic manipulation of fetal hemoglobin levels, and, eventually, it is to be hoped, gene therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/34\">",
"     34",
"    </a>",
"    ]. Optimal care of these patients requires coordination among these modes of therapy and ongoing decision-making about their applicability or inapplicability to each individual patient or family.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Chronic hypertransfusion therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The widespread acceptance of chronic hypertransfusion as the therapy of choice for severe beta thalassemia has greatly altered the typical clinical course for patients in areas of the world with sufficient resources to support hypertransfusion programs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. Transfusion was once used only as a palliative or emergency measure in these patients because of limited availability of blood, fears about the complications of transfusion,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    concerns about the long-term development of iron overload. While intermittent blood transfusion may have sustained patients through acute crises, it provided little in the way of beneficial effects on the progression of the syndrome. In particular, this approach did nothing to check the ravages that massive ineffective erythropoiesis and erythroid hyperplasia inflicted upon the growth, development, and systemic well being of the child with beta thalassemia major.",
"   </p>",
"   <p>",
"    For these reasons, chronic hypertransfusion regimens were introduced in the 1960s [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/32\">",
"     32",
"    </a>",
"    ]. These regimens shared in common the strategy that transfused red cells were to be given often enough and in sufficient quantity to maintain a \"steady state\" hemoglobin level of 9 to 10",
"    <span class=\"nowrap\">",
"     g/dL.",
"    </span>",
"    During the initial phases, this required an increase of about 125 percent in the amount of administered blood. There was considerable fear that this increase would accelerate the rate of iron overload and shorten patient survival. However, as discussed below, this fear was not realized, possibly because hypertransfusion-induced reduction in erythropoiesis also reduces the increased absorption of iron from the gastrointestinal tract. Moreover, suppression of erythropoiesis probably reduces the expanded blood volume otherwise required to supply the hyperplastic marrow. This combination of effects may ultimately lead to a stabilization of long-term chronic red cell requirements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/19,32\">",
"     19,32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642352\">",
"    <span class=\"h4\">",
"     Benefits",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical benefits of hypertransfusion begun during the first decade of life are dramatic, with reductions in hepatosplenomegaly, partial correction of abnormal skeletal development, and at least short-term improvements in cardiac dilatation and systolic function. In most industrialized countries, hypertransfusion regimens have become the norm. As a result, the most dramatic clinical features of severe thalassemia are rarely encountered in these countries [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/32,35,36\">",
"     32,35,36",
"    </a>",
"    ]. It is now well established that chronic hypertransfusion improves oxygen-carrying capacity, cardiac status, and systemic parameters of growth, development, and overall well being. Attendance at school is improved, intercurrent infections appear to be reduced, and overall health appears to be greatly improved during the first 10 to 15 years of therapy. (See",
"    <a class=\"local\" href=\"#H15642333\">",
"     'Overview'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642359\">",
"    <span class=\"h4\">",
"     Initiation of treatment and avoidance of complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Transfusion therapy should be started early in those children clearly exhibiting the stigmata of beta thalassemia major. As already noted, the time to institute therapy in patients of intermediate severity is much less clear and requires close clinical monitoring.",
"   </p>",
"   <p>",
"    Before the first transfusion is given, it is important that extended genotyping of the patient&rsquo;s red cells for Rh Subgroups and minor red cell antigens be performed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/18,32,38\">",
"     18,32,38",
"    </a>",
"    ]. As an example, in a series of children and adults with thalassemia, more than two-thirds of the alloantibodies formed were directed against Kell and Rh subgroups [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/39\">",
"     39",
"    </a>",
"    ]. Given the life-long requirement for frequent transfusions, all possible steps to eliminate alloimmunization must be taken from the onset. This may include attempts at matching donors of the same ethnic origin, as well as the potentially beneficial effects of leukodepletion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/38,40,41\">",
"     38,40,41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=see_link&amp;anchor=H27#H27\">",
"     \"Overview of the management of sickle cell disease\", section on 'Alloimmunization'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Debate currently exists as to whether other steps to avoid related complications (eg, febrile reactions, delayed transfusion reactions, transfusion-related graft versus host disease) should be undertaken routinely in this patient group. Thus, most centers use frozen red cells, leukocyte-poor red cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    washed red cells; widespread use of irradiated red cells is not currently the norm. These patients are at risk for all of the usual blood-borne infections (eg, hepatitis C, HIV) and need to be closely monitored for symptoms or laboratory abnormalities indicative of these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642373\">",
"    <span class=\"h4\">",
"     Hypertransfusion regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depending on the size of the patient, the usual transfusion regimen involves infusion of one to three units of packed red cells every three to five weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. More frequent transfusions may be required initially. Some centers favor an initial \"super transfusion\" to hemoglobin levels of 12 to 14",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    in the hopes that, over the long term, the same chronic blood requirement would maintain a higher hemoglobin concentration and, presumably, more normal physiologic function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/19\">",
"     19",
"    </a>",
"    ]. The efficacy of these regimens remains unproven. Occasional reports of bizarre reactions occurring within the first 24 to 48 hours after transfusion have led to the recommendation that no more than 15 mL of red cells per kg of body weight be administered during any 24-hour period, except in cases of profound emergency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Cardiac monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Frequent monitoring of cardiac function in transfusion-dependent patients may indicate those at risk of developing symptomatic cardiac disease, who might then be candidates for more intensive and sustained transfusional regimens, iron chelation therapy, and the use of cardioactive drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/42\">",
"     42",
"    </a>",
"    ]. In one study, 81 patients with thalassemia major and no history of cardiac disease underwent quantitative annual monitoring of left ventricular ejection fraction (LVEF) by radionuclide ventriculography for a median of six years. The following observations were made [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/43\">",
"     43",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An absolute LVEF &lt;45 percent or a decrease of &gt;10 percentage units was significantly associated with subsequent development of symptomatic cardiac disease and death, with a median interval between the first abnormal LVEF findings and development of symptomatic cardiac disease of 3.5 years.",
"     </li>",
"     <li>",
"      Heart failure",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      arrhythmia, as well as death, were less common in those in whom subcutaneous iron chelation was started before 10 years of age as well as in those who had a serum ferritin &gt;2500",
"      <span class=\"nowrap\">",
"       microg/L",
"      </span>",
"      for less than one-third of follow-up time.",
"     </li>",
"     <li>",
"      Intensified sustained iron chelation therapy was recommended in 34 patients in whom LVEF was &lt;45 percent or decreased by &gt;10 percentage units. All 27 patients complying with intensification survived, while all seven who did not comply died. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"       \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Splenectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;An indication for splenectomy in patients with beta-thalassemia major and intermedia is an increase of 50 percent or more in the red cell transfusion requirement over a one-year period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/1\">",
"     1",
"    </a>",
"    ]. Splenectomy is usually associated with a reduction in red cell transfusion requirement, although the benefit is often transient.",
"   </p>",
"   <p>",
"    Post-splenectomy thrombocytosis is common, and is a risk factor for thromboembolic events [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/15,44,45\">",
"     15,44,45",
"    </a>",
"    ]. However, thromboembolic complications in splenectomized patients with beta thalassemia major are not as frequently noted when compared to patients with thalassemia intermedia who have undergone splenectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/16,46\">",
"     16,46",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14176389\">",
"     'Splenectomy'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p>",
"    Because such spleens may be quite large, the laparoscopic technique may not always be technically possible, and may be associated with a higher incidence of portal vein thrombosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. The decision to pursue splenectomy is therefore a difficult one, and should be made on a case-by-case basis, as there is a fine balance between benefits and risks in this condition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Iron chelation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Iron overload is inevitable in patients requiring life-long transfusion support. Each unit of transfused red cells introduces 200 to 250 mg of elemental iron into the body. Since iron cannot be actively excreted, and is utilized poorly in patients with ineffective erythropoiesis associated with beta thalassemia major, the excess iron is deposited in other viscera, usually the liver, heart, and endocrine organs. When iron stores overwhelm the ability of reticuloendothelial cells to sequester them, parenchymal iron overload develops, leading to end-organ dysfunction (especially heart, liver, and endocrine organs) and death [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The typical thalassemic child receiving a hypertransfusion regimen has an intake of 8 to 16 mg of elemental iron per day, in contrast to 1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    typical of normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/37,49-51\">",
"     37,49-51",
"    </a>",
"    ]. Even though hematopoiesis is partially suppressed by hypertransfusion, accelerated oral iron absorption also contributes to the total iron overload. Aggressive attempts to remove iron from the body pharmacologically are necessary. Clearly, phlebotomy, the most efficacious way to remove iron in other patient groups (eg, hereditary hemochromatosis), is not an option in subjects requiring transfusion.",
"   </p>",
"   <p>",
"    Iron chelation therapy is initiated before the age of six years, often as early as two to four years of age, after approximately 20 to 25 units of red cells have been transfused, at a time when the serum ferritin level is &gt;1000",
"    <span class=\"nowrap\">",
"     ng/mL",
"    </span>",
"    <span class=\"nowrap\">",
"     (mcg/L)",
"    </span>",
"    and the child&rsquo;s liver iron concentration is &gt;3 mg of iron per gram of dry weight as measured either by liver biopsy of noninvasive MRI imaging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link&amp;anchor=H4#H4\">",
"     \"Chelation therapy for iron overload states\", section on 'Use in thalassemia'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Once initiated, an iron chelation program must be rigorously followed and frequently monitored using MRI techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/52\">",
"     52",
"    </a>",
"    ], in order to be medically effective, as well as to prepare the patient for possible hematopoietic cell transplantation at a later date. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This important subject is discussed in depth separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H11#H11\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Transfusional iron overload'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=see_link&amp;anchor=H16#H16\">",
"     \"Iron overload syndromes other than hereditary hemochromatosis\", section on 'Chelation therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link\">",
"     \"Chelation therapy for iron overload states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Osteopenia with cortical thinning, and severe osteoporosis with fractures remain serious complications of beta thalassemia major, even in well-transfused and iron-chelated patients. The mechanisms underlying this complication are unclear. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=see_link&amp;anchor=H5#H5\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Skeletal changes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment of osteoporosis, an important cause of morbidity in adult patients with thalassemia major, requires a concerted, multidisciplinary approach, and includes the following components, although evidence for their effectiveness is incomplete [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/53,54\">",
"     53,54",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bone mineral density studies, starting in adolescence",
"     </li>",
"     <li>",
"      Encouragement of moderate to high impact physical activity",
"     </li>",
"     <li>",
"      Avoidance of smoking",
"     </li>",
"     <li>",
"      Adequate calcium, zinc, and vitamin D intake",
"     </li>",
"     <li>",
"      Early diagnosis and treatment of diabetes mellitus",
"     </li>",
"     <li>",
"      Prevention",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      correction of hypogonadism [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/55\">",
"       55",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Adequate iron chelation",
"     </li>",
"     <li>",
"      Blood transfusions to inhibit excessive bone marrow expansion",
"     </li>",
"     <li>",
"      Potential use of agents that inhibit osteoclast activity (eg, calcitonin, bisphosphonates) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/55-58\">",
"       55-58",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Potential use of",
"      <span class=\"nowrap\">",
"       agents/interventions",
"      </span>",
"      that increase bone formation [",
"      <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/59\">",
"       59",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Continuity of care is essential for improving the morbidity and mortality of children with severe thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/35-37,49-51\">",
"     35-37,49-51",
"    </a>",
"    ]. In addition to close monitoring of transfusion and iron chelation therapy, patients need to be under surveillance for a variety of associated symptoms of anemia and iron overload. These include close monitoring during the ages surrounding puberty for development of primary and secondary sexual characteristics, with appropriate endocrine consultation for intervention if growth, development, and puberty are delayed. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=see_link\">",
"     \"Normal puberty\"",
"    </a>",
"    .) In addition, patients with severe thalassemia are at risk for aplastic crisis from infection with parvovirus B19, during which time transfusion requirements may increase dramatically.",
"   </p>",
"   <p>",
"    Repletion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    because of an increased need secondary to increased erythropoiesis (1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    by mouth) and a cautious use of ascorbic acid (for improving the effectiveness of iron chelation) and zinc supplementation (for its possible beneficial effect on osteoporosis) are indicated for reasons outlined above. Use of antioxidant compounds, such as vitamin E, remains controversial. Although a theoretical basis exists for their use, clinical efficacy has not been proven.",
"   </p>",
"   <p>",
"    The cardinal manifestations of untreated beta thalassemia major (eg, bony fractures, development of masses of extramedullary hematopoiesis, abnormal facies, and dentition) are minimized when proper transfusion therapy is utilized. Nonetheless, patients should be monitored for the development of any suspicious signs or symptoms. Splenectomized patients require appropriate vaccination, and the use of prophylactic antibiotics. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link\">",
"     \"Prevention of sepsis in the asplenic patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18530051\">",
"    <span class=\"h4\">",
"     Pulmonary hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with beta thalassemia major or intermedia may develop pulmonary arterial hypertension (PAH), a common sequel of the hemoglobinopathies associated with hemolytic anemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=see_link&amp;anchor=H18#H18\">",
"     \"Pulmonary complications of sickle cell disease\", section on 'Pulmonary hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports on the management of PAH in thalassemics (Group 1 PAH, formerly called idiopathic PAH) have included treatment with phosphodiesterase type 5 inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/19/33080?source=see_link\">",
"     sildenafil",
"    </a>",
"    ) and the endothelin receptor antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/16/40200?source=see_link\">",
"     bosentan",
"    </a>",
"    , with only anecdotal reports of success [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/60-62\">",
"     60-62",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=see_link&amp;anchor=H16#H16\">",
"     \"Treatment of pulmonary hypertension in adults\", section on 'Advanced therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Hematopoietic cell transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hematopoietic cell transplantation (HCT) has, since the 1980s, become established as an important modality for patients with severe beta thalassemia. There is now extensive experience with HCT in these children, with well over 1000 patients having undergone this procedure. The use of HCT in severe beta thalassemia, including the relative value of medical treatment versus HCT is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"     \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=see_link\">",
"     \"Specific issues related to hematopoietic cell transplantation in beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;With advances in hypertransfusion and iron chelation, some women with beta thalassemia major have had favorable pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/63,64\">",
"     63,64",
"    </a>",
"    ]. However, such pregnancies are recommended only in those with normal cardiac function and adequate hypertransfusion and iron chelation regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/64,65\">",
"     64,65",
"    </a>",
"    ]. Genetic counseling is strongly advised, since these mothers will be transmitting a thalassemic gene to",
"    <strong>",
"     all",
"    </strong>",
"    of their offspring, and partnership with a male with beta thalassemia trait will lead to beta thalassemia major or intermedia in one-half of their offspring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=see_link&amp;anchor=H21397857#H21397857\">",
"     \"Community public health issues and the thalassemic syndromes: Lessons from other countries\", section on 'Genetic counseling of couples'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     MANIPULATION OF FETAL HEMOGLOBIN SWITCHING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of pharmacologic agents capable of promoting substantial levels of fetal hemoglobin synthesis (HbF) during adult life is a promising approach, even though clinical efficacy has not yet been demonstrated in patients with severe thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/66,67\">",
"     66,67",
"    </a>",
"    ]. Continuation of significant degrees of fetal hemoglobin synthesis might reduce clinical severity by providing additional hemoglobin for oxygen transport and reducing the burden of free alpha globin chains [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/68\">",
"     68",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    After many years of study in animal and tissue culture models, it was realized that certain cytotoxic drugs, commonly used in cancer chemotherapy, could elevate fetal hemoglobin synthesis in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/18\">",
"     18",
"    </a>",
"    ]. This effect appears to be due to their alteration of the genetics of primitive stem cells, some of which retain the potential to synthesize fetal hemoglobin. Under normal circumstances, very few of these clones enter the cell cycle for differentiation and maturation into erythroblasts and reticulocytes. Thus, fetal hemoglobin synthesis normally comprises only 0.5 to 1 percent of total adult hemoglobin synthesis. Furthermore, this small percentage is confined to a minor subpopulation of red cell clones called \"F cells.\" Several cytotoxic drugs and other forms of severe bone marrow stress (eg, bone marrow transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/69\">",
"     69",
"    </a>",
"    ], recovery from radiation or other bone marrow suppressants) increase the number of F cell clones, thus increasing fetal hemoglobin synthesis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Hydroxyurea",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     Hydroxyurea",
"    </a>",
"    (HU), a cytotoxic drug commonly used in the treatment of myeloproliferative disorders, has been shown to increase fetal hemoglobin synthesis in patients with beta thalassemia, sickle cell disease, and some individuals with no hemoglobinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]. The effect of HU appears to be somewhat unpredictable in terms of the maximum HbF levels achieved in an individual patient, but the effect is dose-related and reversible within individual patients. Toxicity of HU is largely that of myelosuppression, which, in contrast to many similar agents, is rapidly reversible upon dose reduction or cessation of the drug treatment.",
"   </p>",
"   <p>",
"    HU has achieved increasing clinical usage in sickle cell anemia, where it has been shown to reduce the frequency and severity of acute chest syndrome and painful crises. The use of HU has also been helpful in some patients with beta thalassemia intermedia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/72-77\">",
"     72-77",
"    </a>",
"    ], although its successful use in beta thalassemia major has been less frequently noted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/70,71,75,76,78\">",
"     70,71,75,76,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H3#H3\">",
"     \"Specific therapies for sickle cell disease\", section on 'Reactivating fetal hemoglobin synthesis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=see_link&amp;anchor=H4#H4\">",
"     \"Clinical variability in sickle cell anemia\", section on 'Control of HbF expression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Possible reasons for this discrepancy include the fact that patients with beta thalassemia major have a considerably higher quantitative requirement for fetal hemoglobin synthesis before clinical impact occurs. In addition, patients with severe beta thalassemia are more dependent on marrow hyperactivity than are patients with sickle cell anemia. The myelosuppressive effect of HU may therefore compromise its therapeutic efficacy in thalassemic individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Histone deacetylase inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;The disappointing results obtained with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    in thalassemia have led to a search for other agents capable of increasing the production of HbF. The histone deacetylase inhibitors butyrate and trichostatin A activate gamma globin expression via a p38 mitogen-activating protein kinase (MAPK)-dependent mechanism [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Butyric acid analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most promising histone deacetylase inhibitors presently under study are derivatives of butyric acid, including arginine butyrate,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/39/9845?source=see_link\">",
"     sodium phenylbutyrate",
"    </a>",
"    , and related substances [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/80-84\">",
"     80-84",
"    </a>",
"    ]. Used alone, these agents are inadequately potent in most patients, except at doses that are potentially toxic or poorly tolerated because of the requirement for prolonged intravenous infusions.",
"   </p>",
"   <p>",
"    Promising results have been obtained with the use of combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    and intermittent pulses of butyric acid compounds [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/80-82,85,86\">",
"     80-82,85,86",
"    </a>",
"    ]. For poorly understood reasons, intermittent pulse therapy appears to increase the potency and sustainability of the hemoglobin switching effect obtained with butyric acid compounds. Whether this or other combination regimens will eventually prove to be therapeutically efficacious remains to be seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Kit ligand",
"    </span>",
"    &nbsp;&mdash;&nbsp;In one study, addition of kit ligand, with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , to cell cultures from patients with beta thalassemia intermedia or beta thalassemia major increased cell proliferation, reduced the percent of apoptotic and dyserythropoietic cells and induced a marked increase of gamma globin synthesis required for the production of HbF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/87\">",
"     87",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Confirmatory in vivo studies in experimental animal models of thalassemia will be required before such treatment can be considered in human subjects, especially since infusions of kit ligand (stem cell factor, Stemgen) have been associated with potentially severe allergic side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/88\">",
"     88",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22367756\">",
"    <span class=\"h2\">",
"     Decitabine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cytosine analog",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (5-aza-2&rsquo;-deoxycytidine), which can deplete DNA methyltransferase and potentially activate gamma globin gene expression, has shown efficacy in short- and long-term trials in increasing HbF and total hemoglobin levels in patients with sickle cell anemia failing to respond to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/16/16648?source=see_link\">",
"     hydroxyurea",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=see_link&amp;anchor=H12#H12\">",
"     \"Specific therapies for sickle cell disease\", section on '5-Aza deoxycytidine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The utility of low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/59/39861?source=see_link\">",
"     decitabine",
"    </a>",
"    (0.2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    subcutaneously twice per week for 12 weeks) was also studied in a small pilot study in five subjects with beta thalassemia intermedia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/89\">",
"     89",
"    </a>",
"    ]. This treatment increased total hemoglobin and absolute HbF levels in all five, along with favorable changes in indices of hemolysis. The potential of this approach requires further clinical evaluation. Moreover, the long term toxicity and exact mechanism of action of this agent require further evaluation. This agent is not yet suitable for use except in the setting of a carefully controlled clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642553\">",
"    <span class=\"h1\">",
"     GENE THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even though globin gene expression can be readily manipulated in experimental animals, including murine models of beta thalassemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/90-93\">",
"     90-93",
"    </a>",
"    ], the search for a safe, efficient, and specific targeting vector in humans has been difficult, with limited success to date [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/94\">",
"     94",
"    </a>",
"    ]. The challenges are considerable [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/66,95,96\">",
"     66,95,96",
"    </a>",
"    ]. The donor globin gene must be inserted into the pluripotent hematopoietic stem cell, in a fashion that allows its tightly regulated but high level expression only in the red cell lineage and only during the period of terminal erythroblast maturation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/97-99\">",
"     97-99",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many of the sequences flanking the globin genes that are necessary for this regulation have been identified and utilized effectively in animal models [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/97,100,101\">",
"     97,100,101",
"    </a>",
"    ]. Experiments in animal models suggest that a significant therapeutic benefit could be achieved if the transferred globin gene is expressed at about 15 percent of the level of the alpha-globin mRNA, with about 20 percent of the erythroid precursors expressing the vector genome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/39/7802/abstract/102\">",
"     102",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=see_link\">",
"       \"Patient information: Thalassemia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15642743\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical manifestations are profound in patients homozygous for impaired beta globin synthesis (ie, beta thalassemia intermedia and beta thalassemia major) and much less pronounced in heterozygotes (ie, beta thalassemia minor). (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Definitions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta thalassemia minor (trait)",
"      </strong>",
"       Subjects with beta thalassemia minor (beta thalassemia trait) require no specific therapy. Transfusions may be required in pregnant women with symptomatic \"physiologic\" anemia of pregnancy. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Beta thalassemia minor'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <strong>",
"       Beta thalassemia major",
"      </strong>",
"       Subjects with beta thalassemia major are severely affected and will die of their disease unless given appropriate medical attention. (See",
"      <a class=\"local\" href=\"#H15642333\">",
"       'Overview'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We recommend that all children with beta thalassemia major receive treatment with a hypertransfusion protocol along with iron chelation therapy (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Such treatment should be instituted once the stigmata of the disease become evident and should be rigorously followed. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Chronic hypertransfusion therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=see_link&amp;anchor=H22#H22\">",
"       \"Chelation therapy for iron overload states\", section on 'Transfusion-dependent thalassemia'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Appropriately selected subjects (eg, younger age, availability of HLA-matched donor, presence or absence of",
"      <span class=\"nowrap\">",
"       hepatomegaly/hepatic",
"      </span>",
"      fibrosis, quality of iron chelation therapy) should be considered for potentially curative hematopoietic cell transplantation. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=see_link\">",
"       \"Efficacy of hematopoietic cell transplantation in beta thalassemia major\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Care for other complications (need for splenectomy, cardiac monitoring, osteoporosis, supportive measures) are discussed in the text.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Beta thalassemia intermedia",
"      </strong>",
"       Subjects with beta thalassemia intermedia have clinical complications less severe than those seen in beta thalassemia major, and may not develop the need for any treatment until later in life. Accordingly, all patients should be carefully monitored for development of symptomatic anemia, abnormalities in growth and development, symptomatic splenomegaly, iron overload, and cardiopulmonary complications. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Beta thalassemia intermedia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      We suggest institution of red cell transfusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      a",
"      <span class=\"nowrap\">",
"       hypertransfusion/chelation",
"      </span>",
"      regimen in subjects with disease-related complications such as activity limitations, delayed growth and development,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      the early appearance of skeletal changes (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We suggest that splenectomy be avoided in these patients if at all possible; splenectomy should be considered only in those with severe disease-related complications such as growth retardation, poor health, leukopenia, thrombocytopenia, increased transfusion need, or symptomatic splenomegaly (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/1\">",
"      Rachmilewitz EA, Giardina PJ. How I treat thalassemia. Blood 2011; 118:3479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/2\">",
"      Higgs DR, Engel JD, Stamatoyannopoulos G. Thalassaemia. Lancet 2012; 379:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/3\">",
"      Aessopos A, Kati M, Meletis J. Thalassemia intermedia today: should patients regularly receive transfusions? Transfusion 2007; 47:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/4\">",
"      Nassar AH, Usta IM, Rechdan JB, et al. Pregnancy in patients with beta-thalassemia intermedia: outcome of mothers and newborns. Am J Hematol 2006; 81:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/5\">",
"      Borgna-Pignatti C. Modern treatment of thalassaemia intermedia. Br J Haematol 2007; 138:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/6\">",
"      Premawardhena A, Fisher CA, Olivieri NF, et al. Haemoglobin E beta thalassaemia in Sri Lanka. Lancet 2005; 366:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/7\">",
"      Taher AT, Musallam KM, Cappellini MD, Weatherall DJ. Optimal management of &beta; thalassaemia intermedia. Br J Haematol 2011; 152:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/8\">",
"      Spanos T, Karageorga M, Ladis V, et al. Red cell alloantibodies in patients with thalassemia. Vox Sang 1990; 58:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/9\">",
"      Taher A, Isma'eel H, Cappellini MD. Thalassemia intermedia: revisited. Blood Cells Mol Dis 2006; 37:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/10\">",
"      Cappellini MD, Robbiolo L, Bottasso BM, et al. Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. Br J Haematol 2000; 111:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/11\">",
"      Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002; 99:36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/12\">",
"      Taher AT, Musallam KM, Nasreddine W, et al. Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia. J Thromb Haemost 2010; 8:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/13\">",
"      Mannucci PM. Red cells playing as activated platelets in thalassemia intermedia. J Thromb Haemost 2010; 8:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/14\">",
"      Taher AT, Musallam KM, Karimi M, et al. Splenectomy and thrombosis: the case of thalassemia intermedia. J Thromb Haemost 2010; 8:2152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/15\">",
"      Borgna Pignatti C, Carnelli V, Caruso V, et al. Thromboembolic events in beta thalassemia major: an Italian multicenter study. Acta Haematol 1998; 99:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/16\">",
"      Taher A, Isma'eel H, Mehio G, et al. Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran. Thromb Haemost 2006; 96:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/17\">",
"      Ataga KI, Cappellini MD, Rachmilewitz EA. Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability. Br J Haematol 2007; 139:3.",
"     </a>",
"    </li>",
"    <li>",
"     Forget, BG. Thalassemia syndromes. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman, R, Benz, EJ Jr, Shattil, SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.485.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/19\">",
"      Olivieri NF. The beta-thalassemias. N Engl J Med 1999; 341:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/20\">",
"      Brittenham GM, Sheth S, Allen CJ, Farrell DE. Noninvasive methods for quantitative assessment of transfusional iron overload in sickle cell disease. Semin Hematol 2001; 38:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/21\">",
"      Tony S, Daar S, Elshinawy M, et al. T2* MRI in regularly transfused children with thalassemia intermedia: serum ferritin does not reflect liver iron stores. Pediatr Hematol Oncol 2012; 29:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/22\">",
"      Taher A, El Rassi F, Isma'eel H, et al. Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia. Haematologica 2008; 93:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/23\">",
"      Musallam KM, Cappellini MD, Taher AT. Iron overload in &beta;-thalassemia intermedia: an emerging concern. Curr Opin Hematol 2013; 20:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/24\">",
"      de Alarcon PA, Donovan ME, Forbes GB, et al. Iron absorption in the thalassemia syndromes and its inhibition by tea. N Engl J Med 1979; 300:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/25\">",
"      Taher A, Hershko C, Cappellini MD. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies. Br J Haematol 2009; 147:634.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/26\">",
"      Ladis V, Berdousi H, Gotsis E, Kattamis A. Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia. Br J Haematol 2010; 151:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/27\">",
"      Musallam KM, Cappellini MD, Wood JC, et al. Elevated liver iron concentration is a marker of increased morbidity in patients with &beta; thalassemia intermedia. Haematologica 2011; 96:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/28\">",
"      Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001; 97:3411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/29\">",
"      Aessopos A, Farmakis D, Deftereos S, et al. Thalassemia heart disease: a comparative evaluation of thalassemia major and thalassemia intermedia. Chest 2005; 127:1523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/30\">",
"      Atichartakarn V, Chuncharunee S, Chandanamattha P, et al. Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E/beta-thalassemia patient. Blood 2004; 103:2844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/31\">",
"      Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood 2010; 115:1886.",
"     </a>",
"    </li>",
"    <li>",
"     Bunn HF, Forget BG. Hemoglobin: Molecular, Genetic and Clinical Aspects, WB Saunders, Philadelphia 1986.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/33\">",
"      Rund D, Rachmilewitz E. Beta-thalassemia. N Engl J Med 2005; 353:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/34\">",
"      Wilber A, Hargrove PW, Kim YS, et al. Therapeutic levels of fetal hemoglobin in erythroid progeny of &beta;-thalassemic CD34+ cells after lentiviral vector-mediated gene transfer. Blood 2011; 117:2817.",
"     </a>",
"    </li>",
"    <li>",
"     Weatherall DJ. The thalessemias. In: Molecular Basis of Blood Diseases, 2nd ed, Stamatoyannopoulos G, Nienhuis AW, Majerus PW (Eds), WB Saunders, Philadelphia 1994. p.157.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/36\">",
"      Adams JG 3rd, Coleman MB. Structural hemoglobin variants that produce the phenotype of thalassemia. Semin Hematol 1990; 27:229.",
"     </a>",
"    </li>",
"    <li>",
"     Forget BG, Pearson HA. Hemoglobin synthesis and the thalassemias. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.1525.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/38\">",
"      Chou ST, Liem RI, Thompson AA. Challenges of alloimmunization in patients with haemoglobinopathies. Br J Haematol 2012; 159:394.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/39\">",
"      Azarkeivan A, Ansari S, Ahmadi MH, et al. Blood transfusion and alloimmunization in patients with thalassemia: multicenter study. Pediatr Hematol Oncol 2011; 28:479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/40\">",
"      Singer ST, Wu V, Mignacca R, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly asian descent. Blood 2000; 96:3369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/41\">",
"      Ho HK, Ha SY, Lam CK, et al. Alloimmunization in Hong Kong southern Chinese transfusion-dependent thalassemia patients. Blood 2001; 97:3999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/42\">",
"      Cogliandro T, Derchi G, Mancuso L, et al. Guideline recommendations for heart complications in thalassemia major. J Cardiovasc Med (Hagerstown) 2008; 9:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/43\">",
"      Davis BA, O'Sullivan C, Jarritt PH, Porter JB. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Blood 2004; 104:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/44\">",
"      Moratelli S, De Sanctis V, Gemmati D, et al. Thrombotic risk in thalassemic patients. J Pediatr Endocrinol Metab 1998; 11 Suppl 3:915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/45\">",
"      Michaeli J, Mittelman M, Grisaru D, Rachmilewitz EA. Thromboembolic complications in beta thalassemia major. Acta Haematol 1992; 87:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/46\">",
"      Cappellini MD, Grespi E, Cassinerio E, et al. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005; 1054:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/47\">",
"      Ikeda M, Sekimoto M, Takiguchi S, et al. High incidence of thrombosis of the portal venous system after laparoscopic splenectomy: a prospective study with contrast-enhanced CT scan. Ann Surg 2005; 241:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/48\">",
"      Sok J, Su W, Hopkins MA. Portal vein thrombosis following laparoscopic splenectomy for beta-thalassemia: a case study. Surg Endosc 2001; 15:1489.",
"     </a>",
"    </li>",
"    <li>",
"     Schwartz E, Benz EJ Jr. Thalassemia syndromes. In: Smith's Blood Diseases of Infancy and Childhood, 6th ed, Miller DR, Baehner RL (Eds), CV Mosby, St. Louis 1989. p.428.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/50\">",
"      Beris P. Introduction: management of thalassemia. Semin Hematol 1995; 32:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/51\">",
"      Cao A, Galanello R, Rosatelli MC, et al. Clinical experience of management of thalassemia: the Sardinian experience. Semin Hematol 1996; 33:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/52\">",
"      Kwiatkowski JL, Kim HY, Thompson AA, et al. Chelation use and iron burden in North American and British thalassemia patients: a report from the Thalassemia Longitudinal Cohort. Blood 2012; 119:2746.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/53\">",
"      Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004; 127:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/54\">",
"      Schrier SL, Angelucci E. New strategies in the treatment of the thalassemias. Annu Rev Med 2005; 56:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/55\">",
"      Chatterjee R, Shah FT, Davis BA, et al. Prospective study of histomorphometry, biochemical bone markers and bone densitometric response to pamidronate in &beta;-thalassaemia presenting with osteopenia-osteoporosis syndrome. Br J Haematol 2012; 159:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/56\">",
"      Voskaridou E, Terpos E, Spina G, et al. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003; 123:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/57\">",
"      Otrock ZK, Azar ST, Shamseddeen WA, et al. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006; 85:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/58\">",
"      Mamtani M, Kulkarni H. Bone recovery after zoledronate therapy in thalassemia-induced osteoporosis: a meta-analysis and systematic review. Osteoporos Int 2010; 21:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/59\">",
"      Fung EB, Gariepy CA, Sawyer AJ, et al. The effect of whole body vibration therapy on bone density in patients with thalassemia: a pilot study. Am J Hematol 2012; 87:E76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/60\">",
"      Littera R, La Nasa G, Derchi G, et al. Long-term treatment with sildenafil in a thalassemic patient with pulmonary hypertension. Blood 2002; 100:1516.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/61\">",
"      Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica 2005; 90:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/62\">",
"      Anthi A, Tsangaris I, Hamodraka ES, et al. Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension. Blood 2012; 120:1531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/63\">",
"      Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, preconceptual evaluation and a review of the literature. Br J Obstet Gynaecol 1995; 102:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/64\">",
"      Aessopos A, Karabatsos F, Farmakis D, et al. Pregnancy in patients with well-treated beta-thalassemia: outcome for mothers and newborn infants. Am J Obstet Gynecol 1999; 180:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/65\">",
"      ACOG Committee on Obstetrics. ACOG Practice Bulletin No. 78: hemoglobinopathies in pregnancy. Obstet Gynecol 2007; 109:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/66\">",
"      Quek L, Thein SL. Molecular therapies in beta-thalassaemia. Br J Haematol 2007; 136:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/67\">",
"      Musallam KM, Taher AT, Cappellini MD, Sankaran VG. Clinical experience with fetal hemoglobin induction therapy in patients with &beta;-thalassemia. Blood 2013; 121:2199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/68\">",
"      Bauer DE, Kamran SC, Orkin SH. Reawakening fetal hemoglobin: prospects for new therapies for the &beta;-globin disorders. Blood 2012; 120:2945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/69\">",
"      Paciaroni K, Lucarelli G. Hemopoietic stem cell transplantation failure followed by switch to stable production of fetal hemoglobin. Blood 2012; 119:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/70\">",
"      Olivieri NF. Reactivation of fetal hemoglobin in patients with beta-thalassemia. Semin Hematol 1996; 33:24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/71\">",
"      Olivieri NF, Rees DC, Ginder GD, et al. Treatment of thalassaemia major with phenylbutyrate and hydroxyurea. Lancet 1997; 350:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/72\">",
"      Hoppe C, Vichinsky E, Lewis B, et al. Hydroxyurea and sodium phenylbutyrate therapy in thalassemia intermedia. Am J Hematol 1999; 62:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/73\">",
"      Cario H, Wegener M, Debatin KM, Kohne E. Treatment with hydroxyurea in thalassemia intermedia with paravertebral pseudotumors of extramedullary hematopoiesis. Ann Hematol 2002; 81:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/74\">",
"      Singer ST, Kuypers FA, Olivieri NF, et al. Fetal haemoglobin augmentation in E/beta(0) thalassaemia: clinical and haematological outcome. Br J Haematol 2005; 131:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/75\">",
"      Bradai M, Pissard S, Abad MT, et al. Decreased transfusion needs associated with hydroxyurea therapy in Algerian patients with thalassemia major or intermedia. Transfusion 2007; 47:1830.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/76\">",
"      Koren A, Levin C, Dgany O, et al. Response to hydroxyurea therapy in beta-thalassemia. Am J Hematol 2008; 83:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/77\">",
"      Rigano P, Pecoraro A, Calzolari R, et al. Desensitization to hydroxycarbamide following long-term treatment of thalassaemia intermedia as observed in vivo and in primary erythroid cultures from treated patients. Br J Haematol 2010; 151:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/78\">",
"      Bradai M, Abad MT, Pissard S, et al. Hydroxyurea can eliminate transfusion requirements in children with severe beta-thalassemia. Blood 2003; 102:1529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/79\">",
"      Sangerman J, Lee MS, Yao X, et al. Mechanism for fetal hemoglobin induction by histone deacetylase inhibitors involves gamma-globin activation by CREB1 and ATF-2. Blood 2006; 108:3590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/80\">",
"      Perrine SP, Ginder GD, Faller DV, et al. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the beta-globin disorders. N Engl J Med 1993; 328:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/81\">",
"      Faller DV, Perrine SP. Butyrate in the treatment of sickle cell disease and beta-thalassemia. Curr Opin Hematol 1995; 2:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/82\">",
"      Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood 1994; 84:339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/83\">",
"      Witt O, Monkemeyer S, R&ouml;nndahl G, et al. Induction of fetal hemoglobin expression by the histone deacetylase inhibitor apicidin. Blood 2003; 101:2001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/84\">",
"      Conley BA, Wright JJ, Kummar S. Targeting epigenetic abnormalities with histone deacetylase inhibitors. Cancer 2006; 107:832.",
"     </a>",
"    </li>",
"    <li>",
"     Embury SH, Vichinsky EP. Sickle cell disease. In: Hematology: Basic Principles and Practice, 3rd ed, Hoffman R, Benz EJ Jr, Shattil SJ, et al. (Eds), Churchill Livingstone, New York 2000. p.510.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/86\">",
"      Higgs DR. alpha-Thalassaemia. Baillieres Clin Haematol 1993; 6:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/87\">",
"      Gabbianelli M, Morsilli O, Massa A, et al. Effective erythropoiesis and HbF reactivation induced by kit ligand in beta-thalassemia. Blood 2008; 111:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/88\">",
"      Shpall EJ, Wheeler CA, Turner SA, et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93:2491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/89\">",
"      Olivieri NF, Saunthararajah Y, Thayalasuthan V, et al. A pilot study of subcutaneous decitabine in &beta;-thalassemia intermedia. Blood 2011; 118:2708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/90\">",
"      May C, Rivella S, Chadburn A, Sadelain M. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002; 99:1902.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/91\">",
"      Rivella S, May C, Chadburn A, et al. A novel murine model of Cooley anemia and its rescue by lentiviral-mediated human beta-globin gene transfer. Blood 2003; 101:2932.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/92\">",
"      Persons DA, Allay ER, Sawai N, et al. Successful treatment of murine beta-thalassemia using in vivo selection of genetically modified, drug-resistant hematopoietic stem cells. Blood 2003; 102:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/93\">",
"      Huo Y, McConnell SC, Ryan TM. Preclinical transfusion-dependent humanized mouse model of beta thalassemia major. Blood 2009; 113:4763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/94\">",
"      Cavazzana-Calvo M, Payen E, Negre O, et al. Transfusion independence and HMGA2 activation after gene therapy of human &beta;-thalassaemia. Nature 2010; 467:318.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/95\">",
"      Baum C, D&uuml;llmann J, Li Z, et al. Side effects of retroviral gene transfer into hematopoietic stem cells. Blood 2003; 101:2099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/96\">",
"      Nienhuis AW. Development of gene therapy for blood disorders. Blood 2008; 111:4431.",
"     </a>",
"    </li>",
"    <li>",
"     Atweh GF, Forget BG. Clinical applications of gene therapy: anemias. In: Stem Cell Biology and Gene Therapy, esenberry PJ, Stein GS, Forget BG (Eds), John Wiley, New York 1998. p.411.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/98\">",
"      Nicolini FE, Imren S, Oh IH, et al. Expression of a human beta-globin transgene in erythroid cells derived from retrovirally transduced transplantable human fetal liver and cord blood cells. Blood 2002; 100:1257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/99\">",
"      Puthenveetil G, Scholes J, Carbonell D, et al. Successful correction of the human beta-thalassemia major phenotype using a lentiviral vector. Blood 2004; 104:3445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/100\">",
"      May C, Rivella S, Callegari J, et al. Therapeutic haemoglobin synthesis in beta-thalassaemic mice expressing lentivirus-encoded human beta-globin. Nature 2000; 406:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/101\">",
"      Miccio A, Cesari R, Lotti F, et al. In vivo selection of genetically modified erythroblastic progenitors leads to long-term correction of beta-thalassemia. Proc Natl Acad Sci U S A 2008; 105:10547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/39/7802/abstract/102\">",
"      Persons DA, Allay ER, Sabatino DE, et al. Functional requirements for phenotypic correction of murine beta-thalassemia: implications for human gene therapy. Blood 2001; 97:3275.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7118 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-3548BCC041-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7802=[""].join("\n");
var outline_f7_39_7802=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15642743\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Beta thalassemia minor",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Beta thalassemia intermedia",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Anemia and transfusions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14176389\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Iron overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cardiopulmonary complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Other complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15642333\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Chronic hypertransfusion therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15642352\">",
"      Benefits",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15642359\">",
"      Initiation of treatment and avoidance of complications",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H15642373\">",
"      Hypertransfusion regimen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Cardiac monitoring",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Splenectomy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Iron chelation therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Supportive measures",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H18530051\">",
"      Pulmonary hypertension",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      MANIPULATION OF FETAL HEMOGLOBIN SWITCHING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Hydroxyurea",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Histone deacetylase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Butyric acid analogs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Kit ligand",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22367756\">",
"      Decitabine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15642553\">",
"      GENE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15642743\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7118\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7118|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/29/27089\" title=\"picture 1\">",
"      Beta thalassemia intermedia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7118|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/53/28507\" title=\"table 1\">",
"      Beta thal intermedia variants",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/49/25370?source=related_link\">",
"      Chelation therapy for iron overload states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/63/2041?source=related_link\">",
"      Clinical features and diagnosis of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/32/39434?source=related_link\">",
"      Clinical variability in sickle cell anemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/51/41783?source=related_link\">",
"      Community public health issues and the thalassemic syndromes: Lessons from other countries",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5529?source=related_link\">",
"      Efficacy of hematopoietic cell transplantation in beta thalassemia major",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38856?source=related_link\">",
"      Iron overload syndromes other than hereditary hemochromatosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/25/1434?source=related_link\">",
"      Normal puberty",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39946?source=related_link\">",
"      Overview of the management of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?7/14/7394?source=related_link\">",
"      Patient information: Thalassemia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/28/27082?source=related_link\">",
"      Pulmonary complications of sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25880?source=related_link\">",
"      Specific issues related to hematopoietic cell transplantation in beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/33/34330?source=related_link\">",
"      Specific therapies for sickle cell disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/62/25578?source=related_link\">",
"      Treatment of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/24/35210?source=related_link\">",
"      Treatment of pulmonary hypertension in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_39_7803="Morphologic class gastritis";
var content_f7_39_7803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F80329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F80329&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Morphologic classification of gastritis or gastropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td>",
"       Location of process:",
"      </td>",
"      <td>",
"       Antral predominant, corpus predominant, or pangastritis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Type of inflammation:",
"      </td>",
"      <td>",
"       Acute, chronic, mixed, eosinophilic, or granulomatous",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Topography of inflammation:",
"      </td>",
"      <td>",
"       <p>",
"        Diffuse or focal",
"       </p>",
"       <p>",
"        Gastric site",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atrophy:",
"      </td>",
"      <td>",
"       Present or absent, graded*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Intestinal metaplasia:",
"      </td>",
"      <td>",
"       Present or absent, graded*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Infectious agent:",
"      </td>",
"      <td>",
"       Helicobacter pylori, Helicobacter heilmannii, virus, other",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Mild, moderate, or marked.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7803=[""].join("\n");
var outline_f7_39_7803=null;
var title_f7_39_7804="Dx tests small bowel tumors";
var content_f7_39_7804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F62087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F62087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Comparison of diagnostic tests used in the evaluation of suspected small bowel tumors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"33%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Diagnostic test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Advantages",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disadvantages",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Plain abdominal film",
"       </td>",
"       <td>",
"        May show obstruction",
"       </td>",
"       <td>",
"        Nonspecific",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper gastrointestinal series/small bowel follow through",
"       </td>",
"       <td>",
"        May show mass lesion, mucosal defect, or intussusception",
"       </td>",
"       <td>",
"        No visualization outside lumen; not helpful in staging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Enteroclysis (CT, MRI, or conventional)",
"       </td>",
"       <td>",
"        More sensitive than conventional small bowel follow through",
"       </td>",
"       <td>",
"        May require a duodenal tube",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CT scan",
"       </td>",
"       <td>",
"        Allows staging; may aid in diagnosis of tumor type",
"       </td>",
"       <td>",
"        Lacks visualization of lumen or mucosal surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Upper endoscopy",
"       </td>",
"       <td>",
"        Direct visualization of mucosal surface of duodenum; allows for biopsy; polypectomy possible",
"       </td>",
"       <td>",
"        Invasive; limited to duodenum",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Push enteroscopy",
"       </td>",
"       <td>",
"        Extends visualization into proximal jejunum; allows for biopsy",
"       </td>",
"       <td>",
"        Invasive; does not permit visualization of the entire small bowel",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Double-balloon enteroscopy",
"       </td>",
"       <td>",
"        Allows visualization of entire small bowel with capacity for biopsy and therapeutic intervention",
"       </td>",
"       <td>",
"        Invasive; not widely available; small risk of pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Wireless video capsule endoscopy",
"       </td>",
"       <td>",
"        Noninvasive",
"       </td>",
"       <td>",
"        Does not permit tissue sampling; should not be performed if small bowel obstruction suspected",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7804=[""].join("\n");
var outline_f7_39_7804=null;
var title_f7_39_7805="Overview of selective serotonin reuptake inhibitor poisoning";
var content_f7_39_7805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82567&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Overview of selective serotonin reuptake inhibitor (SSRI) poisoning",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <span style=\"color: #ff0000;\">",
"         To obtain emergent consultation with a medical toxicologist, call the United States Poison Control Network at 1-800-222-1222, or access the World Health Organization's list of international poison centers (",
"        </span>",
"        <a href=\"file://www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html\" target=\"_blank\">",
"         <span style=\"color: #0000ff;\">",
"          www.who.int/gho/phe/chemical_safety/poisons_centres/en/index.html",
"         </span>",
"        </a>",
"        <span style=\"color: #ff0000;\">",
"         ).",
"        </span>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Overview",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        SSRIs rarely cause significant toxicity in isolated ingestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Search for coingestants in any patient with significant symptoms",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin syndrome, seizure, and QTc prolongation are rare but dangerous complications",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Citalopram is the most toxic SSRI in overdose",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        History",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascertain the drugs ingested (including coingestants and formulations)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ascertain the amounts ingested and when the ingestion occurred",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Physical examination",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        First, assess and secure airway, breathing, and circulation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Examination usually unremarkable; infrequently drowsiness, tremor, and vomiting can occur",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Evaluate for serotonin syndrome: hyperthermia, diaphoresis, ocular clonus, hypertonia, tremor, lower extremity hyperreflexia, ankle clonus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Laboratory evaluation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain the following: acetaminophen and salicylate serum concentrationss; serum ethanol concentration; electrocardiogram (ECG); serum bicarbonate; pregnancy test in women of childbearing age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain serial ECGs if QRS or QTc interval is prolonged on initial ECG; admit patient if conduction abnormalities persist; citalopram and escitalopram are most likely to cause prolonged intervals",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Obtain the following if severe serotonin syndrome is suspected: creatine kinase, urine myoglobin; serum creatinine; serum aminotransferases; coagulation studies (aPTT, PT, INR, platelet count, d-dimer); arterial blood gas",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Treatment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Most SSRI ingestions cause minimal toxicity; supportive care is generally sufficient",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Secure airway, breathing, and circulation; intubate as clinically indicated",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Give one dose only of activated charcoal (1 g/kg; standard adult dose is 50 g)",
"        <strong>",
"         without",
"        </strong>",
"        additives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Avoid additional serotonergic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat seizures with benzodiazepines (eg, lorazepam 1 to 2 mg IV every five minutes as needed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat prolonged QRS interval with sodium bicarbonate: 1 to 2 meq/kg IV push; if QRS narrows with bicarbonate bolus, infuse bicarbonate: approximately 133 meq NaHCO3 in one liter D5W, at 250 mL/hour in adults, or twice maintenance fluid infusion rate in children",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Observe patients with prolonged QTc for development of torsades",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Treat torsades with magnesium sulfate (Mg): initial dose 2 g IV over two minutes; may repeat after 10 minutes; infusion may be needed",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        For management of serotonin syndrome, see separate UpToDate topic",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7805=[""].join("\n");
var outline_f7_39_7805=null;
var title_f7_39_7806="Ventricular pacemaker tracing";
var content_f7_39_7806=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F71529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F71529&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 491px\">",
"   <div class=\"ttl\">",
"    Cannon 'a' waves caused by ventricular pacing",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 471px; height: 269px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Simultaneous electrocardiographic and right atrial pressure tracings from a patient with a ventricular pacemaker. Arrows indicate underlying atrial activity. Occasional normal a and v waves are interspersed with cannon 'a' waves (ca). Cannon 'a' waves result from atrial contraction against a closed valve, and are a sign of atrioventricular dissociation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Schriner, DK, Crit Care Nurs Clin N America 1989; 1:563.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7806=[""].join("\n");
var outline_f7_39_7806=null;
var title_f7_39_7807="Perforation of distal thoracic esophagus";
var content_f7_39_7807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F56059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F56059&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Perforation of distal thoracic esophagus - operative exposure",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 295px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts facilitating exposure of the distal esophagus with a Penrose drain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_39_7807=[""].join("\n");
var outline_f7_39_7807=null;
